"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 1940836 A,116-154-141-665-232,1933-12-26,1933,US 62789032 A,1932-08-08,US 62789032 A,1932-08-08,Retractable landing gear,,MANNING & CO,AYER ROBERT W,,https://lens.org/116-154-141-665-232,Granted Patent,no,0,7,1,1,0,B64C25/24;;B64C25/24,B64C25/24,,0,0,,,,EXPIRED
2,US,A,US 2181258 A,117-089-774-573-918,1939-11-28,1939,US 17121937 A,1937-10-27,US 17121937 A,1937-10-27,Operating device for control surfaces for airplanes,,AVIAT MFG CORP,AYER ROBERT W,,https://lens.org/117-089-774-573-918,Granted Patent,no,0,1,1,1,0,B64C13/00;;Y10S60/904;;B64C13/00;;Y10S60/904,B64C13/00,,0,0,,,,EXPIRED
3,US,A,US 2110543 A,052-762-601-393-290,1938-03-08,1938,US 7716936 A,1936-04-30,US 7716936 A,1936-04-30,Tail wheel structure,,AVIAT MFG CORP,AYER ROBERT W,,https://lens.org/052-762-601-393-290,Granted Patent,no,0,1,1,1,0,B64C25/50;;B64C25/50,B64C25/50,,0,0,,,,EXPIRED
4,US,A,US 2058756 A,055-182-906-294-232,1936-10-27,1936,US 68986233 A,1933-09-18,US 68986233 A,1933-09-18,Firearm kit,,TRI PAK GUN KIT INC,EARL AYER ROBERT,,https://lens.org/055-182-906-294-232,Granted Patent,no,0,11,1,1,0,B25F1/00;;F41A29/02;;Y10S242/905;;B25F1/00;;F41A29/02;;Y10S242/905,B25F1/00,,0,0,,,,EXPIRED
5,US,A,US 2084122 A,077-882-561-404-824,1937-06-15,1937,US 1613035 A,1935-04-13,US 1613035 A,1935-04-13,Apparatus for controlling airplane elevators,,STINSON AIRCRAFT CORP,AYER ROBERT W,,https://lens.org/077-882-561-404-824,Granted Patent,no,0,1,1,1,0,B64C17/00;;B64C17/00,B64C17/00,,0,0,,,,EXPIRED
6,AU,A,AU 1972/041786 A,186-938-852-660-184,1973-11-08,1973,AU 1972/041786 A,1972-05-02,AU 1972/041786 A,1972-05-02,ADVERTISING DISPLAY STRUCTURES,,NORMAN BUFFETT DISPLAY IND INC,EATON ROBERT AYER,,https://lens.org/186-938-852-660-184,Patent Application,no,0,2,1,1,0,G09F15/0068,G09F15/00,,0,0,,,,DISCONTINUED
7,EP,A3,EP 2665067 A3,072-428-215-965-010,2016-12-28,2016,EP 13167939 A,2013-05-15,US 201213472724 A,2012-05-16,Heat transfer systems and methods for nuclear plants,"A heat transfer system (400) for a nuclear plant may include a piping system (418) that includes first and second connectors (414, 416), heat exchanger (406), pump (402), and power source (420). The heat transfer system (400) may not be connected to the plant during normal power operations. The power source (420) may be independent of a normal electrical power distribution system for the plant and may be configured to power the pump (402). The piping system (418) may be configured to connect the heat exchanger (406) and pump (402). The connectors (414, 416) may be configured to connect the heat transfer system (400) to a fluid system (500, 600) of the plant. When the connectors connect the heat transfer system (400) to the fluid system, the heat transfer system (400) may be configured to receive fluid from the fluid system (500, 600) of the plant via the first connector (414), to pump the fluid through the heat exchanger (406), and to return the fluid to the fluid system (500, 600) via the second connector (416).
",GE HITACHI NUCLEAR ENERGY AMERICAS LLC,AYER ROBERT;;GINSBERG ROBERT JOSEPH;;BASS JOHN ROBERT,,https://lens.org/072-428-215-965-010,Search Report,yes,3,0,9,9,0,G21D1/02;;G21D3/06;;G21C15/182;;Y02E30/30;;Y02E30/00;;G21D1/02;;G21D3/06;;Y02E30/30;;G21C15/182,G21D3/06;;G21C15/18;;G21D1/02,,0,0,,,,DISCONTINUED
8,TW,B,TW I601156 B,099-645-830-104-416,2017-10-01,2017,TW 102116408 A,2013-05-08,US 201213472724 A,2012-05-16,Heat transfer systems,,GE HITACHI NUCLEAR ENERGY AMERICAS LLC,AYER ROBERT;;GINSBERG ROBERT JOSEPH;;BASS JOHN ROBERT,,https://lens.org/099-645-830-104-416,Granted Patent,no,2,0,9,9,0,G21D1/02;;G21D3/06;;G21C15/182;;Y02E30/30;;Y02E30/00;;G21D1/02;;G21D3/06;;Y02E30/30;;G21C15/182,,,0,0,,,,INACTIVE
9,MX,A,MX 2013005539 A,159-206-456-678-910,2013-11-21,2013,MX 2013005539 A,2013-05-16,US 201213472724 A,2012-05-16,HEAT TRANSFER SYSTEMS AND METHODS FOR NUCLEAR PLANTS.,"A heat transfer system for a nuclear plant may include a piping system that includes first and second connectors, heat exchanger, pump, and power source. The heat transfer system may not be connected to the plant during normal power operations. The power source may be independent of a normal electrical power distribution system for the plant and may be configured to power the pump. The piping system may be configured to connect the heat exchanger and pump. The connectors may be configured to connect the heat transfer system to a fluid system of the plant. When the connectors connect the heat transfer system to the fluid system, the heat transfer system may be configured to receive fluid from the fluid system of the plant via the first connector, to pump the fluid through the heat exchanger, and to return the fluid to the fluid system via the second connector.",GE HITACHI NUCL ENERGY AMERICA,BASS JOHN ROBERT;;GINSBERG ROBERT JOSEPH;;AYER ROBERT,,https://lens.org/159-206-456-678-910,Patent Application,no,0,0,9,9,0,G21C15/182;;G21C15/182;;G21D1/02;;G21D1/02;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,F28D1/00;;G21C3/08;;G21C15/00,,0,0,,,,PENDING
10,TW,A,TW 201411644 A,074-237-554-480-721,2014-03-16,2014,TW 102116408 A,2013-05-08,US 201213472724 A,2012-05-16,Heat transfer systems and methods for nuclear plants,"A heat transfer system (400) for a nuclear plant may include a piping system (418) that includes first and second connectors (414, 416), heat exchanger (406), pump (402), and power source (420). The heat transfer system (400) may not be connected to the plant during normal power operations. The power source (420) may be independent of a normal electrical power distribution system for the plant and may be configured to power the pump (402). The piping system (418) may be configured to connect the heat exchanger (406) and pump (402). The connectors (414, 416) may be configured to connect the heat transfer system (400) to a fluid system (500, 600) of the plant. When the connectors connect the heat transfer system (400) to the fluid system, the heat transfer system (400) may be configured to receive fluid from the fluid system (500, 600) of the plant via the first connector (414), to pump the fluid through the heat exchanger (406), and to return the fluid to the fluid system (500, 600) via the second connector (416).",GE HITACHI NUCL ENERGY AMERICA,AYER ROBERT;;GINSBERG ROBERT JOSEPH;;BASS JOHN ROBERT,,https://lens.org/074-237-554-480-721,Patent of Addition,no,0,0,9,9,0,G21C15/182;;G21C15/182;;G21D1/02;;G21D1/02;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21C15/18;;G21D1/02;;G21D3/06,,0,0,,,,INACTIVE
11,JP,A,JP 2013238597 A,029-899-200-844-277,2013-11-28,2013,JP 2013100820 A,2013-05-13,US 201213472724 A,2012-05-16,HEAT TRANSFER SYSTEMS AND METHODS FOR NUCLEAR PLANTS,"PROBLEM TO BE SOLVED: To provide heat transfer systems which can supplement cooling and/or fluid movement capabilities of an FPC system and/or an RHR system.SOLUTION: The heat transfer system may include a piping system that includes first and second connectors, a heat exchanger, a pump, and a power source. The heat transfer system may not be connected to a nuclear plant during normal power operations. The power source may be independent of a normal electrical power distribution system for the nuclear plant and may be configured to power the pump. The piping system may be configured to connect the heat exchanger and the pump. The connectors may be configured to connect the heat transfer system to a fluid system of the nuclear plant. When the connectors connect the heat transfer system to the fluid system of the nuclear plant, the heat transfer system receives fluid from the fluid system of the nuclear plant via the first connector, pumps the fluid through the heat exchanger, and returns the fluid to the fluid system of the nuclear plant via the second connector.",GE HITACHI NUCL ENERGY AMERICA,ROBERT AYER;;ROBERT JOSEPH GINSBERG;;JOHN ROBERT BASS,,https://lens.org/029-899-200-844-277,Patent Application,no,8,1,9,9,0,G21C15/182;;G21C15/182;;G21D1/02;;G21D1/02;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21C15/18;;G21C19/07,,0,0,,,,INACTIVE
12,EP,A2,EP 2665067 A2,138-163-020-519-848,2013-11-20,2013,EP 13167939 A,2013-05-15,US 201213472724 A,2012-05-16,Heat transfer methods for nuclear plants,"A heat transfer system (400) for a nuclear plant may include a piping system (418) that includes first and second connectors (414, 416), heat exchanger (406), pump (402), and power source (420). The heat transfer system (400) may not be connected to the plant during normal power operations. The power source (420) may be independent of a normal electrical power distribution system for the plant and may be configured to power the pump (402). The piping system (418) may be configured to connect the heat exchanger (406) and pump (402). The connectors (414, 416) may be configured to connect the heat transfer system (400) to a fluid system (500, 600) of the plant. When the connectors connect the heat transfer system (400) to the fluid system, the heat transfer system (400) may be configured to receive fluid from the fluid system (500, 600) of the plant via the first connector (414), to pump the fluid through the heat exchanger (406), and to return the fluid to the fluid system (500, 600) via the second connector (416).
",GE HITACHI NUCL ENERGY AMERICA,AYER ROBERT;;GINSBERG ROBERT JOSEPH;;BASS JOHN ROBERT,,https://lens.org/138-163-020-519-848,Patent Application,yes,0,0,9,9,0,G21C15/182;;G21C15/182;;G21D1/02;;G21D1/02;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21D3/06;;G21C15/18;;G21D1/02,,0,0,,,,DISCONTINUED
13,US,A,US 3098951 A,176-979-479-951-060,1963-07-23,1963,US 84957759 A,1959-10-29,US 84957759 A,1959-10-29,Weldable circuit cards,,SIPPICAN CORP,AYER WILLIAM H;;JOSLIN ROBERT W,,https://lens.org/176-979-479-951-060,Granted Patent,no,16,37,1,1,0,H05K3/4092;;H05K3/4092;;H05K3/202;;H05K3/202;;H05K3/328;;H05K3/328;;H05K3/4084;;H05K3/4084;;H05K2201/0355;;H05K2201/0355;;H05K2201/0394;;H05K2201/0394;;H05K2203/063;;H05K2203/063;;H05K2203/1572;;H05K2203/1572;;H05K2203/308;;H05K2203/308,H05K3/20;;H05K3/32;;H05K3/40,,0,0,,,,EXPIRED
14,US,A,US 3425544 A,195-034-119-339-739,1969-02-04,1969,US 3425544D A,1965-10-14,US 49584165 A,1965-10-14,PACKAGE CONSTRUCTION,,REYNOLDS METALS CO,AYER RONALD M;;WALDROP ROBERT L,,https://lens.org/195-034-119-339-739,Granted Patent,no,13,66,1,1,0,B65D71/10;;B65D2571/00018;;B65D2571/00055;;B65D71/10;;B65D2571/00055;;B65D2571/00018,B65D71/00;;B65D71/10,206/45.33,0,0,,,,EXPIRED
15,US,A,US 5624818 A,197-801-644-735-040,1997-04-29,1997,US 25296694 A,1994-06-01,US 25296694 A;;US 22263894 A;;US 90371092 A;;US 75619591 A,1991-09-09,Nucleic acids encoding regulatory proteins that dimerize with Mad or Max,"An isolated nucleic acid molecule capable of hybridizing under stringent conditions to the mSinA nucleotide sequence shown in FIG. 22 (SEQ ID NO:11), the mSin9A nucleotide sequence shown in FIG. 28 (SEQ ID NO:17), and/or the mSinB nucleotide sequence shown in FIG. 30 (SEQ ID NO:19). This isolated nucleic acid molecule preferably encodes a recombinant polypeptide which associates with a Mad polypeptide to form a recombinant polypeptide:Mad complex, which preferably associates with a Max polypeptide to form a recombinant polypeptide:Mad:Max complex, which preferably binds to a nucleotide sequence comprising CACGTG (SEQ ID NO:16). An isolated nucleic acid molecule capable of hybridizing under stringent conditions to a nucleotide sequence selected from among clone 10 shown in FIG. 24 (SEQ ID NO:9), clone 18 shown in FIG. 25 (SEQ ID NO:10), clone 19 shown in FIG. 26 (SEQ ID NO:11), and clone 20 shown in FIG. 27 (SEQ ID NO:12). This isolated nucleic acid molecule preferably encodes a recombinant polypeptide capable of associating with a Max polypeptide.",HUTCHINSON FRED CANCER RES,EISENMAN ROBERT N;;AYER DONALD E,FRED HUTCHINSON CANCER RESEARCH CENTER (1994-07-07),https://lens.org/197-801-644-735-040,Granted Patent,yes,0,26,1,7,19,C07K14/47;;C07K14/47;;C07K2319/00;;C07K2319/00,C07K14/47,435/69.1;;435/70.1;;435/172.3;;435/252.3;;435/320.1;;536/23.1;;536/23.5;;935/11;;935/22;;935/70;;935/72,99,92,151-935-951-686-300;;035-316-229-595-163;;023-794-173-973-647;;093-133-080-463-93X;;180-117-052-710-490;;180-117-052-710-490;;045-601-754-501-044;;021-917-753-078-221;;116-871-010-760-311;;077-090-783-987-02X;;118-320-430-334-986;;066-268-422-666-147;;036-373-335-706-477;;074-779-163-920-28X;;038-676-233-566-46X;;076-488-794-670-902;;096-929-810-557-245;;108-001-492-437-103;;029-940-540-353-812;;095-847-321-987-644;;151-935-951-686-300;;052-371-366-724-492;;007-619-105-946-550;;007-569-182-093-069;;048-985-459-375-107;;010-970-933-506-776;;053-464-789-172-043;;006-440-539-265-596;;007-776-698-020-997;;053-037-422-527-227;;150-952-254-174-439;;004-356-634-663-90X;;102-081-322-136-206;;034-366-424-775-177;;015-478-680-154-959;;046-730-501-822-605;;052-400-209-971-49X;;021-448-907-232-465;;032-950-994-925-923;;069-053-391-190-801;;012-247-860-298-370;;086-668-187-648-747;;050-163-893-113-336;;037-242-349-071-747;;007-932-358-990-702;;023-925-347-823-954;;000-824-677-496-290;;051-714-932-203-110;;024-157-706-414-755;;020-837-219-579-134;;023-169-754-579-038;;011-396-276-332-501;;123-478-376-626-056;;012-895-985-398-733;;031-871-957-628-733;;078-004-019-449-915;;064-774-929-414-757;;012-694-327-057-901;;151-935-951-686-300;;103-459-012-469-898;;116-871-010-760-311;;045-970-126-218-540;;038-676-233-566-46X;;042-146-708-048-284;;096-258-342-947-386;;095-847-321-987-644;;003-792-012-617-84X;;089-934-889-044-508;;015-887-822-805-073;;006-838-665-358-187;;035-238-960-742-686;;010-285-809-622-459;;107-406-497-522-664;;099-732-635-317-040;;087-636-712-590-02X;;036-416-310-412-285;;015-868-459-397-517;;106-752-467-136-59X;;011-097-478-799-732;;131-006-122-471-01X;;125-735-679-846-491;;059-049-072-219-166;;019-733-483-400-736;;036-448-782-946-329;;048-292-965-725-972;;142-564-616-442-353;;030-302-593-603-802;;031-522-650-075-710;;012-024-963-832-136;;000-710-549-254-136;;102-903-021-601-055;;096-098-835-168-903,2269425;;10.1101/gad.4.12a.2025;;10.1128/mcb.7.5.1697;;pmc365270;;10.1128/mcb.7.5.1697-1709.1987;;3299053;;10.1016/0042-6822(89)90265-1;;2536982;;2668849;;2278885;;2278885;;pmc361227;;10.1128/mcb.10.10.5333-5339.1990;;10.1128/mcb.10.10.5333;;2204813;;10.1128/mcb.10.9.4961;;pmc361121;;2201910;;10.1128/mcb.10.9.4961-4966.1990;;10.1016/0092-8674(90)90207-u;;2180585;;2253873;;10.1101/gad.4.9.1454;;10.1016/0092-8674(89)90682-x;;2493990;;0002493990;;3175662;;10.1126/science.3175662;;pmc54189;;10.1073/pnas.87.12.4722;;2112746;;2503252;;10.1016/0092-8674(89)90434-0;;10.1016/0092-8674(90)90088-v;;2155707;;3289117;;10.1126/science.3289117;;0003289117;;10.1126/science.2911757;;2911757;;2683088;;10.1126/science.2683088;;10.1038/336646a0;;2974122;;10.1126/science.2251503;;2251503;;2269425;;10.1101/gad.4.12a.2025;;10.1016/s0065-230x(08)60200-6;;3096089;;10.1016/0092-8674(91)90641-b;;1988150;;10.1038/337664a0;;2645525;;10.1126/science.1987636;;1987636;;10.1128/mcb.11.2.954-962.1991;;pmc359758;;10.1128/mcb.11.2.954;;1990293;;10.1126/science.2174572;;2174572;;3142691;;10.1016/0092-8674(88)90146-8;;3142692;;10.1016/0092-8674(88)90147-x;;10.1126/science.3130660;;3130660;;10.1016/0092-8674(88)90077-3;;3135941;;3135940;;10.1016/0092-8674(88)90076-1;;6288259;;10.1016/0092-8674(82)90159-3;;6278322;;10.1038/296262a0;;pmc369080;;6513926;;10.1128/mcb.4.11.2486-2497.1984;;10.1128/mcb.4.11.2486;;pmc366736;;10.1128/mcb.5.3.448-456.1985;;3887132;;10.1128/mcb.5.3.448;;10.1128/mcb.6.12.4450;;pmc367228;;10.1128/mcb.6.12.4450-4457.1986;;3796607;;pmc365511;;3054516;;10.1128/mcb.8.10.4381-4388.1988;;10.1128/mcb.8.10.4381;;pmc362320;;2668734;;10.1128/mcb.9.6.2477;;10.1128/mcb.9.6.2477-2486.1989;;10.1002/j.1460-2075.1989.tb03359.x;;pmc400783;;2540955;;6606489;;10.1016/0092-8674(83)90092-2;;3302722;;10.1038/328445a0;;10.1016/0168-9525(90)90169-7;;10.1016/0092-8674(88)90507-7;;3277717;;2537150;;10.1016/0092-8674(89)90583-7;;10.1002/j.1460-2075.1990.tb08126.x;;2303035;;pmc551682;;10.1101/gad.4.10.1730;;2249772;;10.1101/gad.4.10.1741;;2123466;;10.1002/j.1460-2075.1989.tb03481.x;;2663470;;pmc400922;;2503872;;10.1126/science.2503872;;10.1016/0092-8674(88)90506-5;;3124961;;2233723;;10.1128/mcb.10.11.5914;;pmc361386;;10.1128/mcb.10.11.5914-5920.1990;;10.1038/312280a0;;6438521;;10.1101/gad.1.4.347;;3678827;;10.1128/jvi.62.12.4533-4537.1988;;pmc253563;;2972842;;3050531;;10.1038/335683a0;;3367995;;10.1038/333210a0;;2667136;;10.1126/science.2667136;;2269425;;10.1101/gad.4.12a.2025;;2133113;;10.1016/0092-8674(90)90207-u;;2180585;;2156629;;10.1016/0092-8674(90)90214-y;;10.1016/0092-8674(90)90088-v;;2155707;;10.1126/science.2006410;;2006410;;10.1016/0092-8674(91)90457-a;;1840505;;10.1126/science.2251503;;2251503;;10.1128/mcb.8.6.2504;;pmc363451;;3043180;;10.1128/mcb.8.6.2504-2512.1988;;10.1038/314366a0;;3885045;;4065102;;pmc554455;;10.1002/j.1460-2075.1985.tb03885.x;;3982504;;10.1038/314363a0;;6313208;;10.1016/0092-8674(83)90535-4;;2028839;;10.1016/s0065-230x(08)60476-5;;10.1002/j.1460-2075.1983.tb01750.x;;pmc555461;;6321165;;2660073;;10.1038/310655a0;;6088986;;10.1073/pnas.83.21.8167;;3490663;;pmc386888;;10.1128/mcb.6.3.870;;10.1128/mcb.6.3.870-877.1986;;3022135;;pmc367587;;10.1038/320760a0;;3458027;;3093082;;10.1016/0092-8674(86)90361-2;;10.1128/mcb.8.4.1614;;2454393;;10.1128/mcb.8.4.1614-1624.1988;;pmc363321;;10.1016/0022-2836(88)90558-x;;3172238;;6308472;;10.1038/304596a0;;3032456;;10.1016/0092-8674(87)90449-1;;2537153;;10.1016/0092-8674(89)90589-8;;3278812;;10.1016/0092-8674(88)90398-4;;1737614;;10.1101/gad.6.2.166;;1565473;;10.1101/gad.6.1.71;;1730411;;10.1101/gad.6.1.81;;1730412;;1566084;;10.1126/science.256.5055.373;;10.1016/0092-8674(91)90377-b;;2040011;;1630816,"Ayen et al. (1983) Cell vol. 72, pp. 211 222.;;Luscher, B. and R.N. Eisenman, Genes Dev. 4, 2025 (1990).;;Stone, J. et al., Mol. Cell. Biol . 7, 1697 (1987).;;Enrietto, P.J., Virology 168, 256 (1989).;;Nakajima, H., M. Ikeda, N. Tsuchida, S. Nishimura, Y. Taya, Oncogene 4, 999 (1989).;;Crouch, D.H., C. Lang, D.A.F. Gillespie. Definition of the activities and properties of c myc required to inhibit cell differentiation. Oncogene 5, 683 (1990).;;Freytag, S.O., C.V. Dang, W.M.F. Lee, Cell Growth Differ . 1, 339 (1990).;;Smith, M.J., D.C. Charron Prochownik, E.V. Prochownik, Mol. Cell. Biol . 10, 5333 (1990).;;Penn, L.J.Z. et al., Mol. Cell. Biol . 10, 4961 (1990).;;Jones, N. Transcriptional regulation by dimerization: two sides to an incestuous relationship. Cell 61, 9 11 (1990).;;Olson, E.N., Genes Dev . 4, 1454 (1990).;;Murre, C., P.S. McCaw, D. Baltimore. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56, 777 783 (1989).;;Tapscott, S.J., Davis, R.L., Thayer, M.J., Cheng, P.F. Weintraub, H., and Lassar, A.B. A nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 242, 405 411 (1988).;;Voronova, A. and D. Baltimore, Proc. Natl. Acad. Sci. U.S.A. 87, 4722 (1990).;;Murre, C., McCaw, P.S., Vaessin, H., Caudy, M., Jan, L.Y., Jan, Y.N., Cabrera, C.V., Buskin, J.N., Hauschka, S.D., Lassar, A.B., Weintraub, H. and D. Baltimore. Interactions between heterologous helix loop helix proteins generates complexes that bind specifically to a common DNA sequence. Cell 58, 537 544 (1989).;;Davis, R.L., P. F. Cheng, A.B. Lassar, H. Weintraub, Cell . 60, 733 (1990).;;Landschulz, W.H., P.F. Johnson, S.L. McKnight. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240, 1759 1764 (1988).;;O Shea, E.K., R.H. Rutkowski, P.S. Kim. Evidence that the leucine zipper is a coiled coil. Science 243, 538 542 (1989).;;Vinson, C.R., P.B. Sigler, S.L. McKnight, Science 246, 911 (1989).;;Kouzarides, T. and E. Ziff. The role of the leucine zipper in the fos jun interaction. Nature 336, 646 651 (1988).;;Blackwell, T.K., L. Kretzner, E.M. Blackwood, R.N. Eisenman, H. Weintraub. Sequence specific DNA binding by the c Myc protein. Science 250, 1149 (1990).;;Luscher, B. and R.N. Eisenman. New Light on Myc and Myb. Part I. Myc. Genes Dev . 4(12a):2025 2035 (1990).;;Cory, S. Activation of cellular oncogenes in hematopoietic cells by chromosome translocation. Advances in Cancer Research . 1986.;;Eisenman, R.N. Nuclear Oncogenes In: Oncogenes and the Molecular Origins of Cancer . (R. Weinberg, Ed.) Cold Spr. Harbor Press, Cold Springs, N.Y. pp. 175 221 (1989).;;Magrath, I. The pathogenesis of Burkitt s lymphoma. Adv. Cancer Res . 55:134 251 (1990).;;Marshall, C.J. Tumor suppressor genes. Cell . 64(2):313 326, 1991.;;Dang, C.V., M. McGuire, M. Buckmire, W.M.F. Lee, Nature 337, 664 666 (1989).;;Prendergast, G. and E. Ziff. Methylation sensitive sequence specific DNA binding by the c yc basic region. Science 251, 186 189 (1991).;;Dang, C.V., Barrett, J., Villa Garcia, M., Resar, L.M.S., Kato, G.J. and Fearon, E.R. Intracellular leucine zipper interactions suggest c Myc hetero oligonmerization. Mol. Cell. Biol . 11, 954 962 (1991).;;Blackwell, T.K. and H. Weintraub, Science 250, 1104 (1990).;;Nakabeppu, Y., K. Ryder, D. Nathans, Cell 55, 907 (1988).;;Halazonetis, T.D., K. Georgopoulos, M.E. Greenberg, P. Leder, Cell 55, 917 (1988).;;Rauscher, F.J. III et al., Science 240, 1010 (1988).;;Sassone Corsi, P., W.W. Lamph, M. Kamps, I.M. Verma, Cell 54, 553 (1988).;;Chiu, R. et al., Cell 54, 541 (1988).;;Abrams, H., L. Rohrschneider, R.N. Eisenman, Cell 29, 427 (1982).;;Donner, P., I. Greiser Wilke, K. Moelling Nature 296, 262 (1982).;;Hann, S.R. and R.N. Eisenman, Mol. Cell. Biol . 4, 2486 (1984).;;Watt, R.A., A.R. Shatzman, M. Rosenberg, Mol. Cell. Biol . 5, 448 (1985).;;Ramsay, G., L. Stanton, M. Schwab, J.M. Bishop, Mol. Cell. Biol . 6, 4450 (1986).;;De Greve, J. et al., Mol. Cell. Biol .. 8, 4381 (1988).;;Dang, C.V., H.V. Dam, M. Buckmire, W.M.F. Lee, Mol. Cell. Biol . 9, 2477 (1989).;;Saksela, K., T.P. Makela, G. Evan, K. Alitalo, EMBO J . 8, 149 (1989).;;Kelly, K.,B.H. Cochran, C.D. Stiles and P. Leder. Cell specific regulation of the c myc gene by lymphocyte mitogens and platelet derived growth factor. Cell 35:603 610(1983).;;Heikkila, R., G. Schwab, E. Wickstrom, S.L. Loke, D.H. Pluznik, R. Watt and L.M. Neckers. A c myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature . 328:445 449 (1987).;;Macgregor, P.F., C. Abate, T. Curran Oncogene 5, 451 (1990).;;Hann, S.R., M.W. King, D.L. Bentley, C.W. Anderson, R.N. Eisenman, Cell 52, 185 (1988).;;Wright, W.E., D.A. Sassoon, V.K. Lin, Cell 56, 607 (1989).;;Chen, Q. et al., EMBO 9, 415 (1990).;;Gregor, P.D., M.Sawadogo, R.G.Roeder, Genes & Development 4: 1740 (1990).;;Hu, Y. F., B. Luscher, A. Admon, N. Mermod, R. Tijan. Transcription factor AP 4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev . 4, 1741 (1990).;;Luscher, B., E.A. Kuenzel, E.G. Krebs, R.N. Eisenman, EMBO J . 8, 1111 (1989).;;O Shea, E.K., R. Rutkowski, W.F. Stafford III, P.S. Kim, Science 245, 646 (1989).;;Lech, K., K. Anderson, R. Brent, Cell 52, 179 (1988).;;Kato, G.J., J. Barrett, M. Villa Garcia, C.V. Dang. An amino terminal c Myc domain required for neoplastic transformation activates transcription. Mol. Cell. Biol . 10, 5914 5920 (1990).;;Kingston, R.E., A.S. Baldwin, P.A. Sharp, Nature 312, 280 (1984).;;Kaddurah Daouk, R., J.M. Greene, A.S. Baldwin, R.E. Kingston, Genes Dev . 1, 347(1987).;;Onclercq, R., P. Gilardi, A. Lavenu, C. Cremisi, J. Virol . 62, 4533 (1988).;;Ptashne, M. Nature 335, 683 (1988).;;Sigler, P.B. Nature 333, 210 (1988).;;Mitchell, P.J. and R. Tijan, Science 245, 371 (1989).;;Luscher, B., R. N. Eisenman, Genes Dev . 4, 2025 (1990).;;Penn, L.J.Z., E.M. Laufer, H. Land, Semin. Cancer Biol . 1, 69 (1990).;;Jones, N. Cell 61, 9 (1990).;;Benezra, R., R. L. Davis, D. Lockshon, D. L. Turner, H. Weintraub, Cell 61, 49 (1990).;;Davis, R. L., Cheng, P. F., Lassar, A. B., & Weintraub, H., Cell 60, 733 (1990).;;Blackwood, E.M., R. N. Eisenman. Max: a helix loop helix zipper protein that forms a sequence specific DNA binding complex with Myc. Science 251, 1211 1217 (1991).;;Prendergast, G.C., D. Lawe, E. B. Ziff, Cell 65, 395 (1991).;;Blackwell, T.K., L. Kretzner, E. M. Blackwood, R. N. Eisenman, H. Weintraub, Science 250, 1149 (1990).;;Luscher, B., R.N. Eisenman, Mol. Cell. Biol . 8, 2504 (1988).;;Hann, S.R., C.B. Thompson, R.N. Eisenman, Nature 314, 366 (1985).;;Rabbitts, P.H., Watson, J.V., Lamond, A., Forster, A., Stinson, M.A., Evan, G., Fischer, W., Atherton, E., Sheppard, R. and Rabbitts, T.H. Metabolism of c Myc products: c Myc mRNA and protein expression in the cell cycle. EMBO J. 4, 2009 2015 (1985).;;Thompson, C.B., P. B. Challoner, P. E. Neiman, M. Groudine, Nature 314, 363 (1985).;;Smith, M.J., D.C. Charron Prochownik, E. V. Prochownik, Mol. Cell. Biol . 10, 5333 (1990).;;Hann, S.R., H. D. Abrams, L. R. Rohrschenider, R. N. Eisenman, Cell 34, 789 (1983).;;Ramsay, G., L. Stanton, M. Schwab, J. M. Bishop, Mol. Cell. Biol . 6, 4450 (1986).;;Spencer, C.A., M. Groudine, Adv. Cancer Res . 56, 1 (1990).;;Palmieri, S., P. Kahn, and T. Graf. Quail embryo fibroblasts transformed by four v myc containing virus isolates show enhanced proliferation but are non tumorigenic. EMBO J . 2:2385 (1983).;;Karn, J., J.V. Watson, A.D. Lowe, S.M. Green, and W. Vedeckis. Regulation of cell cycle duration by c myc levels. Oncogene 4:773 (1989).;;Armelin, H.A., M.C.S. Armelin, K. Kelly, T. Stewart, P. Leder, B.H. Cochran, and C.D. Stiles. Functional role for c myc in mitogenic response to platelet derived growth factor. Nature 310:655 (1984).;;Sorrentino, V., V. Drosdoff, M.D. McKinney, L. Zeitz, and E. Fleissner. Potentiation of growth factor activity by exogenous c myc expression. Proc. Natl. Acad. Sci . 83:8167 (1986).;;Stern, D., A. Roberts, N.S. Roche, M.B. Sporn, and R.A. Weinberg. Differential responsiveness of myc and ras transfected cells to growth factors: Selective stimulation of myc transfected cells by epidermal growth factors. Mol. Cell. Biol . 6:870 (1986).;;Coppola, J.A. and M.D. Cole. Constitutive c myc oncogene expression blocks mouse erythroleukemia cell differentiation but not commitment. Nature 320:760 (1989).;;Langdon, W.Y., A.W. Harris, S. Cory, and J.M. Adams. The c myc oncogene perturbs B lymphocyte development in Eu myc transgenic mice. Cell 47:11 (1986).;;Freytag, S. Enforces expression of the c myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in Go/G1. Mol. Cell. Biol . 8:1614 (1988).;;Kume, T.U., S. Takada, and M. Obinata. Probability that the commitment of murine erythroleukemia cell differentiation is determined by the c myc level. J. Mol. Biol . 202:779 (1988).;;Land, H., L.F. Parada, and R.A. Weinberg. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596 (1983).;;Sinn, E., W. Muller, P. Pattengale, I. Tepler, R. Wallace, and P. Leder. Coexpression of MMTV/v Ha ras and MMTV/c myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465 (1987).;;van Lohuizen, M., S. Verbeek, P. Krimpenfort, J. Domen, C. Saris, T. Radaszkiewicz, and A. Berns. Predisposition to lymphomagenesis in pim 1 transgenic mice: Cooperation with c myc and N myc in murine leukemia virus induced tumors. Cell 56:673 (1989).;;Weinberg, R.A. 1989. Oncogenes and multistep carcinogenesis. In Oncogenes and the molecular origins of cancer (ed. R.A. Weinberg), p. 307. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.;;DePamphilis, M.L. Transcriptional elements as components of eukaryotic origins of DNA replication. Cell 52:635 (1988).;;Berberich, S.J. and Cole, M.D. Casein kinase II inhibits the DNA binding activity of Max homodimers but not Myc/Max heterodimers. Genes Dev. 6, 166 176 (1992).;;Berberich, S., Hyde DeRuyscher, N., Espenshade, P., and Cole, M.D. Max encodes a sequence specific DNA binding protein and is not regulated by serum growth factors. Oncogene 4, 775 779 (1992).;;Blackwood, E.M., Luscher, B. and Eisenman, R.N. Myc and Max assocaite in vivo. Genes Dev. 6, 71 80 (1992a).;;Kato, G.J., Lee, W.M.F., Chen, L., and Dang, C.V. Max: Functional domains and interaction with c Myc. Genes Dev. 6: 81 92 (1992).;;Makela, T.P., Koskinen, P.J., Vastrik, I., and Alitalo, K. Alternative forms of Max as enhancers or suppressors of Myc Ras cotransformation. Science 256, 373 377 (1992).;;Cole, M.D. Myc meets its max. Cell 65, 715 716 (1991).;;Min, S., Taparowsky, E.J. v Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation. Oncogene 7, 1531 1540 (1992).;;Wang et al., Mol. Cell. Biol. 1, 5927 (1990).",EXPIRED
16,US,A,US 1925080 A,018-655-134-643-353,1933-09-05,1933,US 60537032 A,1932-04-15,US 60537032 A,1932-04-15,Retractable landing gear,,MANNING & CO,AYER ROBERT W;;IRVINE CHARLES R,,https://lens.org/018-655-134-643-353,Granted Patent,no,0,3,1,1,0,B64C25/20;;B64C25/20,B64C25/20,,0,0,,,,EXPIRED
17,US,A1,US 2016/0118148 A1,161-566-509-612-597,2016-04-28,2016,US 201514883414 A,2015-10-14,US 201514883414 A;;US 201213472724 A,2012-05-16,HEAT TRANSFER METHODS FOR NUCLEAR PLANTS,A method of transferring heat from a nuclear plant may include: connecting a heat transfer system to the nuclear plant; and using the heat transfer system to transfer heat from the nuclear plant. The heat transfer system may include: a piping system that includes first and second connectors; a heat exchanger; a pump; and a power source. The heat transfer system may not be connected to the nuclear plant during normal plant power operations. The power source may be independent of a normal electrical power distribution system for the nuclear plant. The power source may be configured to power the pump. The piping system may be configured to connect the heat exchanger and pump. The first and second connectors may be configured to connect the heat transfer system to a fluid system of the nuclear plant.,AYER ROBERT A;;GINSBERG ROBERT J;;BASS JOHN R;;GE HITACHI NUCL ENERGY AMERICA,AYER ROBERT A;;GINSBERG ROBERT J;;BASS JOHN R,,https://lens.org/161-566-509-612-597,Patent Application,yes,1,0,9,9,0,G21C15/182;;G21C15/182;;G21D1/02;;G21D1/02;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21C15/18;;G21D1/02;;G21D3/06,,1,0,,,"Doughton, Sandi. Washington's Hanford nuclear plant has more backup. 14 March 2011. The Seattle Times. available online: <http://www.seattletimes.com/seattle-news/washingtons-hanford-nuclear-plant-has-more-backup/>.",DISCONTINUED
18,US,A1,US 2013/0308738 A1,154-323-594-671-195,2013-11-21,2013,US 201213472724 A,2012-05-16,US 201213472724 A,2012-05-16,HEAT TRANSFER SYSTEMS AND METHODS FOR NUCLEAR PLANTS,"A heat transfer system for a nuclear plant may include a piping system that includes first and second connectors, heat exchanger, pump, and power source. The heat transfer system may not be connected to the plant during normal power operations. The power source may be independent of a normal electrical power distribution system for the plant and may be configured to power the pump. The piping system may be configured to connect the heat exchanger and pump. The connectors may be configured to connect the heat transfer system to a fluid system of the plant. When the connectors connect the heat transfer system to the fluid system, the heat transfer system may be configured to receive fluid from the fluid system of the plant via the first connector, to pump the fluid through the heat exchanger, and to return the fluid to the fluid system via the second connector.",AYER ROBERT A;;GINSBERG ROBERT J;;BASS JOHN R;;GE HITACHI NUCL ENERGY AMERICA,AYER ROBERT A;;GINSBERG ROBERT J;;BASS JOHN R,GE-HITACHI NUCLEAR ENERGY AMERICAS LLC (2012-04-23),https://lens.org/154-323-594-671-195,Patent Application,yes,1,0,9,9,0,G21C15/182;;G21C15/182;;G21D1/02;;G21D1/02;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21C9/00,376/299,0,0,,,,DISCONTINUED
19,TW,A,TW 201341669 A,073-468-956-163-245,2013-10-16,2013,TW 101148506 A,2012-12-19,US 201113340675 A,2011-12-30,Methods and apparatuses for pump sealing during leakage events,"A pump leakage mitigation device includes one or more clamp arms on an outer surface of a pump that can be driven by a biasing element to seat against a shaft of the pump to seal or reduce fluid flow through a breakdown orifice of the pump. The biasing element engages only at threshold temperatures, such as those associated with breakdown orifice failure when additional sealing may be necessary. Clamp arms of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump.",GE HITACHI NUCL ENERGY AMERICA,BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,,https://lens.org/073-468-956-163-245,Patent of Addition,no,0,0,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,F04D27/00;;F04D29/10;;G21C13/10;;G21D1/04,,0,0,,,,ACTIVE
20,JP,A,JP 2013152222 A,136-848-924-895-941,2013-08-08,2013,JP 2012271856 A,2012-12-13,US 201113340675 A,2011-12-30,METHOD AND APPARATUS FOR PUMP SEALING IN LEAKAGE SITUATION,"PROBLEM TO BE SOLVED: To provide seals for a nuclear power plant, which can reinforce a seal function even at a high temperature.SOLUTION: One or more clamp arm parts 120 to be driven by each energization element 110 are provided against a shaft 11 of a pump, and the energization element 110 drives the clamp arm part 120 in accordance with a temperature related to a failure of a function stop aperture 13 and enhances blockage of a fluid flow. Destruction or disassembly of the pump is unnecessary and attachment, actuation, operation, release and/or removal of the pump can be achieved.",GE HITACHI NUCL ENERGY AMERICA,JOHN R BASS;;ROBERT A AYER;;ROBERT J GINSBERG;;CURT J ROBERT,,https://lens.org/136-848-924-895-941,Patent Application,no,13,1,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,G21C15/24;;F04D29/08;;F04D29/14;;G21C15/18;;G21C15/243;;G21C15/25;;G21D1/04,,0,0,,,,ACTIVE
21,US,B2,US 10777329 B2,041-618-288-979-088,2020-09-15,2020,US 201113340675 A,2011-12-30,US 201113340675 A,2011-12-30,Methods and apparatuses for pump sealing during leakage events,"A pump leakage mitigation device includes one or more clamp arms on an outer surface of a pump that can be driven by a biasing element to seat against a shaft of the pump to seal or reduce fluid flow through a breakdown of the pump. The biasing element engages only at threshold temperatures, such as those associated with breakdown orifice failure when additional sealing may be necessary. Clamp arms of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump.",BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J;;GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,GE-HITACHI NUCLEAR ENERGY AMERICAS LLC (2012-01-06),https://lens.org/041-618-288-979-088,Granted Patent,yes,20,0,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,F04D29/10;;F04D15/00;;F04D29/14;;F16J15/00;;F16J15/16;;G21C15/243;;G21D1/04,,5,0,,,"Westinghouse, “Shield Passive Thermal Shutdown Seal for Reactor Coolant Pumps,” Product Brochure, Apr. 2011, 2 pages.;;English translation of Preliminary Rejection in corresponding Japanese Application 2013-254679, dated Nov. 4, 2014.;;Office Action in corresponding Mexican Application MX/a/2012/014743, dated Mar. 3, 2016.;;European Search Report and Opinion issued in connection with corresponding EP Application No. 12197449.7 dated Nov. 25, 2016.;;Unofficial English Translation of Japanese Search Report issued in connection with corresponding JP Application No. 2012-271856 dated Nov. 30, 2016.",ACTIVE
22,US,A1,US 2013/0170594 A1,014-952-208-734-115,2013-07-04,2013,US 201113340675 A,2011-12-30,US 201113340675 A,2011-12-30,METHODS AND APPARATUSES FOR PUMP SEALING DURING LEAKAGE EVENTS,"A pump leakage mitigation device includes one or more clamp arms on an outer surface of a pump that can be driven by a biasing element to seat against a shaft of the pump to seal or reduce fluid flow through a breakdown of the pump. The biasing element engages only at threshold temperatures, such as those associated with breakdown orifice failure when additional sealing may be necessary. Clamp arms of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump.",BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,GE-HITACHI NUCLEAR ENERGY AMERICAS LLC (2012-01-06),https://lens.org/014-952-208-734-115,Patent Application,yes,13,11,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,G21C13/10;;F04D29/10,376/203;;415/231,0,0,,,,ACTIVE
23,TW,B,TW I644024 B,067-185-481-935-901,2018-12-11,2018,TW 101148506 A,2012-12-19,US 201113340675 A,2011-12-30,Methods and apparatuses for pump sealing during leakage events,,GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,,https://lens.org/067-185-481-935-901,Granted Patent,no,5,0,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,,,0,0,,,,ACTIVE
24,EP,A2,EP 2610876 A2,147-921-359-271-825,2013-07-03,2013,EP 12197449 A,2012-12-17,US 201113340675 A,2011-12-30,Methods and apparatuses for pump sealing during leakage events,"A pump leakage mitigation device includes one or more clamp arms (120) on an outer surface of a pump (10) that can be driven by a biasing element (110) to seat against a shaft (11) of the pump (10) to seal or reduce fluid flow through a breakdown of the pump (10). The biasing element (110) engages only at threshold temperatures, such as those associated with breakdown orifice failure (12) when additional sealing may be necessary. Clamp arms (120) of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface (125) and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump (10).
",GE HITACHI NUCL ENERGY AMERICA,BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,,https://lens.org/147-921-359-271-825,Patent Application,yes,0,2,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,G21D1/04;;F04C27/00;;F04D29/10,,0,0,,,,DISCONTINUED
25,MX,B,MX 343079 B,093-033-102-132-093,2016-10-24,2016,MX 2012014743 A,2012-12-14,US 201113340675 A,2011-12-30,METHODS AND APPARATUSES FOR PUMP SEALING DURING LEAKAGE EVENTS.,"A pump leakage mitigation device includes one or more clamp arms on an outer surface of a pump that can be driven by a biasing element to seat against a shaft of the pump to seal or reduce fluid flow through a breakdown of the pump. The biasing element engages only at threshold temperatures, such as those associated with breakdown orifice failure when additional sealing may be necessary. Clamp arms of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump.",GE HITACHI NUCLEAR ENERGY AMERICAS LLC,JOHN R BASS;;ROBERT J GINSBERG;;ROBERT A AYER;;CURT J ROBERT,,https://lens.org/093-033-102-132-093,Granted Patent,no,0,0,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,G21C13/10;;F04D29/10,,0,0,,,,ACTIVE
26,MX,A,MX 2012014743 A,172-912-908-701-050,2013-07-01,2013,MX 2012014743 A,2012-12-14,US 201113340675 A,2011-12-30,METHODS AND APPARATUSES FOR PUMP SEALING DURING LEAKAGE EVENTS.,"A pump leakage mitigation device includes one or more clamp arms on an outer surface of a pump that can be driven by a biasing element to seat against a shaft of the pump to seal or reduce fluid flow through a breakdown of the pump. The biasing element engages only at threshold temperatures, such as those associated with breakdown orifice failure when additional sealing may be necessary. Clamp arms of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump.",GE HITACHI NUCL ENERGY AMERICA,BASS JOHN R;;GINSBERG ROBERT J;;AYER ROBERT A;;ROBERT CURT J,,https://lens.org/172-912-908-701-050,Patent Application,no,0,0,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,F16J15/32;;F04B53/00;;F16J15/08;;F16J15/43;;F16J15/54,,0,0,,,,ACTIVE
27,US,A1,US 2020/0395139 A1,103-816-445-052-257,2020-12-17,2020,US 202017004949 A,2020-08-27,US 202017004949 A;;US 201113340675 A,2011-12-30,METHODS AND APPARATUSES FOR PUMP SEALING DURING LEAKAGE EVENTS,"A pump leakage mitigation device includes one or more clamp arms on an outer surface of a pump that can be driven by a biasing element to seat against a shaft of the pump to seal or reduce fluid flow through a breakdown of the pump. The biasing element engages only at threshold temperatures, such as those associated with breakdown orifice failure when additional sealing may be necessary. Clamp arms of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump.",GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,GE-HITACHI NUCLEAR ENERGY AMERICAS LLC (2012-01-06),https://lens.org/103-816-445-052-257,Patent Application,yes,0,0,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,G21D1/04;;F04D15/00;;F04D29/10;;F04D29/14;;F16J15/00;;F16J15/16;;G21C15/243,,0,0,,,,DISCONTINUED
28,EP,A3,EP 2610876 A3,039-220-103-419-243,2016-12-28,2016,EP 12197449 A,2012-12-17,US 201113340675 A,2011-12-30,Methods and apparatuses for pump sealing during leakage events,"A pump leakage mitigation device includes one or more clamp arms (120) on an outer surface of a pump (10) that can be driven by a biasing element (110) to seat against a shaft (11) of the pump (10) to seal or reduce fluid flow through a breakdown of the pump (10). The biasing element (110) engages only at threshold temperatures, such as those associated with breakdown orifice failure (12) when additional sealing may be necessary. Clamp arms (120) of any number and shape can be used to achieve the desired seal and based on the pump geometry. A sealant surface (125) and/or keeping mechanism are useable with the leakage mitigation device to enhance fluid flow blockage throughout a pump failure transient scenario. Pump leakage mitigation devices are installed on an outside of a variety of different pump types and can thus be installed, actuated, manipulated, disengaged, and/or removed without having to destroy or disassemble the pump (10).
",GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN R;;AYER ROBERT A;;GINSBERG ROBERT J;;ROBERT CURT J,,https://lens.org/039-220-103-419-243,Search Report,yes,4,0,11,11,0,G21D1/04;;F04D15/0077;;F04D29/106;;F04D29/146;;F16J15/008;;F16J15/164;;G21C15/243;;Y02E30/30;;Y02E30/00;;G21D1/04;;F04D29/106;;F04D29/146;;F04D15/0077;;F16J15/164;;F16J15/008;;G21C15/243;;Y02E30/30,G21D1/04;;F04C27/00;;F04D29/10,,0,0,,,,DISCONTINUED
29,DE,B,DE 1192712 B,164-745-458-708-662,1965-05-13,1965,DE S0075497 A,1961-08-29,DE S0075497 A;;GB 2986061 A;;CA 721855T A,1961-08-18,Richtungskoppler,,SANDERS ASSOCIATES INC,AYER DONALD RODNER;;BUTLER JESSE LORENZO;;WILLISTON ROBERT LINCOLN,,https://lens.org/164-745-458-708-662,Patent Application,no,1,0,3,3,0,H01P5/04,H01P5/04,,0,0,,,,DISCONTINUED
30,GB,A,GB 942712 A,092-211-230-810-090,1963-11-27,1963,GB 2986061 A,1961-08-18,GB 2986061 A;;DE S0075497 A;;CA 721855T A,1961-08-18,A variable transmission line coupler,"942,712. Directional couplers. SANDERS ASSOCIATES Inc. Aug. 18, 1961, No. 29860/61. Heading H1W. A variable directional coupler for twoconductor transmission lines comprises means for varying the spacing of the conductors of the respective lines within a coupling section. The invention may be applied to the type of strip line comprising a single inner strip conductor arranged between a pair of broad outer conductors forming a common "" ground."" As shown, the inner conductors 30, 36 (Figs. 2, 3), of the coupled lines share the same pair 22, 24 of ground conductors and variation in coupling (max. of 3 db.) is obtained by lateral movement of the conductor 36 between the positions shown in whole and broken lines (Fig. 2). As the conductor 36 approaches the conductor 30 the capacitance of both lines increases within the coupling section causing mismatch between this section and the output and input sections. In order to avoid this, conductor 36 is associated with a fixed compensatory conductor 27 and conductor 30 with a compensating conductor 26 which moves with the conductor 36. Thus, as the coupled conductors approach each other they withdraw from the region of their compensatory conductors and the capacitance within the coupled section remains constant. The fixed and movable conductors, respectively 27, 30 and 26, 36, may be mounted on dielectric blocks 18, 20 (Figs. 6, 7), arranged within relatively movable, recessed, conductive members 42, 44 which provide the common ground planes of the coupled lines. The member 42 forms the lid of a box 46 and the member 44 is arranged for lateral movement within the box. This is effected by means of a lead-screw and cam mechanism 82, 86. Terminals 56, 58 for the two lines are arranged on the lid 42, the terminals 58 associated with the movable line being connected to sliding contacts 60. Contact pressure between members 42 and 44 is provided by a pair of short resilient tubes (Fig. 5, not shown), mounted between member 44 and the base of the box. The tubes are arranged with their axes perpendicular to the direction of motion of the member 44 and have sufficient resilience to permit this motion.",SANDERS ASSOCIATES INC,AYER DONALD RODNER;;BUTLER JESSE LORENZO;;WILLISTON ROBERT LINCOLN,,https://lens.org/092-211-230-810-090,Granted Patent,no,0,1,3,3,0,H01P5/04,H01P5/04,H1W WCAA          WCAA,0,0,,,,EXPIRED
31,CA,A,CA 721855 A,123-687-565-212-339,1965-11-16,1965,CA 721855D A,,CA 721855T A;;DE S0075497 A;;GB 2986061 A,1961-08-18,VARIABLE TRANSMISSION LINE COUPLER,,SANDERS ASSOCIATES INC,BUTLER JESSE L;;AYER DONALD R;;WILLISTON ROBERT L,,https://lens.org/123-687-565-212-339,Granted Patent,no,0,0,3,3,0,H01P5/04,H01P5/04,,0,0,,,,EXPIRED
32,US,A,US 2827911 A,196-244-044-770-082,1958-03-25,1958,US 43211854 A,1954-05-25,US 43211854 A,1954-05-25,Fluid pressure regulating valve,,KENYON INSTR COMPANY INC,AYER ROBERT W;;STAFFORD PARIS H;;JONES DAVID W,,https://lens.org/196-244-044-770-082,Granted Patent,no,5,6,1,1,0,G05D16/10;;G05D16/10;;G05D16/2086;;Y10T137/2012;;Y10T137/2012;;Y10T137/7771;;Y10T137/7771;;Y10T137/7782;;Y10T137/7782,G05D16/10,,0,0,,,,EXPIRED
33,US,A,US 3095544 A,012-446-937-774-18X,1963-06-25,1963,US 3510260 A,1960-05-10,US 3510260 A,1960-05-10,Variable transmission line coupler,,SANDERS ASSOCIATES INC,AYER DONALD R;;BUTLER JESSE L;;WILLISTON ROBERT L,,https://lens.org/012-446-937-774-18X,Granted Patent,no,3,6,1,1,0,H01P3/085;;H01P3/085;;H01P5/04;;H01P5/04,H01P3/08;;H01P5/04,,0,0,,,,EXPIRED
34,ES,R1,ES 2458920 R1,047-460-065-440-430,2014-11-13,2014,ES 201331302 A,2013-09-04,US 201213611384 A,2012-09-12,Procedimiento y sistema de eliminación de calor de contención de un reactor nuclear de agua en ebullición alternativo,,GE HITACHI NUCL ENERGY AMERICA,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M,,https://lens.org/047-460-065-440-430,Unknown,no,4,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C15/18,,0,0,,,,ACTIVE
35,JP,A,JP 2014055947 A,010-579-620-147-395,2014-03-27,2014,JP 2013185807 A,2013-09-09,US 201213611384 A,2012-09-12,METHOD AND SYSTEM FOR ALTERNATIVE BWR CONTAINMENT HEAT REMOVAL,PROBLEM TO BE SOLVED: To provide an alternative cooling system used to cool a reactor pressure suppression pool of a boiling water reactor (BWR).SOLUTION: The cooling system includes a cooling coil in an isolation condenser 20 located at an elevation that is above the pressure suppression pool 2. The isolation condenser 20 is connected to the pressure suppression pool 2 via inlet and outlet pipes. The system provides a natural convection flow of fluids between the pressure suppression pool 2 and the cooling coil to passively cool the fluids from the pressure suppression pool 2 without requiring external electrical power.,GE HITACHI NUCL ENERGY AMERICA,ROBERT J GINSBERG;;JOHN R BASS;;ROBERT A AYER;;RICHARD M ROGERS,,https://lens.org/010-579-620-147-395,Patent Application,no,8,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C15/18,,0,0,,,,PENDING
36,EP,B1,EP 3179479 B1,022-144-984-574-585,2020-01-15,2020,EP 16201071 A,2016-11-29,US 201514960769 A,2015-12-07,NUCLEAR REACTOR SCRAM CONTROL SYSTEM,,GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN ROBERT;;BAHENSKY TED GORDON;;MIERS SEAN WILSON;;AYER ROBERT A,,https://lens.org/022-144-984-574-585,Granted Patent,yes,1,0,5,5,0,F16K37/0041;;F16K37/0041;;G21C7/16;;G21C7/16;;G21C7/36;;G21C9/02;;G21C9/02;;G21C17/10;;G21C17/10;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21C9/02;;F16K37/00;;G05B9/00;;G21C7/16;;G21C17/10;;G21D3/06;;G21H1/00,,0,0,,,,ACTIVE
37,MX,A,MX 2013010438 A,038-264-273-086-689,2014-03-24,2014,MX 2013010438 A,2013-09-11,US 201213611384 A,2012-09-12,METHOD AND SYSTEM FOR AN ALTERNATIVE BWR CONTAINMENT HEAT REMOVAL SYSTEM.,A method and apparatus for an alternative cooling system used to cool the suppression pool of a Boiling Water Reactor (BWR) nuclear reactor. The cooling system includes a cooling coil in an isolation condenser located at an elevation that is above the suppression pool. The isolation condenser is connected to the suppression pool via inlet and outlet pipes. The system may provide a natural convection flow of fluids between the suppression pool and the cooling coils to passively cool fluid from the suppression pool without requiring external electrical power.,GE HITACHI NUCL ENERGY AMERICA,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M,,https://lens.org/038-264-273-086-689,Patent Application,no,0,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C15/00,,0,0,,,,DISCONTINUED
38,SE,A1,SE 1350987 A1,185-570-352-875-876,2014-03-13,2014,SE 1350987 A,2013-08-28,US 201213611384 A,2012-09-12,Förfarande och system för ett alternativt BWR-inneslutningsvärmebortförselsystem,Förfarande och anordning för ett alternativt kylsystem använt för att kyla undertryckningspoolen i en kokvattenreaktor(BWR)kärnreaktor. Kylsystemet inkluderar en kylspiral i en isolationskondenserare belägen vid en elevation som är över undertryckspoolen. Isolationskondenseraren är ansluten till undertryckspoolen via inlopps- och utloppsrör. Systemet kan tillhandahålla ett naturligt konvektionsflöde med fluider mellan undertryckspoolen och kylspiralerna för att passivt kyla fluid från undertryckspoolen utan att erfordra extern elkraft.,GE HITACHI NUCL ENERGY AMERICA,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M,,https://lens.org/185-570-352-875-876,Patent Application,no,0,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C15/18,,0,0,,,,DISCONTINUED
39,EP,A1,EP 3179479 A1,109-374-792-166-69X,2017-06-14,2017,EP 16201071 A,2016-11-29,US 201514960769 A,2015-12-07,NUCLEAR REACTOR SCRAM CONTROL SYSTEM,"A nuclear reactor scram control system 105 for a nuclear reactor includes a solenoid pilot valve (SSPV) 120. The SSPV includes a solenoid indicator light 124-1 to 124-n electrically coupled to an SSPV solenoid 122-1 to 122-n of the SSPV. The solenoid indicator light may be selectively activated based on an energization state of the SSPV solenoid, thereby providing an immediate and visually observable indication of the SSPV energization state. The immediate and visually observable indication of the SSPV energization state may enable quicker and more reliable verification of SSPV solenoid energization state. As a result, operator radiation exposure associated with verification may be reduced, and a risk of inadvertent nuclear reactor scram based on a de-energized SSPV solenoid may be reduced, thus streamlined nuclear reactor operations.
",GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN ROBERT;;BAHENSKY TED GORDON;;MIERS SEAN WILSON;;AYER ROBERT A,,https://lens.org/109-374-792-166-69X,Patent Application,yes,4,0,5,5,0,F16K37/0041;;G21C9/02;;G21C17/10;;G21D3/06;;G21C7/16;;Y02E30/30;;Y02E30/00;;F16K37/0041;;G21C9/02;;G21C17/10;;G21D3/06;;Y02E30/30;;G21C7/16;;G21C7/36,F16K37/00;;G21C9/02;;G05B9/00;;G21C7/16;;G21C17/10;;G21D3/06,,0,0,,,,ACTIVE
40,TW,A,TW 201415483 A,175-311-194-196-253,2014-04-16,2014,TW 102131102 A,2013-08-29,US 201213611384 A,2012-09-12,Method and system for an alternative BWR containment heat removal system,A method and apparatus for an alternative cooling system used to cool the suppression pool of a Boiling Water Reactor (BWR) nuclear reactor. The cooling system includes a cooling coil in an isolation condenser located at an elevation that is above the suppression pool. The isolation condenser is connected to the suppression pool via inlet and outlet pipes. The system may provide a natural convection flow of fluids between the suppression pool and the cooling coils to passively cool fluid from the suppression pool without requiring external electrical power.,GE HITACHI NUCL ENERGY AMERICA,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M,,https://lens.org/175-311-194-196-253,Patent of Addition,no,0,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C9/012;;G21C15/18,,0,0,,,,PENDING
41,ES,B1,ES 2458920 B1,038-068-933-564-749,2015-08-20,2015,ES 201331302 A,2013-09-04,US 201213611384 A,2012-09-12,Procedimiento y sistema de eliminación de calor de contención de un reactor nuclear de agua en ebullición alternativo,,GE HITACHI NUCL ENERGY AMERICA,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M,,https://lens.org/038-068-933-564-749,Granted Patent,no,0,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C15/18,,0,0,,,,ACTIVE
42,ES,T3,ES 2772826 T3,155-340-906-488-113,2020-07-08,2020,ES 16201071 T,2016-11-29,US 201514960769 A,2015-12-07,Sistema de control de parada rápida de reactor nuclear,"Un sistema (105) de control de parada rápida de reactor nuclear, que comprende: una válvula piloto (120) de solenoide para parada rápida (VPSPR) que incluye una pluralidad de solenoides (de 122-1 a 122-n) de VPSPR y una pluralidad de terminales (330A, 330B) de alimentación, estando la pluralidad de terminales (330A, 330B) de alimentación configurados para estar acoplados a fuentes (320A, 320B) de alimentación individuales, estando la pluralidad de solenoides (de 122-1 a 122-n) de VPSPR acoplados eléctricamente a respectivos terminales individuales (330A, 330B) de alimentación, de la pluralidad de terminales (330A, 330B) de alimentación, estando cada solenoide (de 122-1 a 122-n) de VPSPR de la pluralidad de solenoides (de 122-1 a 122-n) de VPSPR configurado para estar energizado o desenergizado en función de si se suministra energía eléctrica al solenoide (de 122-1 a 122-n) de VPSPR desde un terminal (330A, 330B) de alimentación acoplado eléctricamente de la pluralidad de terminales (330A, 330B) de alimentación, estando la VPSPR (120) configurada para actuar permitiendo que un fluido de trabajo pase a través de la VPSPR (120) para provocar la inserción rápida de una barra de control en un núcleo de reactor nuclear en función, al menos en parte, de si la pluralidad de solenoides (de 122-1 a 122-n) de VPSPR están comúnmente energizados o desenergizados; y una pluralidad de luces indicadoras (de 124-1 a 124-n) de solenoide acopladas a una carcasa de la VPSPR (120), estando la pluralidad de luces indicadoras (de 124-1 a 124-n) de solenoide acopladas eléctricamente a respectivos solenoides individuales (de 122-1 a 122-n) de VPSPR, de la pluralidad de solenoides (de 122-1 a 122-n) de VPSPR, y los respectivos terminales (330A, 330B) de alimentación individuales acoplados eléctricamente a los respectivos solenoides individuales (de 122-1 a 122-n) de VPSPR, de modo que cada luz indicadora individual (de 124-1 a 124-n) de solenoide está configurada para activarse selectivamente en función de si se suministra energía eléctrica desde un terminal individual (330A, 330B) de alimentación, acoplado, de la pluralidad de terminales (330A, 330B) de alimentación a un solenoide individual (de 122-1 a 122-n) de VPSPR, acoplado, de la pluralidad de solenoides (de 122-1 a 122-n) de VPSPR.",GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN ROBERT;;BAHENSKY TED GORDON;;MIERS SEAN WILSON;;AYER ROBERT A,,https://lens.org/155-340-906-488-113,Granted Patent,no,0,0,5,5,0,F16K37/0041;;F16K37/0041;;G21C7/16;;G21C7/16;;G21C7/36;;G21C9/02;;G21C9/02;;G21C17/10;;G21C17/10;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21C9/02;;F16K37/00;;G05B9/00;;G21C7/16;;G21C17/10;;G21D3/06;;G21H1/00,,0,0,,,,ACTIVE
43,US,A1,US 2014/0072089 A1,183-342-817-838-868,2014-03-13,2014,US 201213611384 A,2012-09-12,US 201213611384 A,2012-09-12,METHOD AND SYSTEM FOR AN ALTERNATIVE BWR CONTAINMENT HEAT REMOVAL SYSTEM,A method and apparatus for an alternative cooling system used to cool the suppression pool of a Boiling Water Reactor (BWR) nuclear reactor. The cooling system includes a cooling coil in an isolation condenser located at an elevation that is above the suppression pool. The isolation condenser is connected to the suppression pool via inlet and outlet pipes. The system may provide a natural convection flow of fluids between the suppression pool and the cooling coils to passively cool fluid from the suppression pool without requiring external electrical power.,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M;;GE HITACHI NUCL ENERGY AMERICA,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M,GE-HITACHI NUCLEAR ENERGY AMERICAS LLC (2012-09-04),https://lens.org/183-342-817-838-868,Patent Application,yes,2,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C15/00,376/298,0,0,,,,DISCONTINUED
44,US,A1,US 2017/0162279 A1,059-110-569-822-796,2017-06-08,2017,US 201514960769 A,2015-12-07,US 201514960769 A,2015-12-07,NUCLEAR REACTOR SCRAM CONTROL SYSTEM,"A nuclear reactor scram control system for a nuclear reactor includes a solenoid pilot valve (SSPV). The SSPV includes a solenoid indicator light electrically coupled to an SSPV solenoid of the SSPV. The solenoid indicator light may be selectively activated based on an energization state of the SSPV solenoid, thereby providing an immediate and visually observable indication of the SSPV energization state. The immediate and visually observable indication of the SSPV energization state may enable quicker and more reliable verification of SSPV solenoid energization state. As a result, operator radiation exposure associated with verification may be reduced, and a risk of inadvertent nuclear reactor scram based on a de-energized SSPV solenoid may be reduced, thus streamlined nuclear reactor operations.",BASS JOHN ROBERT;;BAHENSKY TED GORDON;;MIERS SEAN WILSON;;AYER ROBERT A;;GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN ROBERT;;BAHENSKY TED GORDON;;MIERS SEAN WILSON;;AYER ROBERT A,GE-HITACHI NUCLEAR ENERGY AMERICAS LLC (2015-11-20),https://lens.org/059-110-569-822-796,Patent Application,yes,3,3,5,5,0,F16K37/0041;;G21C9/02;;G21C17/10;;G21D3/06;;G21C7/16;;Y02E30/30;;Y02E30/00;;F16K37/0041;;G21C9/02;;G21C17/10;;G21D3/06;;Y02E30/30;;G21C7/16;;G21C7/36,G21C7/16;;G21C7/36,,0,0,,,,ACTIVE
45,US,B2,US 10224120 B2,151-457-595-479-212,2019-03-05,2019,US 201514960769 A,2015-12-07,US 201514960769 A,2015-12-07,Nuclear reactor scram control system,"A nuclear reactor scram control system for a nuclear reactor includes a solenoid pilot valve (SSPV). The SSPV includes a solenoid indicator light electrically coupled to an SSPV solenoid of the SSPV. The solenoid indicator light may be selectively activated based on an energization state of the SSPV solenoid, thereby providing an immediate and visually observable indication of the SSPV energization state. The immediate and visually observable indication of the SSPV energization state may enable quicker and more reliable verification of SSPV solenoid energization state. As a result, operator radiation exposure associated with verification may be reduced, and a risk of inadvertent nuclear reactor scram based on a de-energized SSPV solenoid may be reduced, thus streamlined nuclear reactor operations.",BASS JOHN ROBERT;;BAHENSKY TED GORDON;;MIERS SEAN WILSON;;AYER ROBERT A;;GE HITACHI NUCLEAR ENERGY AMERICAS LLC,BASS JOHN ROBERT;;BAHENSKY TED GORDON;;MIERS SEAN WILSON;;AYER ROBERT A,GE-HITACHI NUCLEAR ENERGY AMERICAS LLC (2015-11-20),https://lens.org/151-457-595-479-212,Granted Patent,yes,21,0,5,5,0,F16K37/0041;;F16K37/0041;;G21C7/16;;G21C7/16;;G21C7/36;;G21C9/02;;G21C9/02;;G21C17/10;;G21C17/10;;G21D3/06;;G21D3/06;;Y02E30/00;;Y02E30/30;;Y02E30/30,G21C7/16;;F16K37/00;;G21C7/36;;G21C9/02;;G21C17/10;;G21D3/06,,1,0,,,"EP Search Report issued for corresponding EP Application No. 16201071.4 dated Apr. 10, 2017.",ACTIVE
46,ES,A2,ES 2458920 A2,045-125-976-442-09X,2014-05-07,2014,ES 201331302 A,2013-09-04,US 201213611384 A,2012-09-12,METHOD AND SYSTEM FOR AN ALTERNATIVE BWR CONTAINMENT HEAT REMOVAL SYSTEM,A method and apparatus for an alternative cooling system used to cool the suppression pool of a Boiling Water Reactor (BWR) nuclear reactor. The cooling system includes a cooling coil in an isolation condenser located at an elevation that is above the suppression pool. The isolation condenser is connected to the suppression pool via inlet and outlet pipes. The system may provide a natural convection flow of fluids between the suppression pool and the cooling coils to passively cool fluid from the suppression pool without requiring external electrical power.,GE HITACHI NUCL ENERGY AMERICA,GINSBERG ROBERT J;;BASS JOHN R;;AYER ROBERT A;;ROGERS RICHARD M,,https://lens.org/045-125-976-442-09X,Patent Application,no,0,0,8,8,0,G21C15/18;;G21C15/18;;G21C15/18;;G21C15/18;;G21C15/26;;G21C15/26;;G21C15/26;;Y02E30/30;;Y02E30/30;;Y02E30/30,G21C15/00,,0,0,,,,ACTIVE
47,CA,A1,CA 2118594 A1,176-226-826-915-384,1993-03-18,1993,CA 2118594 A,1992-09-09,US 75619591 A;;US 90371092 A;;US 9207629 W,1991-09-09,MAX: A HELIX-LOOP-HELIX ZIPPER PROTEIN THAT FORMS A SEQUENCE-SPECIFIC DNA-BINDING COMPLEX WITH MYC AND MAD,"2118594 9305056 PCTABS00020 Nucleic acid molecules capable of hybridizing under stringent conditions to the nucleotide sequence residing between positions 1 and 453 of the max cDNAs shown in Figure 2, or to the nucleotide sequence reisiding between positions 148 and 810 of the mad cDNAs shown in Figure 14. The Max polypeptide when associated with the Myc or Mad polypeptide is capable of binding to nucleotide sequences containing CACGTG.",HUTCHINSON FRED CANCER RES,BLACKWOOD ELIZABETH M;;EISENMAN ROBERT N;;AYER DONALD E JR,,https://lens.org/176-226-826-915-384,Patent Application,no,0,0,6,7,0,C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/23;;C07K2319/73;;C07K2319/80;;C12Q1/6876;;C12Q1/6876;;C07K2319/80;;C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/73;;C07K2319/23,C07K14/47;;C07K14/82;;C12N15/12;;C12Q1/68,,0,0,,,,EXPIRED
48,US,A,US 5302519 A,075-880-313-280-533,1994-04-12,1994,US 90371092 A,1992-06-23,US 90371092 A;;US 75619591 A,1991-09-09,Method of producing a Mad polypeptide,"Nucleic acid molecules capable of hybridizing under stringent conditions to the nucleotide sequence residing between positions 1 and 453 of the max cDNAs shown in FIG. 2, or to the nucleotide sequence residing between positions 148 and 810 of the mad cDNAs shown in FIG. 14. The Max polypeptide when associated with the Myc or Mad polypeptide is capable of binding to nucleotide sequences containing CACGTG.",HUTCHINSON FRED CANCER RES,BLACKWOOD ELIZABETH M;;EISENMAN ROBERT N;;AYER JR DONALD E,FRED HUTCHINSON CANCER RESEARCH CENTER (1992-08-13),https://lens.org/075-880-313-280-533,Granted Patent,yes,0,120,6,7,6,C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/23;;C07K2319/73;;C07K2319/80;;C12Q1/6876;;C12Q1/6876;;C07K2319/80;;C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/73;;C07K2319/23,C07K14/47;;C07K14/82;;C12N15/12;;C12Q1/68,435/69.1;;435/6;;435/69.3;;435/70.21;;435/240.2;;435/320.1;;530/350;;530/351;;536/23.1;;536/23.5,94,89,035-316-229-595-163;;023-794-173-973-647;;093-133-080-463-93X;;180-117-052-710-490;;045-601-754-501-044;;021-917-753-078-221;;116-871-010-760-311;;077-090-783-987-02X;;118-320-430-334-986;;066-268-422-666-147;;036-373-335-706-477;;074-779-163-920-28X;;038-676-233-566-46X;;076-488-794-670-902;;096-929-810-557-245;;108-001-492-437-103;;029-940-540-353-812;;095-847-321-987-644;;151-935-951-686-300;;052-371-366-724-492;;007-619-105-946-550;;007-569-182-093-069;;048-985-459-375-107;;010-970-933-506-776;;053-464-789-172-043;;006-440-539-265-596;;007-776-698-020-997;;053-037-422-527-227;;150-952-254-174-439;;004-356-634-663-90X;;102-081-322-136-206;;034-366-424-775-177;;015-478-680-154-959;;046-730-501-822-605;;052-400-209-971-49X;;021-448-907-232-465;;032-950-994-925-923;;069-053-391-190-801;;012-247-860-298-370;;086-668-187-648-747;;050-163-893-113-336;;037-242-349-071-747;;007-932-358-990-702;;023-925-347-823-954;;000-824-677-496-290;;051-714-932-203-110;;024-157-706-414-755;;020-837-219-579-134;;023-169-754-579-038;;011-396-276-332-501;;123-478-376-626-056;;012-895-985-398-733;;031-871-957-628-733;;078-004-019-449-915;;064-774-929-414-757;;012-694-327-057-901;;116-871-010-760-311;;045-970-126-218-540;;038-676-233-566-46X;;042-146-708-048-284;;096-258-342-947-386;;095-847-321-987-644;;003-792-012-617-84X;;089-934-889-044-508;;015-887-822-805-073;;006-838-665-358-187;;045-601-754-501-044;;035-238-960-742-686;;010-285-809-622-459;;107-406-497-522-664;;099-732-635-317-040;;087-636-712-590-02X;;036-416-310-412-285;;015-868-459-397-517;;106-752-467-136-59X;;011-097-478-799-732;;131-006-122-471-01X;;125-735-679-846-491;;059-049-072-219-166;;019-733-483-400-736;;036-448-782-946-329;;048-292-965-725-972;;142-564-616-442-353;;030-302-593-603-802;;031-522-650-075-710;;012-024-963-832-136;;000-710-549-254-136;;102-903-021-601-055;;096-098-835-168-903,10.1128/mcb.7.5.1697;;pmc365270;;10.1128/mcb.7.5.1697-1709.1987;;3299053;;10.1016/0042-6822(89)90265-1;;2536982;;2668849;;2278885;;pmc361227;;10.1128/mcb.10.10.5333-5339.1990;;10.1128/mcb.10.10.5333;;2204813;;10.1128/mcb.10.9.4961;;pmc361121;;2201910;;10.1128/mcb.10.9.4961-4966.1990;;10.1016/0092-8674(90)90207-u;;2180585;;2253873;;10.1101/gad.4.9.1454;;10.1016/0092-8674(89)90682-x;;2493990;;0002493990;;3175662;;10.1126/science.3175662;;pmc54189;;10.1073/pnas.87.12.4722;;2112746;;2503252;;10.1016/0092-8674(89)90434-0;;10.1016/0092-8674(90)90088-v;;2155707;;3289117;;10.1126/science.3289117;;0003289117;;10.1126/science.2911757;;2911757;;2683088;;10.1126/science.2683088;;10.1038/336646a0;;2974122;;10.1126/science.2251503;;2251503;;2269425;;10.1101/gad.4.12a.2025;;10.1016/s0065-230x(08)60200-6;;3096089;;10.1016/0092-8674(91)90641-b;;1988150;;10.1038/337664a0;;2645525;;10.1126/science.1987636;;1987636;;10.1128/mcb.11.2.954-962.1991;;pmc359758;;10.1128/mcb.11.2.954;;1990293;;10.1126/science.2174572;;2174572;;3142691;;10.1016/0092-8674(88)90146-8;;3142692;;10.1016/0092-8674(88)90147-x;;10.1126/science.3130660;;3130660;;10.1016/0092-8674(88)90077-3;;3135941;;3135940;;10.1016/0092-8674(88)90076-1;;6288259;;10.1016/0092-8674(82)90159-3;;6278322;;10.1038/296262a0;;pmc369080;;6513926;;10.1128/mcb.4.11.2486-2497.1984;;10.1128/mcb.4.11.2486;;pmc366736;;10.1128/mcb.5.3.448-456.1985;;3887132;;10.1128/mcb.5.3.448;;10.1128/mcb.6.12.4450;;pmc367228;;10.1128/mcb.6.12.4450-4457.1986;;3796607;;pmc365511;;3054516;;10.1128/mcb.8.10.4381-4388.1988;;10.1128/mcb.8.10.4381;;pmc362320;;2668734;;10.1128/mcb.9.6.2477;;10.1128/mcb.9.6.2477-2486.1989;;10.1002/j.1460-2075.1989.tb03359.x;;pmc400783;;2540955;;6606489;;10.1016/0092-8674(83)90092-2;;3302722;;10.1038/328445a0;;10.1016/0168-9525(90)90169-7;;10.1016/0092-8674(88)90507-7;;3277717;;2537150;;10.1016/0092-8674(89)90583-7;;10.1002/j.1460-2075.1990.tb08126.x;;2303035;;pmc551682;;10.1101/gad.4.10.1730;;2249772;;10.1101/gad.4.10.1741;;2123466;;10.1002/j.1460-2075.1989.tb03481.x;;2663470;;pmc400922;;2503872;;10.1126/science.2503872;;10.1016/0092-8674(88)90506-5;;3124961;;2233723;;10.1128/mcb.10.11.5914;;pmc361386;;10.1128/mcb.10.11.5914-5920.1990;;10.1038/312280a0;;6438521;;10.1101/gad.1.4.347;;3678827;;10.1128/jvi.62.12.4533-4537.1988;;pmc253563;;2972842;;3050531;;10.1038/335683a0;;3367995;;10.1038/333210a0;;2667136;;10.1126/science.2667136;;10.1016/0092-8674(90)90207-u;;2180585;;2156629;;10.1016/0092-8674(90)90214-y;;10.1016/0092-8674(90)90088-v;;2155707;;10.1126/science.2006410;;2006410;;10.1016/0092-8674(91)90457-a;;1840505;;10.1126/science.2251503;;2251503;;10.1128/mcb.8.6.2504;;pmc363451;;3043180;;10.1128/mcb.8.6.2504-2512.1988;;10.1038/314366a0;;3885045;;4065102;;pmc554455;;10.1002/j.1460-2075.1985.tb03885.x;;3982504;;10.1038/314363a0;;pmc361227;;10.1128/mcb.10.10.5333-5339.1990;;10.1128/mcb.10.10.5333;;2204813;;6313208;;10.1016/0092-8674(83)90535-4;;2028839;;10.1016/s0065-230x(08)60476-5;;10.1002/j.1460-2075.1983.tb01750.x;;pmc555461;;6321165;;2660073;;10.1038/310655a0;;6088986;;10.1073/pnas.83.21.8167;;3490663;;pmc386888;;10.1128/mcb.6.3.870;;10.1128/mcb.6.3.870-877.1986;;3022135;;pmc367587;;10.1038/320760a0;;3458027;;3093082;;10.1016/0092-8674(86)90361-2;;10.1128/mcb.8.4.1614;;2454393;;10.1128/mcb.8.4.1614-1624.1988;;pmc363321;;10.1016/0022-2836(88)90558-x;;3172238;;6308472;;10.1038/304596a0;;3032456;;10.1016/0092-8674(87)90449-1;;2537153;;10.1016/0092-8674(89)90589-8;;3278812;;10.1016/0092-8674(88)90398-4;;1737614;;10.1101/gad.6.2.166;;1565473;;10.1101/gad.6.1.71;;1730411;;10.1101/gad.6.1.81;;1730412;;1566084;;10.1126/science.256.5055.373;;10.1016/0092-8674(91)90377-b;;2040011;;1630816,"Stone, J. et al., Mol. Cell. Biol. 7, 1697 (1987).;;Enrietto, P. J., Virology 168, 256 (1989).;;Nakajima, H., M. Ikeda, N. Tsuchida, S. Nishimura, Y. Taya, Oncogene 4, 999 (1989).;;Crouch, D. H., C. Lang, D. A. F. Gillespie. Definition of the activities and properties of c myc required to inhibit cell differentiation. Oncogene 5, 863 (9190).;;Freytag, S. O., C. V. Dang, W. M. F. Lee, Cell Growth Differ. , 1, 339 (1990).;;Smith, M. J., D. C. Charron Prochownik, E. V. Prochownik, Mol. Cell. Biol. 10, 5333 (1990).;;Penn, L. J. Z. et al., Mol. Cell. Biol. 10, 4961 (1990).;;Jones, N. Transcriptional regulation by dimerization: two sides to an incestuous relationship. Cell 61, 9 11 (1990).;;Olson, E. N., Genes Dev. 4, 1454 (1990).;;Murre, C., P. S. McCaw, D. Baltimore. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56, 777 783 91989).;;Tapscott, S. J., Davis, R. L., Thayer, M. J., Cheng, P. F. Weintraub, H. and Lassar, A. B. A nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 242, 405 411 (1988).;;Voronova, A. and D. Baltimore, Proc. Natl. Acad. Sci. U.S.A. 87, 4722 (1990).;;Murre, C., McCaw, P. S. Vaessin, H., Caudy, M., Jan, L. Y., Jan, Y. N. Cabrera, C. V., Buskin, J. N., Hauschka, S. D., Lassar, A. B., Weintraub, H. and D. Baltimore. Interactions between heterologous helix loop helix proteins generates complexes that bind specifically to a common DNA sequence. Cell 58, 537 544 (1989).;;Davis, R. L., P. F. Cheng, A. B. Lassar, H. Weintraub, Cell. 60, 733 (1990).;;Landschulz, W. H., P. F. Johnson, S. L. McKnight. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240, 1759 1764 (1988).;;O Shea, E. K., R. H. Rutkowski, P. S. Kim. Evidence that the leucine zipper is a coiled coil. Science 243, 538 542 (1989).;;Vinson, C. R., P. B. Sigler, S. L. McKnight, Science 246, 911 (1989).;;Kouzarides, T. and E. Ziff. The role of the leucine zipper in the fos jun interaction. Nature 336, 646 651 (1988).;;Blackwell, T. K., L. Kretzner, E. M. Blackwood, R. N. Eisenman, H. Weintraub. Sequence Specific DNA Binding by the c Myc protein. Science 250, 1149 (1990.;;Luscher, B. and R. N. Eisenman, New Light on Myc and Myb. Part I. Myc. Genes Dev. 4(12a):2025 2035 (1990).;;Cory, S. Activation of cellular oncogenes in hematopoietic cells by chromosome translocation. Advances in Cancer Research. 1986.;;Eisenman, R. N. Nuclear Oncogenes In: Oncogenes and the Molecular Origins of Cancer . (R. Weinberg, Ed.) Cold Spr. Harbor Press, Cold Springs, N.Y. pp. 175 221 (1989).;;Magrath, I. The pathogenesis of Burkitt s lymphoma. Adv. Cancer Res. 55:134 251 (1990).;;Marshall, C. J. Tumor suppressor genes. Cell. 64(2):313 326, 1991.;;Dang, C. V. M. McGuire, M. Buckmire, W. M. F. Lee, Nature 337, 664 666 (1989).;;Prendergast, G. and E. Ziff. Methylation sensitive sequence specific DNA binding by the c yc basic region. Science 251, 186 189 (1991).;;Dang, C. V., Barrett, J., Villa Garcia, M., Resar, L. M. S., Kato, G. J. and Fearon, E. R. Intracellular leucine zipper interactions suggest c Myc hetero oligonmerization. Mol. Cell. Biol. 11, 954 962 (1991).;;Blackwell, T. K. and H. Weintraub, Science 250, 1104 (1990).;;Nakabeppu, Y., K. Ryder, D. Nathans, Cell 55, 907 (1988).;;Halazonetis, T. D., J. Georgopoulos, M. E. Greenberg, P. Leder, Cell 55, 917 (1988).;;Rauscher, F. J. III et al., Science 240, 1010 (1988).;;Sassone Corsi, P., W. W. Lamph, M. Kamps, I. M. Verma, Cell 54, 553 (1988).;;Chiu, R. et al., Cell 54, 541 (1988).;;Abrams, H., L. Rohrschneider, R. N. Eisenman, Cell 29, 427 (1982).;;Donner, P., I. Gresier Wilke, K. Moelling Nature 296, 262 (1982).;;Hann, S. R. and R. N. Eisenman, Mol. Cell. Biol. 4, 2486 (1984).;;Watt, R. A., A. R. Shatzman, M. Rosenberg, Mol. Cell Biol. 5, 448 (1985).;;Ramsay, G. L. Stanton, M. Schwab, J. M. Bishop, Mol. Cell. Biol. 6, 4450 (1986).;;De Greve, J. et al., Mol. Cell. Biol., 8, 4381 (1988).;;Dang, C. V., H. V. Dam, M. Buckmire, W. M. F. Lee, Mol. Cell. Biol. 9, 2477 (1989).;;Saksela, K., T. P. Makela, G. Evan, K. Alitalo, EMBO J. 8, 149 (1989).;;Kelly, K., B. H. Cochran, C. D. Stiles and P. Leder, Cell specific regulation of the c myc gene by lymphocyte mitogens and platelet derived growth factor. Cell. 35:603 610 (1983).;;Heikkila, R., G. Schwab, E. Wickstrom, S. L. Loke, D. H. Pluznik, R. Watt and L. M. Neckers. A c myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature.;;Macgregor, P. F., C. Abate, T. Curran, Oncogene 5, 451 (1990).;;Hann, S. R., M. W. King, D. L. Bentley, C. W. Anderson, R. N. Eisenman, Cell 52, 185 (1988).;;Wright, W. E., D. A. Sassoon, V. K. Lin, Cell 56, 607 (1989).;;Chen, Q. et al., EMBO 9, 415 (1990).;;Gregor, P. D., M. Sawadogo, R. G. Roeder, Genes & Development 4: 1740 (1990).;;Hu, Y. F., B. Luscher, A. Admon, N. Mermod, R. Tijan. Transcription factor AP 4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev. 4, 1741 (1990).;;Luscher, B., E. A. Kuenzel, E. G. Krebs, R. N. Eisenman, EMBO J. 8, 1111 (1989).;;O Shea, E. K., R. Rutkowski, W. F. Stafford III, P. S. Kim, Science 245, 646 (1989).;;Lech, K., K. Anderson, R. Brent, Cell 52, 179 (1988).;;Kato, G. J., J. Barrett, M. Villa Garcia, C. V. Dang. An amino terminal c Myc domain required for neoplastic transformation activates transcription. Mol. Cell. Biol. 10, 5914 5920 (1990).;;Kingston, R. E., A. S. Baldwin, P. A. Sharp, Nature 312, 280 (1984).;;Kaddurah Daouk, R., J. M. Greene, A. S. Baldwin, R. E. Kingston, Genes Dev. 1, 347 (1987).;;Onclercq, R., P. Gilardi, A. Lavenu, C. Cremisi, J. Virol. 62, 4533 (1988).;;Ptashne, M. Nature 335, 683 (1988).;;Sigler, P. B. Nature 333, 210 (1988).;;Mitchell, P. J. and R. Tijan, Science 245, 371 (1989).;;Jones, N. Cell 61, 9 (1990).;;Benezra, R., R. L. Davis, D. Lockshon, D. L. Turner, H. Weintraub, Cell 61, 49 (1990).;;Davis, R. L., Cheng, P. F., Lassar, A. B., & Weintraub, H., Cell 60, 733 (1990).;;Blackwood, E. M., R. N. Eisenman. Max: a helix loop helix zipper protein that forms a sequence specific DNA binding complex with Myc. Science 251, 1211 1217 (1991).;;Prendergast, G. C., D. Lawe, E. B. Ziff, Cell 65, 395 (1991).;;Blackwell, T. K., L. Kretzner, E. M. Blackwood, R. N. Eisenman, H. Weintraub, Science 250, 1149 (1990).;;Luscher, B., R. N. Eisenman, Mol. Cell. Biol. 8, 2504 (1988).;;Hann, S. R., C. B. Thompson, R. N. Eisenman, Nature 314, 366 (1985).;;Rabbitts, P. H., Watson, J. V., Lamond, A., Forster, A., Stinson, M. A., Evan, G., Fischer, W., Atherton, E., Sheppard, R. and Rabbitts, T. H. Metabolism of c Myc products: c Myc mRNA and protein expression in the cell cycle. EMBO J. 4, 2009 2015 (1985).;;Thompson, C. B., P. B. Challoner, P. E. Neiman, M. Groudine, Nature 314, 363 (1985).;;Smith, M. J., D. C. Charron Prochownik, E. V. Prochownik, Mol. Cell. Biol. 10, 5333 (1990).;;Hann, S. R., H. D. Abrams, L. R. Rohrschneider, R. N. Eisenman, Cell 34, 789 (1983).;;Ramsay, G., L. Stanton, M. Schwab, J. M. Bishop, Mol. Cell. Biol. 6, 4450 (1986).;;Spencer, C. A., M. Groudine, Adv. Cancer Res. 56, 1 (1990).;;Palmieri, S., P. Kahn, and T. Graf. Quail embryo fibroblasts transformed by four v myc containing virus isolates show enhanced proliferation but are non tumorigenic. EMBO J. 2:2385 (1983).;;Karn, J., J. V. Watson, A. D. Lowe, S. M. Green, and W. Vedeckis. Regulation of cell cycle duration by c myc levels. Oncogene 4:773 (1989).;;Armelin, H. A., M. C. S. Armelin, K. Kelly, T. Stewart, P. Leder, B. H. Cochran, and C. D. Stiles. Functional role for c myc in mitogenic response to platelet derived growth factor. Nature 310:655 (1984).;;Sorrentino, V., V. Drosdoff, M. D. McKinney, L. Zeitz, and E. Fleissner. Potentiation of growth factor activity by exogenous c myc expression. Proc. Natl. Acad. Sci. 83:8167 (1986).;;Stern, D., A. Roberts, N. S. Roche, M. B. Sporn, and R. A. Weinberg. Differential responsiveness of myc and ras transfected cells to growth factors: Selective stimulation of myc transfected cells by epidermal growth factors. Mol. Cell. Biol. 6:870 (1986).;;Coppola, J. A. and M. D. Cole. Constitutive c myc oncogene expression blocks mouse erythroleukemia cell differentiation but not commitment. Nature 320:760 (1989).;;Langdon, W. Y., A. W. Harris, S. Cory, and J. M. Adams. The c myc oncogene perturbs B lymphocyte development in Eu myc transgenic mice. Cell 47:11 (1986).;;Freytag, S. Enforces expression of the c myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in Go/G1. Mol. Cell. Biol. 8:1614 (1988).;;Kume, T. U., S. Takada, and M. Obinata. Probability that the commitment of murine erythroleukemia cell differentiation is determined by the c myc level. J. Mol. Biol. 202:779 (1988).;;Land, H., L. F. Parada, and R. A. Weinberg. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596 (1983).;;Sinn, E., W. Muller, P. Pattengale, I. Tepler, R. Wallace, and P. Leder. Coexpression of MMTV/v Ha ras and MMTV/c myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465 (1987).;;van Lohuizen, M., S. Verbeek, P. Krimpenfort, J. Domen, C. Saris, T. Radaszkiewicz, and A. Berns. Predisposition to lymphomagenesis in pim 1 transgenic mice: Cooperation with c myc and N myc in murine leukemia virus induced tumors. Cell 56:673 (1989).;;Weinberg, R. A. 1989. Oncogenes and multistep carcinogenisis (sic). In Oncogenes and the molecular origins of cancer (ed. R. A. Weinberg), p. 307. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.;;DePamphilis, M. L. Transcriptional elements as components of eukaryotic origins of DNA replication. Cell 52:635 (1988).;;Berberich, S. J. and Cole, M. D. Casein kinase II inhibits the DNA binding activity of Max homodimers but not Myc/Max heterodimers. Genes Dev. 6, 166 176 (1992).;;Berberich, S., Hyde DeRuyscher, N., Espenshade, P., and Cole, M. D. Max encodes a sequence specific DNA binding protein and is not regulated by serum growth factors. Oncogene 4, 775 779 (1992).;;Blackwood, E. M., Luscher, B. and Eisenman, R. N. Myc and Max associate in vico. Genes Dev. 6, 71 80 (1992a).;;Kato, G. J., Lee, W. M. F., Chen, L., and Dang, C. V. Max: Functional domains and interaction with c Myc. Genes Dev. 6: 81 92 (1992).;;Makela, T. P., Koskinen, P. J., Vastrik, I., and Alitalo, K. Alternative forms of Max as enhancers or suppressors of Myc Ras cotransformation. Science 256, 373 377 (1992).;;Cole, M. D. Myc meets its max. Cell 65, 715 716 (1991).;;Min, S., Taparowsky, E. J. v Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation. Oncogene 7, 1531 1540 (1992).",EXPIRED
49,CA,C,CA 2118594 C,184-238-274-374-185,2004-02-03,2004,CA 2118594 A,1992-09-09,US 75619591 A;;US 90371092 A;;US 9207629 W,1991-09-09,MAX: A HELIX-LOOP-HELIX ZIPPER PROTEIN THAT FORMS A SEQUENCE-SPECIFIC DNA-BINDING COMPLEX WITH MYC AND MAD,"Nucleic acid molecules capable of hybridizing under stringent conditions to the nucleotide sequence residing between positions 1 and 453 of the max cDNAs shown in Figure 2, or to the nucleotide sequence reisiding between positions 148 and 810 of the mad cDNAs shown in Figure 14. The Max polypeptide when associated with t he Myc or Mad polypeptide is capable of binding to nucleotide sequences containing CACGTG.",,BLACKWOOD ELIZABETH MARIE;;EISENMAN ROBERT NEIL;;AYER DONALD E JR,,https://lens.org/184-238-274-374-185,Granted Patent,no,0,0,6,7,0,C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/23;;C07K2319/73;;C07K2319/80;;C12Q1/6876;;C12Q1/6876;;C07K2319/80;;C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/73;;C07K2319/23,C07K14/47;;C07K14/82;;C12N15/12;;C12Q1/68,,0,0,,,,EXPIRED
50,AU,A,AU 1992/025992 A,075-820-638-526-891,1993-04-05,1993,AU 1992/025992 A,1992-09-09,US 75619591 A;;US 90371092 A,1991-09-09,A HELIX-LOOP-HELIX ZIPPER PROTEIN THAT FORMS A SEQUENCE-SPECIFIC DNA-BINDING COMPLEX WITH MYC AND MAD,,HUTCHINSON FRED CANCER RES,ELIZABETH MARIE BLACKWOOD;;ROBERT NEIL EISENMAN;;DONALD E. JR. AYER,,https://lens.org/075-820-638-526-891,Patent Application,no,0,0,6,7,0,C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/23;;C07K2319/73;;C07K2319/80;;C12Q1/6876;;C12Q1/6876;;C07K2319/80;;C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/73;;C07K2319/23,C07K14/47;;C07K14/82;;C12N15/12;;C12Q1/68,,0,0,,,,PENDING
51,WO,A1,WO 1993/005056 A1,156-774-839-162-555,1993-03-18,1993,US 9207629 W,1992-09-09,US 75619591 A;;US 90371092 A,1991-09-09,A HELIX-LOOP-HELIX ZIPPER PROTEIN THAT FORMS A SEQUENCE-SPECIFIC DNA-BINDING COMPLEX WITH MYC AND MAD,"Nucleic acid molecules capable of hybridizing under stringent conditions to the nucleotide sequence residing between positions 1 and 453 of the max cDNAs shown in Figure 2, or to the nucleotide sequence reisiding between positions 148 and 810 of the mad cDNAs shown in Figure 14. The Max polypeptide when associated with the Myc or Mad polypeptide is capable of binding to nucleotide sequences containing CACGTG.",HUTCHINSON FRED CANCER RES,BLACKWOOD ELIZABETH MARIE;;EISENMAN ROBERT NEIL;;AYER DONALD E JR,,https://lens.org/156-774-839-162-555,Patent Application,yes,0,2,6,7,0,C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/23;;C07K2319/73;;C07K2319/80;;C12Q1/6876;;C12Q1/6876;;C07K2319/80;;C07K14/47;;C07K14/82;;C07K2319/00;;C07K2319/73;;C07K2319/23,C07K14/47;;C07K14/82;;C12N15/12;;C12Q1/68,,2,2,095-847-321-987-644;;042-146-708-048-284,10.1126/science.2251503;;2251503;;10.1126/science.2006410;;2006410,"SCIENCE, Volume 250, issued 23 November 1990, BLACKWELL et al., ""Sequence-Specific DNA Binding by the C-MYC Protein"", pages 1149-1151.;;SCIENCE, Volume 251, issued 08 March 1991, BLACKWOOD et al., ""Max: A Helix-Loop-Helix Zipper Protein that Forms a Sequence-Specific DNA-Binding Complex with MYC"", pages 1211-1217.",PENDING
52,US,A,US 6003218 A,175-410-499-809-392,1999-12-21,1999,US 85738097 A,1997-05-14,US 85738097 A,1997-05-14,Apparatus for cutting and assembling slats for window blind units,"A modular assembly station for slotting and stringedly assembling a plurality of window-blind slats for subsequent construction of a window-blind unit. The assembly station includes at least one and preferably two or more slot cutter assemblies having a cutter member for cutting a slot in a slat through which a pull cord can pass a saw cutting assembly for trimming opposite ends of the slat, and a ladder-string applicator in lateral spaced relationship with the cutter assembly and including an entrance chamber for a slat and a ladder string having an opening thereof presented in alignment with the entrance chamber. A conveyor is located between the slot cutter assembly and the entrance chamber of the applicator for receiving a slat from the slot cutter assembly and laterally advancing it to the entrance chamber. Automatic operation of the assembly station is accomplished conventionally whereby respective operator motors or mechanical actuators associated with each step are in communication with a programmable coordinating controller programmed both for precise location placement with respect to the slats and for continuous operation.",3 DAY BLINDS INC,SCHUMANN ARTHUR I;;MCCARTY MICHAEL J;;AYER TERRY N;;JACKSON ROBERT,3 DAY BLINDS INC (1997-04-29),https://lens.org/175-410-499-809-392,Granted Patent,yes,8,43,1,1,0,B23P19/04;;E06B9/266;;Y10T29/39;;Y10T29/53539;;Y10T29/39;;Y10T29/53539;;E06B9/266;;B23P19/04,B23P19/04;;E06B9/266,29/24.5;;29/822,0,0,,,,EXPIRED
53,CA,A1,CA 2316887 A1,143-763-875-618-016,1999-07-08,1999,CA 2316887 A,1998-12-21,US 7017897 P;;US 9827208 W,1997-12-31,OSMOTIC DRUG DELIVERY MONITORING SYSTEM AND METHOD,Performance of delivery systems for delivering beneficial agents to an animal are monitored to determine the delivery rate of the beneficial agent and the proper operation of the beneficial agent delivery device. Performance monitoring can be achieved by monitoring the physical configuration of the implanted osmotic delivery device from the exterior of the body to determine the amount of beneficial agent delivered and/or the delivery rate of the beneficial agent. The monitoring of the physical configuration of the implanted osmotic delivery device may be performed in different manners such as by X-ray or fluoroscopic monitoring of the implant structure or magnetic determination of a piston location within the implant. Performance monitoring can also be achieved by use of a performance marker within the beneficial agent to produce a specifically detectable response which can be measured noninvasively in body fluids or by-products.,ALZA CORP;;ECKENHOFF BONNIE J,ECKENHOFF JAMES B;;AYER RUPAL;;STEWART GREGORY ROBERT;;BERRY STEPHEN;;JORDAN SCOTT DARWIN,,https://lens.org/143-763-875-618-016,Patent Application,no,0,0,21,24,0,A61K9/0004;;A61K9/0024;;A61M5/1424;;A61M5/1684;;A61M25/0108;;A61M31/002;;A61M2250/00;;A61K9/0004;;A61M5/1424;;A61M25/0108;;A61K9/0024;;A61M31/002;;A61M5/1684;;A61M2250/00,A61K9/00;;A61K9/22;;A61M5/142;;A61M5/168;;A61M25/01;;A61M31/00,,0,0,,,,EXPIRED
54,CA,C,CA 2316887 C,153-177-837-904-979,2008-04-08,2008,CA 2316887 A,1998-12-21,US 7017897 P;;US 9827208 W,1997-12-31,OSMOTIC DRUG DELIVERY MONITORING SYSTEM AND METHOD,Performance of delivery systems for delivering beneficial agents to an animal are monitored to determine the delivery rate of the beneficial agent and the proper operation of the beneficial agent delivery device. Performance monitoring can be achieved by monitoring the physical configuration of the implanted osmotic delivery device from the exterior of the body to determine the amount of beneficial agent delivered and/or the delivery rate of the beneficial agent. The monitoring of the physical configuration of the implanted osmotic delivery device may be performed in different manners such as by X-ray or fluoroscopic monitoring of the implant structure or magnetic determination of a piston location within the implant. Performance monitoring can also be achieved by use of a performance marker within the beneficial agent to produce a specifically detectable response which can be measured noninvasively in body fluids or by-products.,ECKENHOFF BONNIE J;;ALZA CORP,JORDAN SCOTT DARWIN;;AYER RUPAL;;ECKENHOFF JAMES B;;BERRY STEPHEN;;STEWART GREGORY ROBERT,,https://lens.org/153-177-837-904-979,Granted Patent,no,0,0,21,24,0,A61K9/0004;;A61K9/0024;;A61M5/1424;;A61M5/1684;;A61M25/0108;;A61M31/002;;A61M2250/00;;A61K9/0004;;A61M5/1424;;A61M25/0108;;A61K9/0024;;A61M31/002;;A61M5/1684;;A61M2250/00,A61M37/00;;A61K9/00;;A61K9/22;;A61M5/142;;A61M5/168;;A61M25/01;;A61M31/00,,0,0,,,,EXPIRED
55,US,S,US D0432221 S,114-386-196-794-058,2000-10-17,2000,US 9458798 F,1998-10-06,US 9458798 F,1998-10-06,Humidifier,,HONEYWELL INT INC,COX PAUL;;CHAN THOMAS S;;HARRIS JR KENNETH DAVID;;AYER W COREY;;KETELHOHN ROBERT A,KAZ INC (2002-06-26);;RECKITT BENCKISER (UK) LIMITED (2000-09-01);;HONEYWELL INTELLECTUAL PROPERTIES INC (2002-06-26);;HELEN OF TROY LIMITED (2013-11-01),https://lens.org/114-386-196-794-058,Design Right,yes,11,4,1,1,0,,,D23/356;;2304,0,0,,,,EXPIRED
56,WO,A1,WO 2014/149732 A1,098-300-204-227-806,2014-09-25,2014,US 2014/0020599 W,2014-03-05,US 201361790274 P,2013-03-15,ENHANCED WEAR RESISTANT STEEL AND METHODS OF MAKING THE SAME,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",EXXONMOBIL RES & ENG CO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK,,https://lens.org/098-300-204-227-806,Patent Application,yes,4,8,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/04;;C21D6/00;;C21D9/08;;C21D9/44,,3,1,001-185-577-956-702,10.4236/jmmce.2008.73021,"S.A. BALOGUN, D.E. ESEZOBOR, J.O. AGUNSOYE: ""Effect of Melting Temperature on the Wear Characteristics of Austenitic Manganese Steel"", JOURNAL OF MINERALS & MATERIALS CHARACTERISATION & ENGINEERING, vol. 7, no. 3, 12 December 2012 (2012-12-12), USA, pages 227 - 289, XP002725911;;T.V. RAJAN, C.P. SHARMA, ASHOK SHARMA: ""Heat Treatment: Principles and Techniques, Second Edition"", 31 January 2011, ASOKE K. GHOSH, PHI LEARNING PRIVATE LIMITED & RAJKAMAL ELECTRIC PRESS, New Delhi & Sonepat, Haryana, ISBN: 978-81-203-4095-4, article ""Heat Treatment of Commercial Steels"", pages: 214 - 215, XP002725912;;SELCUK KUYUCAK, RENATA ZADAVIL, VAL GERSTMAN: ""HEAT TREATMENT PROCESSING OF AUSTENITIC MANGANESE STEELS"", 1 January 2004 (2004-01-01), XP002725913, Retrieved from the Internet <URL:http://www.academia.edu/800180/HEAT-TREATMENT_PROCESSING_OF_AUSTENITIC_MANGANESE_STEELS> [retrieved on 20140616]",PENDING
57,US,B2,US 9999748 B2,109-282-578-936-587,2018-06-19,2018,US 201414509187 A,2014-10-08,US 201414509187 A;;US 201361895171 P,2013-10-24,Flexible catheter shaft and method of manufacture,"The present disclosure provides a strong, flexible catheter shaft for use in a catheter system. The flexible catheter shaft includes a nitinol tube having one or more sets of cuts therein in combination with one or more outer jacket layers. The flexible catheter shaft provides a shaft having sufficient stiffness and kink resistance to allow an operator to advance an electrode basket connected to the flexible catheter shaft through a guide catheter to a target ablation site without causing vessel trauma. The distal tip of the flexible catheter shaft is designed to have sufficient flexibility to reduce any risk of kicking out a guide catheter when tracking the electrode basket around turns in the vasculature of a patient.",ST JUDE MEDICAL CARDIOLOGY DIV INC,CAJAMARCA TOBIAS;;STRONG JEFFREY JOHN;;TERWEY RUSSELL D;;WEIR BRUCE ROBERT;;AYER JANSON LEE;;BUESSELER RYAN KENNETH,ST. JUDE MEDICAL CARDIOLOGY DIVISION INC (2013-10-28),https://lens.org/109-282-578-936-587,Granted Patent,yes,136,0,4,4,0,A61M25/0051;;A61M25/0051;;A61B18/1492;;A61B18/1492;;A61B2017/00526;;A61B2017/00526;;A61B2018/00267;;A61B2018/00267;;A61B2018/1475;;A61B2018/1475;;A61M25/0013;;A61M25/0013;;A61M25/0045;;A61M25/0045;;Y10T29/49812;;Y10T29/49812,A61M25/00;;A61B17/00;;A61B18/00;;A61B18/14,,252,218,156-441-037-868-622;;025-931-539-478-474;;035-633-914-228-299;;064-350-271-190-646;;077-044-622-483-931;;107-100-806-025-409;;093-823-551-518-529;;108-332-833-612-309;;118-381-784-825-319;;047-045-434-285-58X;;042-842-149-206-934;;010-047-692-763-608;;083-592-278-922-652;;099-635-488-594-595;;024-291-761-424-38X;;073-464-580-057-437;;025-684-383-782-975;;019-593-211-036-780;;007-383-152-831-440;;012-366-752-815-31X;;077-733-527-775-446;;006-902-476-267-351;;039-766-960-326-302;;005-420-994-398-759;;091-851-230-871-140;;010-951-893-684-514;;074-318-490-882-901;;058-455-766-960-36X;;013-459-004-600-363;;118-690-029-896-913;;079-520-664-235-378;;113-125-731-130-017;;032-361-157-072-294;;076-336-342-529-438;;009-990-848-086-319;;075-319-798-902-682;;003-608-736-394-79X;;002-637-790-623-289;;053-014-289-119-811;;013-417-345-500-63X;;111-150-442-575-177;;007-011-540-059-23X;;022-670-648-870-094;;011-568-263-050-749;;008-698-420-358-892;;077-721-491-846-733;;157-611-097-458-962;;117-678-272-004-489;;091-894-122-447-350;;004-822-737-313-123;;044-423-579-786-437;;032-359-720-208-208;;048-751-498-207-059;;045-043-961-803-105;;080-642-605-286-205;;026-490-525-343-021;;006-067-140-930-600;;056-887-577-189-285;;024-497-206-633-952;;044-291-638-719-540;;014-861-292-970-271;;005-574-293-848-077;;049-996-200-524-011;;099-255-199-945-892;;026-835-375-592-604;;044-264-036-062-752;;028-180-914-172-739;;021-229-913-428-421;;042-907-663-632-391;;042-907-663-632-391;;052-895-206-414-089;;020-186-588-298-008;;025-644-316-746-839;;043-816-660-566-264;;021-283-877-224-313;;025-624-279-809-088;;123-435-934-389-383;;047-992-550-147-892;;091-289-594-627-178;;046-986-842-365-288;;027-085-322-335-264;;000-097-844-636-150;;113-618-158-260-243;;064-687-677-297-201;;008-383-690-930-645;;077-536-577-129-482;;048-262-847-451-002;;073-897-772-340-505;;051-526-824-916-617;;024-647-897-385-863;;058-151-229-949-285;;022-611-244-695-939;;003-533-883-829-366;;022-799-338-240-502;;138-204-048-745-036;;083-326-640-607-566;;075-982-537-771-929;;053-611-035-247-034;;012-248-788-160-485;;081-338-559-849-90X;;017-298-584-505-784;;033-106-764-523-622;;077-684-562-271-309;;040-072-226-665-069;;002-464-534-449-362;;021-606-132-505-560;;088-376-691-008-974;;061-265-555-487-112;;039-777-350-998-076;;012-327-073-674-701;;032-870-520-690-990;;002-256-143-527-494;;042-960-931-165-463;;015-714-410-640-262;;039-521-507-799-51X;;082-443-844-559-515;;048-073-997-124-952;;025-283-264-180-894;;032-219-883-026-375;;159-605-519-315-323;;019-828-519-169-129;;002-542-485-056-546;;043-367-321-650-591;;063-739-302-626-617;;083-492-594-231-599;;084-500-156-494-499;;011-571-301-640-027;;100-309-523-224-11X;;057-495-003-930-541;;147-598-971-903-756;;054-568-098-416-427;;019-543-187-949-620;;025-649-713-721-208;;082-341-824-215-136;;052-601-797-911-100;;009-569-238-747-387;;084-309-520-088-134;;040-918-790-799-646;;026-440-375-951-412;;045-434-411-542-404;;046-853-040-908-579;;044-045-743-180-678;;077-227-889-090-864;;001-239-157-499-753;;033-817-096-422-05X;;061-705-677-216-149;;000-039-102-246-449;;087-767-955-019-602;;181-792-815-134-635;;059-002-476-054-072;;030-484-146-146-419;;069-218-923-201-421;;121-338-533-142-155;;061-210-080-718-82X;;021-845-269-925-433;;042-792-567-272-835;;050-148-644-316-305;;019-315-478-365-276;;020-687-470-519-616;;044-686-479-510-390;;092-793-157-652-972;;035-078-595-017-83X;;056-707-300-862-157;;088-415-873-523-386;;113-299-881-016-949;;083-093-786-326-391;;098-555-663-151-69X;;117-374-770-785-908;;039-765-935-440-360;;052-215-786-260-140;;051-532-063-132-164;;127-970-934-768-914;;066-628-906-880-015;;011-750-352-480-215;;040-428-444-760-51X;;015-627-877-260-719;;019-847-107-628-345;;022-691-951-753-328;;051-389-710-687-870;;054-793-164-101-855;;017-784-939-371-679;;015-783-589-014-454;;055-487-075-406-543;;028-510-011-837-284;;085-794-548-651-935;;060-138-622-050-474;;127-648-734-121-31X;;114-596-049-580-119;;049-076-137-312-734;;097-273-350-190-16X;;000-524-047-642-324;;024-118-902-556-927;;117-362-229-630-598;;062-700-916-138-023;;039-520-823-488-495;;103-704-757-427-98X;;132-490-957-650-255;;034-361-840-938-999;;018-205-172-333-278;;085-817-566-068-283;;067-218-056-974-772;;071-770-226-177-180;;057-200-981-075-928;;154-792-449-620-916;;141-134-773-493-30X;;017-490-393-498-817;;029-727-419-740-746;;005-705-203-939-213;;096-270-856-357-916;;080-945-887-168-722;;047-886-751-794-499;;037-970-830-869-080;;046-302-753-741-536;;107-727-122-789-642;;043-950-807-310-683;;025-928-278-341-770;;055-013-607-744-478;;080-682-678-031-154,10.1111/j.1525-1594.1987.tb02710.x;;3326559;;2486445;;pmc2376505;;23357181;;10.1161/hypertensionaha.111.00633;;10.1097/00041552-200203000-00011;;11856913;;10.1161/01.hyp.0000113047.47711.fa;;14707153;;19332354;;10.1016/s0140-6736(09)60624-3;;10.1023/a:1009797206514;;9870024;;23836798;;10.1161/hypertensionaha.113.01452;;10.1046/j.1365-201x.2003.01089.x;;12608997;;10.1016/s0140-6736(10)62039-9;;21093036;;2828236;;10.1161/01.hyp.11.1.3;;10.1016/0002-9343(60)90184-4;;13821037;;10.1172/jci100838;;pmc424844;;16694459;;3511641;;10.2214/ajr.146.3.593;;4912789;;10.1056/nejm197007302830502;;pmc1947259;;4590796;;10.1016/s1051-0443(97)70604-3;;9232566;;7109808;;10.1002/lsm.1900020101;;9449393;;10.1161/01.hyp.31.1.68;;10.1161/01.hyp.31.1.64;;9449392;;17859363;;pmc1514176;;18130295;;10.1097/00000658-194906000-00012;;13092784;;10.1097/00000658-195310000-00006;;pmc1609434;;10.1097/00000658-194111440-00018;;pmc1385824;;17857907;;10.1097/00000658-194110000-00018;;10.1126/science.2063193;;2063193;;14314206;;10.1016/0002-9149(65)90008-1;;13274399;;10829088;;10.1590/s0100-879x2000000600001;;12623970;;10.1161/01.hyp.0000052314.95497.78;;10.2214/ajr.174.6.1741592;;10845488;;10.1016/s1051-0443(07)61712-6;;11742028;;8062514;;10.1042/cs0870013;;pmc1390721;;10.1097/00000658-193610440-00025;;17856867;;18909517;;pmc1871165;;8203557;;10.1152/ajprenal.1994.266.5.f738;;14859394;;10.1161/01.cir.4.2.173;;10.1016/j.jash.2012.04.004;;22694986;;10.1136/heartjnl-2013-304238;;24038167;;10.1016/j.ijcard.2013.12.183;;24480181;;pmc101052;;10928505;;10.1093/ckj/sft130;;25859344;;pmc4389153;;9719050;;10.1161/01.hyp.32.2.249;;10.1681/asn.2012050513;;22677558;;9876289;;10.1590/s0100-879x1998000900015;;10.1007/s11906-999-0030-9;;10981075;;11141209;;10.1023/a:1026573816874;;5775865;;10.1152/ajplegacy.1969.216.4.693;;1918808;;10.1016/0165-1838(91)90082-e;;13024041;;11079666;;10.1016/s0735-1097(00)00900-1;;10.1002/ccd.10486;;12720241;;11760889;;10.1046/j.1469-7580.2001.19950585.x;;pmc1468369;;10529550;;10.1159/000008715;;10.1161/01.cir.98.5.458;;9714097;;10.1148/radiology.148.1.6856864;;6856864;;10.3317/jraas.2000.046;;17199212;;10.1136/bmj.1.5115.142;;pmc1992240;;13618577;;12173906;;10.1002/clc.4950250808;;pmc6653828;;10.1161/01.hyp.6.5.622;;6389335;;11833842;;10.1007/s380-002-8317-8;;10.1111/j.1540-8159.1997.tb06094.x;;9358496;;2302330;;10.1093/ajh/3.1.62;;1735574;;10.1161/01.hyp.19.2_suppl.ii17;;7659577;;10.1111/j.1540-8159.1995.tb06963.x;;10.3109/08037051.2011.613296;;21905971;;10.1161/hc0902.104712;;11877358;;9043809;;10.1111/j.1440-1681.1997.tb01786.x;;10.1111/j.1440-1681.1997.tb01785.x;;9043808;;10553921;;10.1253/jcj.63.783;;14429757;;10.7326/0003-4819-51-2-196;;14429757;;10.7326/0003-4819-51-2-196;;pmc424650;;16694275;;10.1172/jci100652;;16694318;;pmc424699;;10.1172/jci100695;;10.1172/jci100635;;16694258;;pmc436038;;10.1161/01.cir.102.21.2619;;11085966;;10.1093/eurheartj/ehs041;;22507981;;11743264;;pmc4136670;;10.1016/s0022-5347(05)65371-2;;10.1097/00005392-200201000-00004;;18918421;;10.1016/0002-9610(48)90284-0;;18610006;;10.1136/hrt.7.3.139;;pmc480990;;pmc3607230;;22851728;;10.1161/hypertensionaha.112.195263;;9892601;;10.1161/01.cir.99.2.319;;9495267;;10.1161/01.hyp.31.3.823;;10.1016/0002-9610(64)90245-4;;14099507;;11325577;;10.1016/s1056-8719(00)00125-8;;2138921;;10.1136/bmj.300.6724.569;;pmc1662367;;21796327;;10.1007/s00392-011-0346-8;;10.2215/cjn.07561009;;19965523;;9832181;;10.1016/s0895-7061(98)00154-x;;11132191;;10.1114/1.1310219;;10568673;;10.1016/s0002-9149(99)00714-6;;9277544;;10.1152/ajpregu.1997.273.2.r597;;2644526;;24060456;;10.1016/j.jacc.2013.07.094;;23141482;;10.1016/j.jacc.2012.09.027;;10.1002/ccd.24557;;22807098;;10.1152/ajpheart.00340.2009;;20348221;;22573363;;10.1002/clc.22008;;pmc6652693;;11676886;;10.1007/s11916-001-0069-z;;7721450;;10.1161/01.hyp.25.4.893;;6172449;;10.1172/jci110441;;pmc371168;;10.1161/01.hyp.3.4.404;;7030950;;19917336;;10.1016/j.pcad.2009.09.003;;15294267;;10.1016/j.eupc.2004.04.007;;14032613;;10.1161/01.res.11.6.987;;2012227;;10.1152/ajpheart.1991.260.4.h1254;;10.1007/bf01717340;;2681964;;9202549;;10.1046/j.1464-410x.1997.00157.x;;10.1016/s0002-8703(99)70009-8;;10539815;;2858894;;10.1111/j.1469-7793.2001.0527i.x;;11230524;;pmc2278472;;10.1016/s0140-6736(09)60566-3;;19332353;;21242507;;10.1161/circulationaha.110.971580;;10.1161/01.res.33.6.704;;4357570;;pmc3532113;;10.1371/journal.pone.0052229;;23284945;;10.1109/10.284921;;8026844;;10.1161/hypertensionaha.112.200865;;23071129;;10.3349/ymj.1999.40.6.545;;10661030;;10067797;;10.1097/00004872-199917020-00012;;pmc1993623;;13651736;;10.1136/bmj.1.5134.1361;;11023625;;10.1016/s0165-1838(00)00103-x;;9876762;;pmc3015306;;10.2214/ajr.178.1.1780047;;11756085;;10.1093/eurheartj/ehu195;;pmc5994825;;24829361;;10445872;;10.1016/s0033-0620(99)70024-1;;10.1093/eurheartj/eht154;;23620497;;10.1161/01.hyp.34.4.724;;10523349;;10.1007/0-387-28674-8_1;;9474697;;10.1111/j.1540-8159.1998.tb01113.x;;1937659;;10.1161/01.hyp.18.5.575;;10.1097/00000658-197203000-00016;;pmc1355189;;5077800;;10.1136/pgmj.65.768.729;;pmc2429847;;2616398;;10.1161/01.hyp.4.3.208;;10.1161/01.cir.6.1.131;;14936210;;2759678;;10.1161/01.hyp.14.2.177;;10.1161/01.cir.0000097118.75179.83;;14581401;;9486295;;10.1152/ajpregu.1998.274.2.r383;;10.1016/j.jash.2012.01.003;;22341199;;9216950;;10.1152/jappl.1997.83.1.95;;10.1139/y92-098;;1423018;;2396676;;10.1152/ajprenal.1990.259.3.f503;;pmc1250644;;10.1097/00000658-198502000-00014;;3970603;;10.1172/jci108355;;pmc436757;;947953;;pmc436571;;1141432;;10.1172/jci108069;;9326990;;pmc484896;;10.1136/hrt.78.2.160;;10.1161/01.cir.97.14.1368;;9577948;;10.1016/j.jcin.2011.12.011;;22440489;;11157719;;10.1161/01.cir.103.4.538;;10.1093/ndt/gfr190;;21505095;;10831622;;10.1093/ndt/15.6.755;;10.1056/nejm199702133360702;;9017938;;10.1161/hypertensionaha.112.201186;;23045466;;10.1016/j.jcin.2012.09.005;;23266234;;11693214;;10.1016/s0735-1097(99)00047-9;;10334440;;10.1093/ndt/9.7.741;;7970112;;10.1007/s11906-002-0016-3;;12003710;;7721447;;10.1161/01.hyp.25.4.878;;7485145;;10.1016/0272-6386(95)90456-5;;24077243;;10.1097/hjh.0b013e328364d3f1;;3550529;;10.1016/0304-3940(87)90043-7;;3531006;;10.1161/01.hyp.8.10.925;;11884269;;10.1007/s11906-002-0038-x;;1454086;;10.1056/nejm199212313272704;;10.1097/00000658-193806000-00003;;pmc1386871;;17857203;;10.1053/euhj.1999.1717;;10666349;;10.1097/00007890-198102000-00007;;7020172;;pmc2616110;;18858683;;pmc2616255;;18871934;;18857084;;pmc2616239;;10.1016/j.jacc.2013.04.010;;23644092;;11581498;;10.1152/physrev.2001.81.4.1599;;11986898;;10.1038/sj.jhh.1001346;;10.1152/physrev.1997.77.1.75;;9016301;;19955493;;10.1152/ajpregu.00647.2009;;10.1161/01.hyp.13.6.539;;2661424;;10.1152/ajpregu.2000.279.5.r1517;;11049831;;12623969;;10.1161/01.hyp.0000047205.52509.8a;;10.1161/01.cir.98.17.1769;;9788832;;9918893;;10.1042/cs19980149;;10.1042/cs0960137;;10.4330/wjc.v5.i4.94;;23675555;;pmc3653017;;10.1016/j.jacc.2012.08.1002;;23141491;;11094046;;10.1161/01.cir.102.22.2774;;10.1016/j.jacc.2013.08.1616;;24021387;;19822798;;10.1161/hypertensionaha.109.138610;;10.1056/nejmc0904179;;19710497;;22469838;;10.1097/hjh.0b013e328352ce78;;10.4244/eijv9sra11;;23732157;;10.1001/archsurg.1964.01320050126011;;14216033;;10.1111/j.1464-410x.1936.tb11344.x;;841806;;10.1016/0090-4295(77)90351-x;;10.7863/jum.2000.19.4.277;;10759352;;10.1097/00000658-197602000-00013;;1247314;;pmc1344079;;10.1097/00000658-196805000-00005;;5646289;;pmc1387114;;10.3171/jns.1981.55.2.0246;;7252548;;pmc1929921;;15392665;;13061307;;10.1001/jama.1953.03690160001001;;3693861;;10.1016/s0168-8278(87)80569-x;;10.1161/01.hyp.37.4.1053;;11304502;;10.1016/s0002-9610(97)00094-9;;9293822;;10.1097/00004872-198604000-00007;;3519762;;10.1161/01.cir.87.2.487;;8425296;;10.1016/s1051-0443(92)72202-7;;1540711;;9719172;;10.1093/ndt/13.8.2092;;8009275;;6246596;;10.3949/ccjm.79a.12040;;22751635;;10.1161/01.hyp.22.6.839;;8244515;;9825377;;10.1111/j.1540-8159.1998.tb01211.x;;11209012;;10.1093/ndt/16.1.160;;8203638;;10.1152/ajpregu.1994.266.5.r1599;;22920752;;10.1016/s0140-6736(12)61145-3;;7884244;;10.3109/02656739409012377;;10.3109/10641968709160163;;2824099;;10.1042/cs0900287;;8777835;;pmc371533;;10.1172/jci109966;;7000828;;14638619;;10.1161/01.hyp.0000103630.72812.10;;3942241;;10.1152/ajpheart.1986.250.1.h82;;2737724;;10.1161/01.hyp.13.6.870;;10.1001/archneur.1961.00450070085009;;13787490,"Dibona, Gerald F., Renal Innervation and Denervation: Lessons from Renal Transplantation Reconsidered, Artificial Organs, vol. 11, No. 6, 1987, 457-462.;;Dibona, Gerald F., Role of the Renal Nerves in Renal Sodium Retention and Edema Formation, Trans Am Clin Climatol Assoc. 1990; 101: 38-45.;;Dibona, Gerald F., Sympathetic Nervous System and Hypertension, Hypertension Journal of The American Heart Association, 2013; 61: 556-560.;;Dibona, Gerald F., Sympathetic Nervous System and the Kidney in Hypertension, Curr Opin Nephrol Hypertens. Mar. 2002;11(2):197-200.;;Dibona, Gerald F., The Sympathetic Nervous System and Hypertension, Hypertension Journal of The American Heart Association, Vo. 43, Feb. 2004, 147-150.;;Doumas, Michael et al, Interventional Management of Resistant Hypertension, The Lancet, vol. 373, Apr. 11, 2009, pp. 1228-1230.;;Dubuc, Marc et al, Feasibility of Cardiac Cryoablation Using a Transvenous Steerable Electrode Catheter, Journal of Interventional Cardiac Electrophysiology, 1998, 2: 285-292.;;Elmula, Fadl et al, Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure, Hypertension. 2013;62:526-532.;;Esler, M. et al, Sympathetic Nerve Activity and Neurotransmitter Release in Humans: Translation from Pathophysiology into Clinical Practice, Scandinavian Physiological Society, 2003, 177, 275-284.;;Esler, Murray D. et al, Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial, Lancet, 2010; 376:1903-1909.;;Esler, Murray et al, Assessment of Human Sympathetic Nervous System Activity from Measurements of Norepinephrine Turnover, Hypertension Journal of The American Heart Association, vol. 11, No. 1, Jan. 1988, 3-20.;;Evelyn, Kenneth A. et al, Effect of Thoracolumbar Sympathectomy on the Clinical Course of Primary (Essential) Hypertension, American Journal of Medicine, Feb. 1960, 188-221.;;Freyberg, R. H. et al, The Effect on the Kidney of Bilateral Splanchnicectomy in Patients with Hypertension, The Journal of Clinical Investigation, vol. 16, Issue 1, Jan. 1937, 49-65.;;Gafoor, Sameer et al, Nonresponders to Renal Denervation for Resistant Hypertension, Endovascular Today, Oct. 2013, 63-70.;;Garel, L. et al, Fatal Outcome After Ethanol Renal Ablation in Child with End-Stage Kidneys; AJR 146:593-594, Mar. 1986.;;Gazdar, A. F. et al, Neural Degeneration and Regeneration in Human Renal Transplants, The New England Journal of Medicine, vol. 238, No. 5, Jul. 1970, 222-224.;;Goldberg, Michael R. et al, Reconstructive Vascular Surgery for Renovascular Hypertension, Can Med Assoc J. Feb. 2, 1974;110(3):275-80.;;Golwyn, Daniel H. et al, Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease, Journal of Vascular and Interventional Radiology, Jul.-Aug. 1997, vol. 8, No. 4, 527-533.;;Gorisch, Wolfram et al, Heat-Induced Contraction of Blood Vessels, Lasers in Surgery and Medicine 2:I-13 (1982).;;Grassi, Guido et al, Baroreflex Control of Sympathetic Nerve Activity in Essential and Secondary Hypertension, Hypertension Journal of The American Heart Association, 1998;31:68-72.;;Grassi, Guido et al, Dissociation Between Muscle and Skin Sympathetic Nerve Activity in Essential Hypertension, Obesity, and Congestive Heart Failure, Hypertension. 1998;31:64-67.;;Grimson, Keith S. et al, Results of Treatment of Patients with Hypertension by Total Thoracic and Partial to Total Lumbar Sympathectomy, Splanchnicectomy and Celiac Ganglionectomy, Annals of Surgery, Jun. 1949, vol. 129, No. 6, 850-871.;;Grimson, Keith S. et al, Total Thoracic and Partial to Total Lumbar Sympathectomy, Splanchnicectomy and Celiac Ganglionectomy for Hypertension, Annals of Surgery, Oct. 1953, vol. 138, No. 4, 532-547.;;Grimson, Keith S., Total Thoracic and Partial to Total Lumbar Sympathectomy and Celiac Ganglionectomy in the Treatment of Hypertension, Annals of Surgery, Oct. 1941, vol. 114, No. 4, 753-775.;;Guyton, Arthur C., Blood Pressure Control Special Role of the Kidneys and Body Fluids, Science, vol. 252, Jun. 1991, 1813-1816.;;Hafkenschiel, Joseph H. et al, Primary Hypertension Survey of the Survival of Patients with Established Diastolic Hypertension After Ten Years of Medical and Surgical Treatment, The American Journal of Cardiology, vol. 16, Jul. 1965, 61-66.;;Hafkenschiel, Joseph H. et al, The Surgical Treatment of Hypertension with Particular Reference to Andrenalectomy and Sympathectomy, Transactions. American College of Cardiology, vol. 5, Dec. 1955, pp. 107-112.;;Hall, J.E. et al, Role of Sympathetic Nervous System and Neuropeptides in Obesity Hypertension, Brazilian Journal of Medical and Biological Research, 2000, 33:605-618.;;Hall, John E., The Kidney, Hypertension, and Obesity, Hypertension. 2003;41:625-633.;;Hall, Winthrop H. et al, Combined Embolization and Percutaneous Radiofrequency Ablation of a Solid Renal Tumor, American Journal of Roentgenology, 174, Jun. 2000, 1592-1594.;;Hamm, Christian et al, Confluence, Issue eight, Apr. 2014.;;Han, Young-Min et al, Renal Artery Embolization with Diluted Hot Contrast Medium: An Experimental Study, Journal of Vascular and Interventional Radiology, Jul. 2001;12(7):862-868.;;Hansen, Jesper Melchoir et al, The Transplanted Human Kidney Does Not Achieve Functional Reinnervation, Clinical Science, (1994) 87, 13-20.;;Heuer, George J., The Surgical Treatment of Essential Hypertension, Annals of Surgery, Oct. 1936, vol. 104, No. 3, 771-786.;;Hinton, J. William, End Results of Thoracolumbar Sympathectomy for Advanced Essential Hypertension, The Bulletin, Apr. 1948, 239-252.;;Holmer, Stephan et al, Role of Renal Nerves for the Expression of Renin in Adult Rat Kidney, The American Journal of Physiology, May 1994;266(5 Pt 2):F738-F745.;;Hoobler, S.W. et al, The Effects of Splanchnicectomy on the Blood Pressure in Hypertension, Circulation Journal of The American Heart Association, vol. IV, Aug. 1951, 173-183.;;Hoppe, Uta C. et al, Minimally Invasive System for Baroreflex Activation Therapy Chronically Lowers Blood Pressure with Pacemaker-like Safety Profile: Results from the Barostim Neo Ttrial, J Am Soc Hypertens. Jul.-Aug. 2012;6(4):270-6.;;Howard, James P. et al, Size of Blood Pressure Reduction from Renal Denervation: Insights from Meta-Analysis of Antihypertensive Drug Trials of 4121 Patients with Focus on Trial Design: The CONVERGE Report, Heart 2013;0:1-9.;;Howard, James P. et al, Unintentional Overestimation of an Expected Antihypertensive Effect in Drug and Device Trials: Mechanisms and Solutions, International Journal of Cardiology, vol. 172, Issue 1, Mar. 1. 2014, pp. 29-35.;;Howell, Marcus H. et al, Tandem Stenting of Crossed Renal Arteries with Ostial Stenosis, Tex Heart Inst J. 2000; 27(2):166-169.;;Hoye, Neil A. et al, Endovascular Renal Denervation: A Novel Sympatholytic with Relevance to Chronic Kidney Disease, Clinical Kidney Journal Advance Access, (2013) 0: 1-8.;;Huang, Shoei K. Stephen et al, Radiofrequency Catheter Ablation of Cardiac Arrhythmias, Basic Concepts and Clinical Applications, Wiley-Blackwell, Jun. 2000, 1-12.;;Huang, Wann-Chu, Renal Denervation Prevents and Reverses Hyperinsulinemia-Induced Hypertension in Rats, Hypertension Journal of The American Heart Association, 1998;32:249-254.;;Humpreys, Michael H., Renal Nerves and CKD: Is Renal Denervation the Answer?, Journal of The American Socity of Nephrology, 2012, 23: 1-3.;;International Search Report and Written Opinion for Application No. PCT/US2010/054637 dated Jan. 3, 2011.;;International Search Report and Written Opinion for Application No. PCT/US2010/054684 dated Jan. 10, 2011.;;Irigoyen, M.C.C. et al, Baroreflex Control of Sympathetic Activity in Experimental Hypertension, Brazilian Journal of Medical and Biological Research, (1998) 31: 1213-1220.;;Izzo, JR, Joseph L. et al, The Sympathetic Nervous System and Baroreflexes in Hypertension and Hypotension, Current Hypertension Reports 1999, 3:254-263.;;Jackman, Warren M. et al, Catheter Ablation of Arrhythmias, Proposed Anatomy and Catheter Ablation of Epicardial Posteroseptal and Left Posterior Accessory AV Pathways (Chapter 16), 2002, Futura Publishing Company, Inc., 321-343.;;Moak, Jeffrey P. et al, Case Report: Pulmonary Vein Stenosis Following RF Ablation of Paroxysmal Atrial Fibrillation: Successful Treatment with Balloon Dilation, Journal of Interventional Cardiac Electrophysiology, Dec. 2000, 4, 4:621-631.;;Mogil, Robert A. et al, Renal Innervation and Renin Activity in Salt Metabolism and Hypertension, American Journal of Physiology, vol. 216, No. 4, Apr. 1969, 693-697.;;Morita, Hironobu et al, Neural Control of Urinary Sodium Excretion During Hypertonic NaC1 Load in Conscious Rabbits: Role of Renal and Hepatic Nerves and Baroreceptors, Journal of the Autonomic Nervous System, 34 (1991) 157-170.;;Morrissey, D.M. et al, Sympathectomy in the Treatment of Hypertension, The Lancet, Feb. 1953, 403-408.;;Mortara, Andrea et al, Nonselective Beta-Adrenergic Blocking Agent, Carvedilol, Improves Arterial Baroflex Gain and Heart Rate Variability in Patients With Stable Chronic Heart Failure, Journal of the American College of Cardiology, vol. 36, No. 5, 2000, 1612-1618.;;Moss, Jonathan, Interventional Radiology and Renal Denervation, Interventions, vol. 13, Issue 3, 2013.;;Naghavi, Morteza et al, Thermography Basket Catheter: In Vivo Measurement of the Temperature of Atherosclerotic Plaques for Detection of Vulnerable Plaques, Catheterization and Cardiovascular Interventions 59:52-59 (2003).;;Naidoo, N. et al, Thoracic Splanchnic Nerves: Implications for Splanchnic Denervation, Journal of Anatomy, Nov. 2001;199(Pt 5):585-590.;;Nakagawa, A. et al, Selective Ablation of Porcine and Rabbit Liver Tissue Using Radiofrequency: Preclinical Study, European Surgical Research, 1999;31:371-379.;;Nakagawa, Hiroshi et al, Inverse Relationship Between Electrode Size and Lesion Size During Radiofrequency Ablation With Active Electrode Cooling, Circulation. Aug. 4, 1998;98(5):458-465.;;Nanni, Gregg S. et al, Control of Hypertension by Ethanol Renal Ablation, Radiology 148: 51-54, Jul. 1983.;;Ndegwa, S., Catheter-Based Renal Denervation for Treatment-Resistant Hypertension [Issues in emerging health technologies issue 121]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2013.;;Neutel, Joel M., Hypertension and Its Management: A Problem in Need of New Treatment Strategies, Journal of Renin-Angiotensin-Aldosterone System 2000 1: S10-S13.;;Newcombe, C.P. et al, Sympathectomy for Hypertension, British Medical Journal, Jan. 1959, 142-144.;;Ng, Fu Siong et al, Catheter Ablation of Atrial Fibrillation, Clinical Cardiology, 25, 384-394 (2002).;;Norman, Roger A. et al, Role of the Renal Nerves in One-Kidney, One Clip Hypertension in Rats, Hypertension Journal of The American Heart Association, 1984;6:622-626.;;Nozawa, Takashi et al, Effects of Long-Term Renal Sympathetic Denervation on Heart Failure After Myocardial Infarction in Rats, Heart Vessels (2002) 16:51-56.;;O'Connor, Brian K. et al, Radiofrequency Ablation of a Posteroseptal Accessory Pathway Via the Middle Cardiac Vein in a Six-Year-Old Child, PACE, vol. 20, Oct. 1997, Part 1, 2504-2507.;;O'Hagen, Kathleen P. et al, Renal Denervation Decreases Blood Pressure in DOCA-Treated Miniature Swine With Established Hypertension, American Journal of Hypertension, 1990; 3:62-64.;;Oliveira, Vera L.L. et al, Renal Denervation Normalizes Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats, Hypertension vol. 19, No. 2 Feb. 1992, Supplement II, II-17-II-21.;;Omran, Heyder et al, Echocardiographic Imaging of Coronary Sinus Diverticula and Middle Cardiac Veins in Patients with Preexcitation Syndrome: Impact—on Radiofrequency Catheter Ablation of Posteroseptal Accessory Pathways, PACE, vol. 18, Jun. 1995, 1236-1243.;;Oparil, Suzanne et al, Renal Nerve Ablation: Emerging Role in Therapeutics; Blood Pressure, Oct. 2011, vol. 20, No. 5 , pp. 253-255.;;Oral, Hakan et al, Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation, Circulation Journal of The American Heart Association, 2002;105:1077-1081.;;Osborn, Jeffrey L. et al, Long-Term Increases in Renal Sympathetic Nerve Activity and Hypertension, Clinical and Experimental Pharmacology and Physiology (1997) 24,72-76.;;Osborn, John W., The Sympathetic Nervous System and Long-Term Regulation of Arterial Pressure: What Are the Critical Questions?, Clinical and Experimental Pharmacology and Physiology (1997) 24, 68-71.;;Ou, Baiqing et al, Baroreflex Sensitivity Predicts the Induction of Ventricular Arrhythmias by Cesium Chloride in Rabbits, Japanese Circulation Journal, 1999; 63: 783-788.;;Oz, Mehmet, Pressure Relief, TIME Magazine, Monday, Jan. 9, 2012.;;Page, Irvine H. et al, Mechanisms, Diagnosis and Treatment of Hypertension of Renal Vascular Origin, Annal of Internal Medicine, Aug. 1959, vol. 51, No. 2, 196-211.;;Page, Irvine H. et al, Mechanisms, Diagnosis and Treatment of Hypertension of Renal Vascular Origin; Annals of Internal Medicine, Aug. 1959;51:196-211.;;Page, Irvine H. et al, The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension, Journal of Clinical Investigation, 1935;14(1):27-30.;;Page, Irvine H. et al, The Effects of Renal Denervation on Patients Suffering from Nephritis, J Clin Invest. 1935;14(4):443-458.;;Page, Irvine H., The Effect of Renal Efficiency of Lowering Arterial Blood Pressure in Cases of Essential Hypertension and Nephritis, Journal of Clinical Investigation, Nov. 1934; 13(6): 909-915.;;Page, Max, Section of Surgery, Discussion on the Surgical Treatment of Hypertension, Proceedings of the Royal Society of Medicine, vol. XLI, Feb. 1948, 359-372.;;Papademetriou, Vasilios, Hypertension and the Simplicity Renal Denervation System, Scientific Background, www.medtronic.com, 2011.;;Pappone, Carlo et al, Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia: A New Anatomic Approach for Curing Atrial Fibrillation, Circulation, Journal of The American Heart Association, 2000;102:2619-2628.;;Parati, Gianfranco et al, The Human Sympathetic Nervous System: Its Relevance in Hypertension and Heart Failure, European Heart Journal (2012) 33, 1058-1066.;;Parmar, Arundhati, Analyst: Medtronic Will Likely Acquire Another Hypertension Therapy Firm, Medcity News, Apr. 27, 2012; 3:06 p.m.; medcitynews.com.;;Pavlovich, Christian P. et al, Percutaneous Radio Requency Ablation of Small Renal Tumors: Initial Results; The Journal of Urology, vol. 167, Jan. 10-15, 2002.;;Pearce, John A. et al, Blood Vessel Architectural Features and Their Effect on Thermal Phenomena, Critical Reviews, vol. CR75, Bellingham, WA: SPIE Optical Engineering Press; 2000, p. 231-277.;;Peet, Max Minor, Hypertension and Its Surgical Treatment by Bilateral Supradiaphragmatic Splanchnicectomy, American Journal of Surgery, vol. 75, Issue 1, Jan. 1948, 48-68.;;Perry, C. Bruce, Malignant Hypertension Cured by Unilateral Nephrectomy, British Heart Journal, Jul. 1945; 7(3):139-142.;;Persu, Alexandre et al, Renal Denervation: Ultima Ratio or Standard in Treatment-Resistant Hypertension, Hypertension Journal of The American Heart Association, Sep. 2012;60(3):596-606.;;Peterson, Helen Hogh et al, Lesion Dimensions During Temperature-Controlled Radiofrequency Catheter Ablation of Left Ventricular Porcine Myocardium Impact of Ablation Site, Electrode Size, and Convective Cooling, Circulation Journal of The American Heart Association, 1999;99:319-325.;;Plouin, Pierre-Francois et al, Blood Pressure Outcome of Angioplasty in Atherosclerotic Renal Artery Stenosis a Randomized Trial, Hypertension Journal of The American Heart Association, 1998;31:823-829.;;Poutasse, Eugene F., Surgical Treatment of Renal Hypertension, American Journal of Surgery, vol. 107, Jan. 1964, 97-103.;;Pugsley, M.K. et al, The Vascular System an Overview of Structure and Function, Journal of Pharmacological and Toxicological Methods 44 (2000) 333-340.;;Putney, John Paul, Are Secondary Considerations Still “Secondary”?:An Examination of Objective Indicia of Nonobviousness Five Years After KSR, Intellectual Property Brief, vol. 4, Issue 2, Article 5, 2012, 45-59.;;Ramsay, Lawrence E. et al, Blood Pressure Response to Percutaneous Transluminal Angioplasty for Renovascular Hypertension: An Overview of Published Series; British Medical Journal Mar. 3, 1990; 300(6724): 569-572.;;Rippy, Marian K. et al, Catheter-Based Renal Sympathetic Denervation: Chronic Preclinical Evidence for Renal Artery Safety, Clin Res Cardiol (2011) 100:1095-1101.;;Ritz, Eberhard, New Approaches to Pathogenesis and Management of Hypertension, Clin J Am Soc Nephrol 4:1886-1891, 2009.;;Zazgornik, Jan et al, Bilateral Nephrectomy: The Best, but Often Overlooked, Treatment for Refractory Hypertension in Hemodialysis Patients, AJH 1998; 11:1364-1370.;;International Search Report and Written Opinion for Application PCT/US2014/059609 dated Dec. 15, 2014.;;Jaff, Michael R. et al, Kidney Stenting Lowers Blood Pressure in Patients with Severe Hypertension; Catheterization and Cardiovascular Interventions; Published Online: Jun. 27, 2012 (DOI: 10.1002/ccd.24449); Print Issue Date: Sep. 2012. URL: http://onlinelibrary.wiley.com/doi/10.1002/ccd.24449/abstract.;;Jain, Mudit K. et al, A Three-Dimensional Finite Element Model of Radiofrequency Ablation with Blood Flow and Its Experimental Validation, Annals of Biomedical Engineering, vol. 28, pp. 1075-1084, 2000.;;Jais, Pierre et al, Efficacy and Safety of Septal and Left-Atrial Linear Ablation for Atrial Fibrillation, The American Journal of Cardiology, vol. 84 (9A), Nov. 1999, 139R-146R.;;Janssen, Ben J.A. et al, Frequency-Dependent Modulation of Renal Blood Flow by Renal Nerve Activity in Conscious Rabbits, American Journal of Physiology, 1997, 273:R597-R608.;;Janssen, Ben J.A. et al, Renal Nerves in Hypertension, Miner Electrolyte Metab 1989;15:74-82.;;Jin, Yu et al, No Support for Renal Denervation in a Meta-Analysis, JACC vol. 62, No. 21, 2013 Correspondence Nov. 19/26, 2013:2029-30.;;Kaltenbach, Benjamin et al, Renal Artery Stenosis After Renal Sympathetic Denervation, J Am Coll Cardiol. Dec. 25, 2012;60(25):2694-5.;;Kaltenbach, Benjamin et al, Renal Sympathetic Denervation as Second-Line Therapy in Mild Resistant Hypertension: A Pilot Study, Catheterization and Cardiovascular Interventions 81:335-339 (2013).;;Kamiya, Atsunori et al, Parallel Resetting of Arterial Baroreflex Control of Renal and Cardiac Sympathetic Nerve Activities During Upright Tilt in Rabbits, Am J Physiol Heart Circ Physiol 298: H1966-H1975, 2010.;;Kandzari, David E. et al, Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN-3 Trial, Clin. Cardiol. 35, 9, 528-535 (2012).;;Kapural, Leonardo et al, Radiofrequency Ablation for Chronic Pain Control, Current Pain and Headache Reports 2001, 5:517-525.;;Kassab, Salah et al, Renal Denervation Attenuates the Sodium Retention and Hypertension Associated with Obesity, Hypertension vol. 25, No. 4, Part 2 Apr. 1995.;;Katholi, Richard E. et al, Decrease in Peripheral Sympathetic Nervous System Activity following Renal Denervation or Unclipping in the One-Kidney One-Clip Goldblatt Hypertensive Rat, The Journal of Clinical Investigation, Jan. 1982;69(1):55-62.;;Katholi, Richard E. et al, Role of the Renal Nerves in the Pathogenesis of One-Kidney Renal Hypertension in the Rat, Hypertension. 1981;3:404-409.;;Katholi, Richard E. et al, The Role of Renal Sympathetic Nerves in Hypertension: Has Percutaneous Renal Denervation Refocused Attention on Their Clinical Significance?; Progress in Cardiovascular Disease 52 (2009) 243-248.;;Katritsis, Demosthenes et al, Recurrence of Left Atrium-Pulmonary Vein Conduction Following Successful Disconnection in Asymptomatic Patients, Europace (2004) 6, 425e432.;;Killip III, Thomas, Oscillation of Blood Flow and Vascular Resistance During Mayer Waves, Circulation Research, vol. XI, Dec. 1962, 987-993.;;Kingwell, Bronwyn A. et al, Assessment of Gain of Tachycardia and Bradycardia Responses of Cardiac Baroreflex, Am J Physiol Heart Circ Physiol 260:H1254-H1263, 1991.;;Kirchheim, H. et al, Sympathetic Modulation of Renal Hemodynamics, Renin Release and Sodium Excretion, Klin Wochenschr (1989) 67: 858-864.;;Klein, GE et al, Endovascular Treatment of Renal Artery Aneurysms with Conventional Non-Detachable Microcoils and Guglielmi Detachable Coils, Br J Urol. Jun. 1997; 79(6):852-860.;;Knight, Eric L. et al, Predictors of Decreased Renal Function in Patients with Heart Failure During Angiotensin-Converting Enzyme Inhibitor Therapy: Results from the Studies of Left Ventricular Dysfunction (SOLVD), American Heart Journal, vol. 138, No. 5, Part 1, Nov. 1999, 849-855.;;Koepke, John P. et al, Functions of the Renal Nerves, The Physiologist, vol. 28, No. 1, Feb. 1985, 47-52.;;Kompanowska-Jezierska, Elzbieta et al, Early Effects of Renal Denervation in the Anaesthetised Rat: Natriuresis and Increased Cortical Blood Flow, Journal of Physiology (2001), 531.2, pp. 527-534.;;Krum, Henry et al, Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Multicentre Safety and Proof-of-Principle Cohort Study, www.thelancet.com vol. 373 Apr. 11, 2009 1275-1281.;;Krum, Henry et al, Device-Based Antihypertensive Therapy: Therapeutic Modulation of the Autonomic Nervous System, Circulation. 2011;123:209-215.;;La Grange, Ronald G. et al, Selective Stimulation of Renal Nerves in the Anesthetized Dog: Effect on Renin Release During Controlled Changes in Renal Hemodynamics, Circulation Research, Journal of The American Heart Association, 1973;33:704-712.;;Labeit, Alexander Michael et al, Changes in the Prevalence, Treatment and Control of Hypertension in Germany? A Clinical-Epidemiological Study of 50.000 Primary Care Patients, PLOS ONE, Dec. 2012, vol. 7, Issue 12, e52229, 1-11.;;Labonte, Sylvain, Numerical Model for Radio-Frequency Ablation of the Endocardium and its Experimental Validation, IEEE Transactions on Biomedical Engineering, vol. 41, No. 2. Feb. 1994, 108-115.;;Lambert, Gavin W. et al, Health-Related Quality of Life After Renal Denervation in Patients With Treatment-Resistant Hypertension, Hypertension. 2012;60:1479-1484.;;Lee, Sang Joon et al, Ultrasonic Energy in Endoscopic Surgery, Yonsei Medical Journal, vol. 40, No. 6, pp. 545-549, 1999.;;Leertouwer, Trude C. et al, In-Vitro Validation, with Histology, of Intravascular Ultrasound in Renal Arteries, Journal of Hypertension 1999, vol. 17 No. 2, 271-277.;;Leishman, A.W.D., Hypertension—Treated and Untreated, British Medical Journal, May 1959, 1361-1368.;;Leonard, Bridget L. et al, Differential Regulation of the Oscillations in Sympathetic Nerve Activity and Renal Blood Flow Following Volume Expansion, Autonomic Neuroscience: Basic and Clinical 83 (2000) 19-28.;;Levin, Stephen, Ardian: Succeeding Where Drugs Fail Treating Hypertension in the Cath Lab, In Vivo: The Business & Medicine Report, vol. 27, No. 10, Nov. 2009.;;Litynski, Grzegorz S., Kurt Semm and the Fight against Skepticism: Endoscopic Hemostasis, Laparoscopic Appendectomy, and Semm's Impact on the “Laparoscopic Revolution”, JSLS. Jul.-Sep. 1998; 2(3): 309-313.;;Lu, David S.K. et al, Effect of Vessel Size on Creation of Hepatic Radiofrequency Lesions in Pigs: Assessment of the “Heat Sink” Effect, American Journal of Radiology, 178, Jan. 2002, 47-51.;;Luscher, Thomas F. et al, Renal Nerve Ablation After SYMPLICITY HTN-3: Confused at the Higher Level?; European Heart Journal, doi:10.1093/eurheartj/ehu195; May 14, 2014.;;Lustgarten, Daniel L. et al, Cryothermal Ablation: Mechanism of Tissue Injury and Current Experience in the Treatment of Tachyarrhythmias, Progress in Cardiovascular Diseases, vol. 41, No. 6 May/Jun. 1999: pp. 481-498.;;Mahfoud, Felix et al, Expert Consensus Document from the European Society of Cardiology on Catheter-Based Renal Denervation, European Heart Journal, Jul. 2013;34(28):2149-57.;;Mancia, Giuseppe et al, Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage, Hypertension Journal of The American Heart Association, 1999, 34:724-728.;;McGahan, John P. et al, History of Ablation, Tumor Ablation, 2005, pp. 3-16.;;Medtronic, Inc., J.P. Morgan Healthcare Conference, Corrected Transcript, Jan. 13, 2014, Factset:Callstreet, www.callstreet.com.;;Medtronic, Inc., Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint, www.medtronic.com, Jan. 9, 2014.;;Medtronic, Inc., RDN Therapy with the Symplicity Renal Denervation System, Procedure Fact Sheet, www.medtronic.com, 2011.;;Medtronic, Inc., Renal Denervation (RDN) Novel Catheter-based Treatment for Hypertension, Symplicity RDN System Common Q&A, 2011.;;Medtronic, Inc., Scientific Basis Behind Renal Denervation for the Control of Hypertension, Dec. 2012, http://www.icimeeting.com/2012/images/stories/PDF/1448_Wilcox_I_Mon.pdf.;;Mehdirad, Ali et al, Temperature Controlled RF Ablation in Canine Ventricle and Coronary Sinus using 7 Fr or 5 Fr Ablation Electrodes, PACE, vol. 21, Jan. 1998, Part II, 316-321.;;Meredith, I T et al, Exercise Training Lowers Resting Renal But Not Cardiac Sympathetic Activity in Humans; Hypertension Journal of The American Heart Association, 1991;18:575-582.;;Michaelis, Lawrence L. et al, Effects of Renal Denervation and Renin Depletion on the Renal Responses to Intravascular Volume Expansion, Ann Surg. Mar. 1972; 175(3): 424-430.;;Millard, F.C. et al, Renal Embolization for Ablation of Function in Renal Failure and Hypertension, Postgraduate Medical Journal (1989) 65, 729-734.;;Abboud, Francois M., The Sympathetic System in Hypertension, State-of-the-Art Review, Hypertension Journal of the American Heart Association, Hypertension 4 (suppl II): II-208-II-225, 1982.;;Allen, Edgar V., Sympathectomy for Essential Hypertension, Circulation Journal of the American Heart Association, vol. VI, Jul. 1952, 131-140.;;Anderson, Erling A. et al, Elevated Sympathetic Nerve Activity in Borderline Hypertensive Humans, Evidence From Direct Intraneural Recordings, Hypertension Journal of the American Heart Association, vol. 14, No. 2, Aug. 1989, 177-183.;;Ardian, Inc., Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension, PR Newswire, Jun. 3, 2010.;;Arentz, Thomas et al, Feasibility and Safety of Pulmonary Vein Isolation Using a New Mapping and Navigation System in Patients with Refractory Atrial Fibrillation, Circulation Journal of the American Heart Association, Nov. 18, 2003, 2484-2490.;;Badder, Emilio et al, Cardiac Afferents Play the Dominant Role in Renal Nerve Inhibition Elicited by Volume Expansion in the Rabbit, American Journal of Physiology, 1998, R383-R388.;;Bakris, George L. et al, Baroreflex Activation Therapy Provides Durable Benefit in Patients with Resistant Hypertension: Results of Long-Term Follow-up in the Rheos Pivotal Trial, J Am Soc Hypertens. Mar.-Apr. 2012;6(2):152-8.;;Bao, Gang et al, Blood Pressure Response to Chronic Episodic Hypoxia: Role of the Sympathetic Nervous System, American Journal of Physiology, 1997, 95-101.;;Barajas, Luciano et al, Anatomy of the Renal Innervation: Intrarenal Aspects and Ganglia of Origin, Canadian Journal of Physiology and Pharmacology, vol. 70, No. 5, May 1992, 735-749.;;Barajas, Luciano et al, Monoaminergic Innervation of the Rat Kidney: A Quantitative Study, American Journal of Physiology, vol. 259, No. 3, Sep. 1990, F503-F511.;;Bardram, Linda et al, Late Results After Surgical Treatment of Renovascular Hypertension, A Follow-up Study of 122 Patients 2-18 Years After Surgery, Annals of Surgery, vol. 201, No. 2, Feb. 1985, 219-224.;;Bello-Reuss, Elsa et al, Effect of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption, The Journal of Clinical Investigation, vol. 57, Apr. 1976, 1104-1107.;;Bello-Reuss, Elsa et al, Effects of Acute Unilateral Renal Denervation in the Rat, The Journal of Clinical Investigation, vol. 56, Jul. 1975, 208-217.;;Benito, Fernando et al, Radiofrequency Catheter Ablation of Accessory Pathways in Infants, Heart, 1997, 78, 160-162.;;Bernardi, Luciano et al, Influence of Type of Surgery on the Occurrence of Parasympathetic Reinnervation After Cardiac Transplantation, Circulation Journal of The American Heart Association, Apr. 14, 1998;97(14):1368-74.;;Bertog, Stefan C. et al, Renal Denervation for Hypertension, JACC: Cardiovascular Interventions, vol. 5, No. 3, Mar. 2012, 249-258.;;Bertram, Harald et al, Coronary Artery Stenosis After Radiofrequency Catheter Ablation of Accessory Atrioventricular Pathways in Children with Ebstein's Malformation, Circulation Journal of the American Heart Association, 2001, 538-543.;;Blankestijn, Peter J. et al, Renal Denervation: Potential Impact on Hypertension in Kidney Disease?, Nephrol Dial Transplant (2011) 0: 1-3.;;Blankestijn, Peter J. et al, Sympathetic Overactivity in Renal Failure Controlled by ACE Inhibition: Clinical Significance, Nephrol Dial Transplant, 2000, 15, 755-758.;;Blum, Ulrich et al, Treatment of Ostial Renal-Artery Stenoses with Vascular Endoprostheses After Unsuccessful Balloon Angioplasty, The New England Journal of Medicine, vol. 336, No. 7, Feb. 1997, 459-465.;;Brinkmann, Julia et al, Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients Prospective Case Series, Hypertension. 2012;60:1485-1490.;;Brookes, Linda et al, Renal Denervation: Is Reality Meeting Expectations?, An Interview with Michel Azizi, MD, PhD, Medscape, Jan. 7, 2013.;;Bunte, Matthew C. et al, Endovascular Treatment of Resistant and Uncontrolled Hypertension, JACC: Cardiovascular Interventions, vol. 6, No. 1, 2013, 1-9.;;Calleary, Hickey D. et al, Pre-Transplant Bilateral Native Nephrectomy for Medically Refractory Hypertension, The Irish Medical Journal, Jul.-Aug. 2001;94(7):214-6.;;Callens, David J. et al, Narrowing of the Superior Vena Cava-Right Atrium Junction During Radiofrequency Catheter Ablation for Inappropriate Sinus Tachycardia: Analysis with Intracardiac Echocardiography, Journal of the American College of Cardiology, vol. 33, No. 6, 1999, 1667-1670.;;Campese, V.M., Is Hypertension in Chronic Renal Failure Neurogenic in Nature?, Nephrol Dial Transplant, 1994, 9:741-742.;;Campese, Vito M. et al, Neurogenic Factors in Renal Hypertension, Current Hypertension Reports, 2002 4: 256-260.;;Campese, Vito M. et al, Renal Afferent Denervation Prevents Hypertension in Rats With Chronic Renal Failure, Hypertension, 1995, 25, 878-882.;;Campese, Vito M. et al, Renal Afferent Denervation Prevents the Progression of Renal Disease in the Renal Ablation Model of Chronic Renal Failure in Rat, American Journal of Kidney Disease, vol. 26, No. 5, Nov. 1995, 861-865.;;Campese, Vito M., Interventional Hypertension: A New Hope or a New Hype? The Need to Redefine Resistant Hypertension, J Hypertens. Nov. 2013;31(11):2118-21.;;Canadian Agency for Drugs and Technologies in Health, Catheter-Based Renal Denervation for Treatment-Resistant Hypertension; Issues in Emerging Health Technologies, Issue 121, Mar. 2013.;;Carlstedt, Thomas et al, Regrowth of Lesioned Dorsal Root Nerve Fibers into the Spinal Cord of Neonatal Rats, Neuroscience Letters Feb. 10, 1987;74(1):14-8.;;Chabanier, H. et al, On the Decapsulation and Neurectomy of the Kidnesy in Permanent Hypertensive States, The Medical Press, Feb. 22, 1936, No. 16, 307-310.;;Ciccone, C D et al, Effects of Acute Renal Denervation on Kidney Function in Deoxycorticosterone Acetate-Hypertensive Swine, Hypertension Journal of the American Heart Association, Oct. 1986, vol. 8, No. 10, 925-931.;;Ciriello, John et al, Renal Afferents and Hypertension, Current Hypertension Reports 2002, 4:136-142.;;Converse, Richard L. et al, Sympathetic Overactivity in Patients with Chronic Renal Failure, The New England Journal of Medicine, vol. 327, No. 27, 1992, 1912-1918.;;Crile, George, The Clinical Results of Celiac Ganglionectomy in the Treatment of Essential Hypertension, Annals of Surgery, Jun. 1938; 107(6): 909-916.;;Cruickshank, J.M., Beta-Blockers Continue to Surprise Us, European Heart Journal (2000) 21, 354-364. et al.",ACTIVE
58,US,A1,US 2015/0119862 A1,035-720-864-169-723,2015-04-30,2015,US 201414509187 A,2014-10-08,US 201414509187 A;;US 201361895171 P,2013-10-24,FLEXIBLE CATHETER SHAFT AND METHOD OF MANUFACTURE,"The present disclosure provides a strong, flexible catheter shaft for use in a catheter system. The flexible catheter shaft includes a nitinol tube having one or more sets of cuts therein in combination with one or more outer jacket layers. The flexible catheter shaft provides a shaft having sufficient stiffness and kink resistance to allow an operator to advance an electrode basket connected to the flexible catheter shaft through a guide catheter to a target ablation site without causing vessel trauma. The distal tip of the flexible catheter shaft is designed to have sufficient flexibility to reduce any risk of kicking out a guide catheter when tracking the electrode basket around turns in the vasculature of a patient.",ST JUDE MEDICAL CARDIOLOGY DIV,CAJAMARCA TOBIAS;;STRONG JEFFREY JOHN;;TERWEY RUSSELL D;;WEIR BRUCE ROBERT;;AYER JANSON LEE;;BUESSELER RYAN KENNETH,ST. JUDE MEDICAL CARDIOLOGY DIVISION INC (2013-10-28),https://lens.org/035-720-864-169-723,Patent Application,yes,9,9,4,4,0,A61M25/0051;;A61M25/0051;;A61B18/1492;;A61B18/1492;;A61B2017/00526;;A61B2017/00526;;A61B2018/00267;;A61B2018/00267;;A61B2018/1475;;A61B2018/1475;;A61M25/0013;;A61M25/0013;;A61M25/0045;;A61M25/0045;;Y10T29/49812;;Y10T29/49812,A61M25/00,604/530;;29/424,0,0,,,,ACTIVE
59,US,B2,US 11155905 B2,050-687-316-765-550,2021-10-26,2021,US 201815977796 A,2018-05-11,US 201815977796 A;;US 201414196010 A;;US 201361790274 P,2013-03-15,Enhanced wear resistant steel and methods of making the same,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",EXXONMOBIL RES & ENG CO;;POSCO,JIN HYUNWOO;;MA NING;;AYER RAGHAVAN;;MUELLER RUSSELL ROBERT;;LEE HAK-CHEOL;;CHOI JONG-KYO;;SUH IN-SHIK,POSCO (2017-09-15);;EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2022-04-01),https://lens.org/050-687-316-765-550,Granted Patent,yes,16,0,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/38;;C21D6/00;;C21D8/00;;C21D9/08;;C21D9/44;;C22C38/02;;C22C38/04;;C22C38/06;;C22C38/20;;G01N17/04,,4,1,001-185-577-956-702,10.4236/jmmce.2008.73021,"The International Search Report and Written Opinion of PCT/US2014/020599 dated Jun. 27, 2014.;;Balogun, S.A. et al., “Effect of Melting Temperature on the Wear Characteristics of Austenitic Manganese Steel,” Journal of Minerals & Materials Characterization & Engineering, 2008, vol. 7, No. 3, pp. 277-289.;;Rajan, T.V. et al., “Heath Treatment of Commercial Steels,” Heat Treatment: Principals and Techniques, Second Edition, 2011, pp. 214-215.;;Kuyucak, S et al., “Heat Treatment Processing of Austenitic Manganese Steels,” 2004, retrieved from the Internet: http://www.academ ia.edu/800180/HEAT-TREATM ENT_P ROC ESSIN G_OF_AUSTEN ITIC_MAN GANESE_STE ELS.",ACTIVE
60,CA,A1,CA 2899199 A1,029-865-422-722-771,2014-09-25,2014,CA 2899199 A,2014-03-05,US 201361790274 P;;US 2014/0020599 W,2013-03-15,ENHANCED WEAR RESISTANT STEEL AND METHODS OF MAKING THE SAME,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,,https://lens.org/029-865-422-722-771,Patent Application,no,0,0,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/04;;C21D6/00;;C21D9/08;;C21D9/44,,0,0,,,,ACTIVE
61,CN,A,CN 105026597 A,069-793-108-809-116,2015-11-04,2015,CN 201480013200 A,2014-03-05,US 2014/0020599 W;;US 201361790274 P,2013-03-15,Enhanced wear resistant steel and methods of making the same,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,,https://lens.org/069-793-108-809-116,Patent Application,no,3,23,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/04;;C21D6/00;;C21D9/08;;C21D9/44,,0,0,,,,DISCONTINUED
62,CA,C,CA 2899199 C,196-391-657-809-875,2021-04-13,2021,CA 2899199 A,2014-03-05,US 201361790274 P;;US 2014/0020599 W,2013-03-15,ENHANCED WEAR RESISTANT STEEL AND METHODS OF MAKING THE SAME,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,,https://lens.org/196-391-657-809-875,Granted Patent,no,0,0,19,19,0,C21D6/005;;C21D9/08;;C21D9/44;;C22C38/04;;G01N17/046;;C22C38/38;;C21D8/005;;C22C38/02;;C22C38/06;;C22C38/20;;C21D6/00;;C22C38/04;;C22C38/38;;C21D8/005;;C22C38/02;;C22C38/06;;C22C38/20;;C21D6/005;;C21D9/08;;C21D9/44;;C22C38/04;;G01N17/046,C22C38/04;;C21D6/00;;C21D9/08;;C21D9/44,,0,0,,,,ACTIVE
63,EP,B1,EP 2971211 B1,135-074-758-361-430,2020-04-15,2020,EP 14714002 A,2014-03-05,US 201361790274 P;;US 2014/0020599 W,2013-03-15,METHODS OF MAKING ENHANCED WEAR RESISTANT STEEL,,EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,POSCO (2022-07-06);;EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2022-07-06),https://lens.org/135-074-758-361-430,Granted Patent,yes,1,1,19,19,0,C21D6/005;;C21D9/08;;C21D9/44;;C22C38/04;;G01N17/046;;C22C38/38;;C21D8/005;;C22C38/02;;C22C38/06;;C22C38/20;;C21D6/00;;C22C38/04;;C22C38/38;;C21D8/005;;C22C38/02;;C22C38/06;;C22C38/20;;C21D6/005;;C21D9/08;;C21D9/44;;C22C38/04;;G01N17/046,C21D6/00;;C21D8/00;;C21D9/08;;C21D9/44;;C22C38/04;;C22C38/06;;C22C38/20;;C22C38/38;;G01N17/04,,0,0,,,,INACTIVE
64,CN,A,CN 110724883 A,140-453-691-974-910,2020-01-24,2020,CN 201911127800 A,2014-03-05,US 201361790274 P;;CN 201480013200 A,2013-03-15,Enhanced wear resistant steel and methods of making the same,"The present disclosure provides a method of manufacturing a high-manganese steel component. The method includes a) providing a composition composed as described in the specification; b) heating the composition to at least about 1000 DEG C; c) cooling the composition at a rate of about 2 DEG C/sec to about 60 DEG C/sec, then performing hot rolling on the composition at a temperature in the range ofabout 700 DEG C to about 1000 DEG C; d) subjecting the composition to a slow cooling or holding treatment; and e) quenching the composition to a temperature in the range of from about 700 DEG C to about 1000 DEG C at a temperature of at least about 10 DEG C, or accelerated cooling or air-cooling the composition to a temperature in the range of about 0 DEG C to about 500 DEG C per second.",EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,,https://lens.org/140-453-691-974-910,Patent Application,no,7,1,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/04;;C21D1/18;;C21D8/02;;C22C38/02;;C22C38/06;;C22C38/08;;C22C38/10;;C22C38/12;;C22C38/14;;C22C38/16;;C22C38/20;;C22C38/22;;C22C38/24;;C22C38/26;;C22C38/28;;C22C38/30;;C22C38/32;;C22C38/34;;C22C38/36;;C22C38/38;;C22C38/42;;C22C38/44;;C22C38/46;;C22C38/48;;C22C38/50;;C22C38/52;;C22C38/54;;C22C38/56;;C22C38/58,,0,0,,,,PENDING
65,AU,A1,AU 2014/237897 A1,125-906-808-074-269,2015-09-03,2015,AU 2014/237897 A,2014-03-05,US 201361790274 P;;US 2014/0020599 W,2013-03-15,Enhanced wear resistant steel and methods of making the same,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",POSCO;;EXXONMOBIL RES & ENG CO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,,https://lens.org/125-906-808-074-269,Patent Application,no,0,0,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/04;;C21D6/00;;C21D9/08;;C21D9/44,,0,0,,,,INACTIVE
66,EP,A1,EP 2971211 A1,097-376-384-024-380,2016-01-20,2016,EP 14714002 A,2014-03-05,US 201361790274 P;;US 2014/0020599 W,2013-03-15,METHODS OF MAKING ENHANCED WEAR RESISTANT STEEL,,EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,POSCO (2022-07-06);;EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2022-07-06),https://lens.org/097-376-384-024-380,Patent Application,yes,0,5,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/04;;C21D6/00;;C21D9/08;;C21D9/44,,1,0,,,See references of WO 2014149732A1,INACTIVE
67,KR,A,KR 20160006166 A,116-576-809-365-871,2016-01-18,2016,KR 20157029306 A,2014-03-05,US 201361790274 P;;US 2014/0020599 W,2013-03-15,ENHANCED WEAR RESISTANT STEEL AND METHODS OF MAKING THE SAME,"본 발명은 개선된 강철 조성물 및 이의 제조 방법을 제공한다. 본 발명은 유리한 내마모성 강철을 제공한다. 보다 특히, 본 발명은 향상된 내마모성을 갖는 고 망간(Mn)강, 및 향상된 내마모성을 갖는 고 망간강 조성물을 제조하는 방법을 제공한다. 본 발명의 유리한 강철 조성물/부품은 하기 특성들 중의 하나 이상을 개선시킨다: 내마모성, 연성, 균열 저항, 침식 저항, 피로 수명, 표면 경도, 응력 부식 저항, 피로 저항, 및/또는 환경 균열 저항. 일반적으로, 본 발명은 마모 및/또는 침식에 저항하도록 조정된 고 망간강을 제공한다.",EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG KYO;;JIN HYUNWOO;;LEE HAK CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN SHIK;;MA NING,,https://lens.org/116-576-809-365-871,Patent Application,no,4,9,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C21D8/00;;C21D9/08;;C21D9/44;;C22C38/02;;C22C38/04;;C22C38/06;;C22C38/20;;C22C38/38,,0,0,,,,ACTIVE
68,US,A1,US 2014/0261918 A1,166-248-229-192-936,2014-09-18,2014,US 201414196010 A,2014-03-04,US 201414196010 A;;US 201361790274 P,2013-03-15,ENHANCED WEAR RESISTANT STEEL AND METHODS OF MAKING THE SAME,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",JIN HYUNWOO;;MA NING;;AYER RAGHAVAN;;MUELLER RUSSELL ROBERT;;LEE HAK-CHEOL;;CHOI JONG-KYO;;SUH IN-SHIK;;EXXONMOBIL RES & ENG CO,JIN HYUNWOO;;MA NING;;AYER RAGHAVAN;;MUELLER RUSSELL ROBERT;;LEE HAK-CHEOL;;CHOI JONG-KYO;;SUH IN-SHIK,POSCO (2017-09-15);;EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2014-02-12),https://lens.org/166-248-229-192-936,Patent Application,yes,6,33,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/38;;C21D8/00;;C22C38/02;;C22C38/06;;C22C38/20,148/620;;148/621;;148/654;;148/609;;148/329;;148/337;;148/325;;148/327;;148/333;;148/336;;148/332;;148/330,0,0,,,,DISCONTINUED
69,US,A1,US 2018/0258515 A1,015-705-481-429-478,2018-09-13,2018,US 201815977796 A,2018-05-11,US 201815977796 A;;US 201414196010 A;;US 201361790274 P,2013-03-15,ENHANCED WEAR RESISTANT STEEL AND METHODS OF MAKING THE SAME,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",EXXONMOBIL RES & ENG CO;;POSCO,JIN HYUNWOO;;MA NING;;AYER RAGHAVAN;;MUELLER RUSSELL ROBERT;;LEE HAK-CHEOL;;CHOI JONG-KYO;;SUH IN-SHIK,POSCO (2017-09-15);;EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2022-04-01),https://lens.org/015-705-481-429-478,Patent Application,yes,4,2,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C22C38/38;;C21D6/00;;C21D8/00;;C21D9/08;;C21D9/44;;C22C38/02;;C22C38/04;;C22C38/06;;C22C38/20;;G01N17/04,,0,0,,,,ACTIVE
70,AU,B2,AU 2014/237897 B2,022-540-204-050-591,2017-02-16,2017,AU 2014/237897 A,2014-03-05,US 201361790274 P;;US 2014/0020599 W,2013-03-15,Enhanced wear resistant steel and methods of making the same,"Improved steel compositions and methods of making the same are provided. The present disclosure provides advantageous wear resistant steel. More particularly, the present disclosure provides high manganese (Mn) steel having enhanced wear resistance, and methods for fabricating high manganese steel compositions having enhanced wear resistance. The advantageous steel compositions/components of the present disclosure improve one or more of the following properties: wear resistance, ductility, crack resistance, erosion resistance, fatigue life, surface hardness, stress corrosion resistance, fatigue resistance, and/or environmental cracking resistance. In general, the present disclosure provides high manganese steels tailored to resist wear and/or erosion.",EXXONMOBIL RES & ENG CO;;POSCO,AYER RAGHAVAN;;CHOI JONG-KYO;;JIN HYUNWOO;;LEE HAK-CHEOL;;MUELLER RUSSELL ROBERT;;SUH IN-SHIK;;MA NING,,https://lens.org/022-540-204-050-591,Granted Patent,no,1,0,19,19,0,C21D6/005;;C21D9/08;;C21D9/44;;C22C38/04;;G01N17/046;;C22C38/38;;C21D8/005;;C22C38/02;;C22C38/06;;C22C38/20;;C21D6/00;;C22C38/04;;C22C38/38;;C21D8/005;;C22C38/02;;C22C38/06;;C22C38/20;;C21D6/005;;C21D9/08;;C21D9/44;;C22C38/04;;G01N17/046,C22C38/04;;C21D6/00;;C21D9/08;;C21D9/44,,0,0,,,,INACTIVE
71,BR,A2,BR 112015020329 A2,186-841-553-574-023,2017-07-18,2017,BR 112015020329 A,2014-03-05,US 2014/0020599 W;;US 201361790274 P,2013-03-15,aço com resistência a desgaste aumentada e métodos para a produção do mesmo,"1/1 resumo “aço com resistência a desgaste aumentada e métodos para a produção do mesmo” são apresentadas composições de aço melhorado e métodos para a produção do mesmo. a apresentação atual produz um aço vantajosamente resistente a desgaste. mais especialmente, a apresentação atual produz um aço com alto teor de manganês (mn) tendo uma resistência a desgaste melhorada, e métodos para a fabricação de composições com alto teor de manganês tendo uma resistência a desgaste melhorada. as vantagens das composições/componentes de aço vantajosas da apresentação atual melhoram uma ou mais das seguintes propriedades: resistência a desgaste, dutibilidade, resistência a fraturas, resistência a erosão, vida em fadiga, dureza superficial, resistência a corrosão por tensão, resistência a fadiga, e/ou resistência a fraturas causada pelo meio ambiente. em geral, a apresentação atual produz aços com alto teor de manganês preparados para resistirem ao desgaste e/ou erosão.",EXXONMOBIL RES & ENG CO;;POSCO,HAK-CHEOL LEE;;HYUN WOO JIN;;IN-SHIK SUH;;JONG-KYO CHOI;;NING MA;;RAGHAVAN AYER;;RUSSELL ROBERT MUELLER,,https://lens.org/186-841-553-574-023,Patent Application,no,0,0,19,19,0,C22C38/38;;C22C38/38;;C21D6/00;;C22C38/04;;C21D6/005;;C21D6/005;;C21D8/005;;C21D8/005;;C21D9/08;;C21D9/08;;C21D9/44;;C21D9/44;;C22C38/02;;C22C38/02;;C22C38/04;;C22C38/04;;C22C38/06;;C22C38/06;;C22C38/20;;C22C38/20;;G01N17/046;;G01N17/046,C21D6/00;;C21D9/08;;C21D9/44;;C22C38/04,,0,0,,,,DISCONTINUED
72,US,A1,US 2004/0115262 A1,073-363-400-876-169,2004-06-17,2004,US 62897003 A,2003-07-28,US 62897003 A;;US 39999302 P;;US 46851903 P,2002-07-29,Formulations and dosage forms for controlled delivery of topiramate,"
   Dosage forms and devices for enhancing controlled delivery of lowly soluble active agents including topiramate by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a drug core composition for delivering high doses of lowly soluble topiramate in solid oral drug delivery systems that are convenient to swallow, for once-a-day administration. The drug core composition contains topiramate, a surfactant and a carrier in ratios for optimal solubility and delivery. 
",JAO FRANK;;EDGREN DAVID;;WONG PATRICK S.L.;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;AYER ATUL;;LI SHAOLING;;TO WINNIE,JAO FRANK;;EDGREN DAVID;;WONG PATRICK S L;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;AYER ATUL;;LI SHAOLING;;TO WINNIE,ALZA CORPORATION (2003-07-15),https://lens.org/073-363-400-876-169,Patent Application,yes,80,29,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,424/468,0,0,,,,DISCONTINUED
73,PE,A1,PE 20040103 A1,132-343-795-034-31X,2004-02-25,2004,PE 2003000646 A,2003-06-26,US 39212802 P,2002-06-26,METODO Y FORMAS DE DOSIFICACION PARA INCREMENTAR LA SOLUBILIDAD DE COMPOSICIONES DE FARMACO PARA ADMINISTRACION CONTROLADA,"SE REFIERE A UNA COMPOSICION TERAPEUTICA DE LIBERACION CONTROLADA, QUE COMPRENDE: 1)UN AGENTE TERAPEUTICO DE BAJA SOLUBILIDAD; 2)UN PORTADOR DE POLIMERO ESTRUCTURAL; Y, 3)ENTRE 5% Y 50% DE UN SURFACTANTE SOLUBILIZANTE ADAPTADO PARA LIBERAR UNA ALTA DOSIS DE AGENTE TERAPEUTICO ENTRE 1µg Y 750 mg, SELECCIONADO ENTRE POLIOXIL 40 ESTEARATO, POLIOXIL 50 ESTEARATO, POLOXAMEROS, ENTRE OTROS. SIENDO, EL POLIMERO ESTRUCTURAL OXIDO DE POLIETILENO CON UN PESO MOLECULAR DE 100 000 A 200 000",ALZA CORP,EDGREN DAVID;;LI SHU;;BHATTI GURDIH;;ATUL AYER;;WONG PATRICIA;;SKLUZACEK ROBERT;;JAO FRANK;;TO WINNIE;;LI SHAOLING;;LAM ANDREW,,https://lens.org/132-343-795-034-31X,Patent Application,no,0,0,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
74,UY,A1,UY 27866 A1,069-694-750-207-549,2003-10-31,2003,UY 27866 A,2003-06-26,UY 27866 A,2003-06-26,MÉTODOS Y MODALIDADES DE DOSIFICACIÓN PARA AUMENTAR LA SOLUBILIDAD DE COMPUESTOS DE DROGA PARA UNA ADMINISTRACIÓN CONTROLADA,"Se describen modalidades de dosificación y dispositivos para mejorar la administración controlada de agentes farmacéuticos mediante el uso de un compuesto nuclear de droga que aumenta la solubilidad del agente farmacéutico. La presente invención proporciona un medio para administrar altas dosis de droga poco soluble en sistemas orales de administración de drogas, convenientes para ser ingeridos en una única administación diaria.",ALZA CORP,EDGREN DAVID;;WONG PATRICK;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;LI SHAOLING;;ATUL AYER;;TO WINNIE;;LAM ANDREW;;BHATTI GURDISH,,https://lens.org/069-694-750-207-549,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
75,TW,A,TW 200410728 A,049-168-802-023-94X,2004-07-01,2004,TW 92120701 A,2003-07-29,US 39999302 P;;US 46851903 P,2002-07-29,Formulations and dosage forms for controlled delivery of topiramate,"Dosage forms and devices for enhancing controlled delivery of lowly soluble active agents including topiramate by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a drug core composition for delivering high doses of lowly soluble topiramate in solid oral drug delivery systems that are convenient to swallow, for once-a-day administration. The drug core composition contains topiramate, a surfactant and a carrier in ratios for optimal solubility and delivery.",ALZA CORP,JAO FRANK;;EDGREN DAVID;;WONG PATRICK S L;;SKLUZACEK ROBERT;;LI SHU;;ANDREW LAM;;SHAOLING LI;;WINNIE TO;;AYER ATUL D,,https://lens.org/049-168-802-023-94X,Patent of Addition,no,0,1,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/22;;A61K9/00;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,PENDING
76,WO,A1,WO 2004/010970 A1,096-637-865-405-607,2004-02-05,2004,US 0323438 W,2003-07-28,US 39999302 P;;US 46851903 P,2002-07-29,FORMULATIONS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF TOPIRAMATE,"Dosage forms and devices for enhancing controlled delivery of lowly soluble active agents including topiramate by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a drug core composition for delivering high doses of lowly soluble topiramate in solid oral drug delivery systems that are convenient to swallow, for once-a-day administration. The drug core composition contains topiramate, a surfactant and a carrier in ratios for optimal solubility and delivery.",ALZA CORP,JAO FRANK;;EDGREN DAVID;;WONG PATRICK S L;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;AYER ATUL D;;LI SHAOLING;;TO WINNIE,,https://lens.org/096-637-865-405-607,Patent Application,yes,6,23,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,PENDING
77,UY,A1,UY 27908 A1,081-269-985-049-722,2003-11-28,2003,UY 27908 A,2003-07-31,US 39999302 P;;US 46851903 P,2002-07-29,FORMULACIONES Y FORMAS DE DOSIFICACIÓN PARA LA ADMINISTRACIÓN CONTROLADA DE TOPIRAMATO,"Se describen formas de dosificación y dispositivos para mejorar la liberación controlada de agentes activos poco solubles que incluyen topiramato mediante el uso de una composición de un núclio de droga que aumenta la solubridad del agente farmacéutico. La presente invención provee una composición de un núcleo de droga para liberar elevadas dosis de topiramato poco soluble en los sistemas de liberación de droga oral sólida que son convenientes para deglutir, en una administración de una vez por día. La composición del núcleo de droga contiene topiramato y un portador en relaciones para una solubilidad y liberación óptimas.",ALZA CORP,JAO FRANK;;EDGREN DAVID;;WONG PATRICK S L;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;AYER ATUL D;;LI SHAOLING;;TO WINNIE,,https://lens.org/081-269-985-049-722,Patent Application,no,0,0,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,PENDING
78,CA,A1,CA 2494233 A1,174-294-419-306-559,2004-02-05,2004,CA 2494233 A,2003-07-28,US 39999302 P;;US 46851903 P;;US 0323438 W,2002-07-29,FORMULATIONS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF TOPIRAMATE,"Dosage forms and devices for enhancing controlled delivery of lowly soluble active agents including topiramate by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a drug core composition for delivering high doses of lowly soluble topiramate in solid oral drug delivery systems that are convenient to swallow, for once-a-day administration. The drug core composition contains topiramate, a surfactant and a carrier in ratios for optimal solubility and delivery.",ALZA CORP,LI SHU;;LAM ANDREW;;SKLUZACEK ROBERT;;AYER ATUL D;;EDGREN DAVID;;JAO FRANK;;WONG PATRICK S L;;LI SHAOLING;;TO WINNIE,,https://lens.org/174-294-419-306-559,Patent Application,no,0,0,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
79,EP,A1,EP 1534238 A1,180-525-675-837-95X,2005-06-01,2005,EP 03771915 A,2003-07-28,US 0323438 W;;US 39999302 P;;US 46851903 P,2002-07-29,FORMULATIONS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF TOPIRAMATE,,ALZA CORP,JAO FRANK;;EDGREN DAVID;;WONG PATRICK S L;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;AYER ATUL D;;LI SHAOLING;;TO WINNIE,,https://lens.org/180-525-675-837-95X,Patent Application,yes,0,0,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
80,NZ,A,NZ 537543 A,093-201-430-957-190,2007-08-31,2007,NZ 53754303 A,2003-07-28,US 39999302 P;;US 46851903 P;;US 0323438 W,2002-07-29,Formulations and high dose osmotic dosage forms for controlled delivery of topiramate,"Disclosed is a high dose osmotic dosage form comprising: (a) a capsule shaped tablet core containing a plurality of layers wherein at least one layer comprises about 50-60% of topiramate, about 5-15% of a structural polymer carrier and about 15-40% of a solubilizing surfactant and at least one other layer comprises a suitable fluid-expandable polymer; (b) a semipermeable membrane surrounding the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment; and (c) an orifice formed through the semipermeable membrane and into the capsule shaped tablet core to permit topiramate to be released from within the compartment into the external fluid environment; which provides a substantially ascending rate of release of the topiramate for a prolonged period of time.",ALZA CORP,JAO FRANK;;EDGREN DAVID;;WONG PATRICK S L;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;AYER ATUL D;;LI SHAOLING;;TO WINNIE,,https://lens.org/093-201-430-957-190,Patent Application,no,0,0,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,PENDING
81,PE,A1,PE 20040131 A1,136-723-276-605-475,2004-03-06,2004,PE 2003000750 A,2003-07-30,US 39999302 P;;US 46851903 P,2002-07-29,FORMULACIONES Y FORMAS DE DOSIFICACION PARA LA ADMINISTRACION CONTROLADA DE TOPIRAMATO,"QUE COMPRENDE: 1)DE 50% A 60% DE UN AGENTE ACTIVO QUE ES TOPIRAMATO, CUYA DOSIS APROXIMADA ES DE 10 mg A 750 mg; 2)DE 5% A 15% DE UN PORTADOR POLIMERICO ESTRUCTURAL, QUE PUEDE SER OXIDO DE POLIETILENO DE PESO MOLECULAR ENTRE 100 000 Y 200 000; Y, 3)DE 5% A 15% DE UN SURFACTANTE SOLUBILIZANTE, ADAPTADO PARA LIBERAR EL TOPIRAMATO POR UN PERIODO DE TIEMPO PROLONGADO, EL CUAL ES SELECCIONADO DE ESTEARATO DE POLIOXILO 40, ESTEARATO DE POLIOXILO 50, POLOXAMEROS Y COPOLIMEROS DE TRES BLOQUES COMO OXIDO DE ETILENO:OXIDO DE PROPILENO:OXIDO DE ETILENO. SE REFIERE TAMBIEN A FORMAS DE DOSIFICACION DE LIBERACION CONTROLADA TALES COMO SISTEMA DE MATRIZ, SISTEMA OSMOTICO. SE REFIERE TAMBIEN A FORMAS DE DOSIFICACION ORALES QUE COMPRENDEN: a)UN NUCLEO, QUE A SU VEZ INCLUYE: i)TOPIRAMATO; ii)UN POLIMERO ESTRUCTURAL; iii)UN SURFACTANTE SOLUBILIZANTE; b)UNA MEMBRANA SEMIPERMEABLE QUE RODEA POR LO MENOS PARCIALMENTE A (a); Y, c)UN ORIFICIO DE SALIDA A TRAVES DE (b) QUE SE COMUNICA CON (a), A FIN DE PERMITIR LA LIBERACION DE (i)",ALZA CORP,LI SHAOLING;;TO WINNIE;;EDGREN DAVID;;SKLUZACEK ROBERT;;LAM ANDREW;;AYER ATUL D;;LI SHU;;WONG PATRICK S L;;JAO FRANK,,https://lens.org/136-723-276-605-475,Patent Application,no,0,0,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
82,AU,A1,AU 2003/256848 A1,121-057-808-328-573,2004-02-16,2004,AU 2003/256848 A,2003-07-28,US 39999302 P;;US 46851903 P;;US 0323438 W,2002-07-29,FORMULATIONS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF TOPIRAMATE,,ALZA CORP,WONG PATRICK S L;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;AYER ATUL D;;LI SHAOLING;;TO WINNIE;;JAO FRANK;;EDGREN DAVID,,https://lens.org/121-057-808-328-573,Patent Application,no,0,1,12,63,0,A61K9/0004;;A61K31/35;;A61P25/08;;A61K31/35;;A61K9/0004,A61K9/00;;A61K9/22;;A61K9/24;;A61K31/35;;A61K31/357;;A61K47/14;;A61K47/32;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
83,US,A1,US 2004/0091529 A1,011-988-722-098-225,2004-05-13,2004,US 60657503 A,2003-06-26,US 60657503 A;;US 39212802 P,2002-06-26,Methods and dosage forms for increasing solubility of drug compositions for controlled delivery,"
   Dosage forms and devices for enhancing controlled delivery of pharmaceutical agents by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a means of delivering high doses of lowly soluble drug in oral drug delivery systems that are convenient to swallow, for once-a-day administration. 
",EDGREN DAVID;;WONG PATRICK S.L.;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;BHATTI GURDISH;;LI SHAOLING;;AYER ATUL;;TO WINNIE,EDGREN DAVID;;WONG PATRICK S L;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;BHATTI GURDISH;;LI SHAOLING;;AYER ATUL;;TO WINNIE,ALZA CORPORATION (2003-12-05),https://lens.org/011-988-722-098-225,Patent Application,yes,76,46,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,424/468,0,0,,,,DISCONTINUED
84,WO,A2,WO 2004/002447 A2,110-977-903-992-467,2004-01-08,2004,US 0320070 W,2003-06-26,US 39212802 P,2002-06-26,DOSAGE FORMS FOR INCREASING THE SOLUBILITY AND EXTENDING THE RELEASE OF DRUGS SUCH AS E.G. TOPIRAMATE AND PHENYTON,"Dosage forms and devices for enhancing controlled delivery of pharmaceutical agents by use of a drug core composition containing a polymer carrier (e.g. polyethylene oxide) and a surfactant (e.g. polyoxyl stearate, poloxamer) that increases the solubility of the pharmaceutical agent are described. The present invention provides a means of delivering high doses of lowly soluble drug in oral drug delivery systems that are convenient to swallow, for once-a-day administration. Osmotic devices are described.",ALZA CORP,EDGREN DAVID;;WONG PATRICK S L;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;BHATTI GURDISH;;LI SHAOLING;;AYER ATUL;;TO WINNIE,,https://lens.org/110-977-903-992-467,Patent Application,yes,0,24,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,PENDING
85,AU,A1,AU 2003/280087 A1,125-056-116-446-983,2004-01-19,2004,AU 2003/280087 A,2003-06-26,US 39212802 P;;US 0320070 W,2002-06-26,METHODS AND DOSAGE FORMS FOR INCREASING SOLUBILITY OF DRUG COMPOSITIONS FOR CONTROLLED DELIVERY,,ALZA CORP,AYER ATUL;;TO WINNIE;;EDGREN DAVID;;WONG PATRICK S L;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;BHATTI GURDISH;;LI SHAOLING,,https://lens.org/125-056-116-446-983,Patent Application,no,0,0,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
86,CN,A,CN 1678290 A,136-228-992-890-440,2005-10-05,2005,CN 03820111 A,2003-06-26,US 39212802 P,2002-06-26,Dosage forms for increasing the solubility of slow releas drugs,,ALZA CORP,DAVID EDGREN;;WONG PATRICK S L;;FRANK JAO;;ROBERT SKLUZACEK;;SHU LI;;ANDREW LAM;;GURDISH BHATTI;;SHAOLING LI;;ATUL AYER;;WINNIE TO,,https://lens.org/136-228-992-890-440,Patent Application,no,0,1,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
87,AU,A8,AU 2003/280087 A8,187-608-464-735-564,2004-01-19,2004,AU 2003/280087 A,2003-06-26,US 39212802 P;;US 0320070 W,2002-06-26,Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton,,ALZA CORP,TO WINNIE;;EDGREN DAVID;;WONG PATRICK S L;;LI SHAOLING;;LAM ANDREW;;SKLUZACEK ROBERT;;AYER ATUL;;LI SHU;;JAO FRANK;;BHATTI GURDISH,,https://lens.org/187-608-464-735-564,Patent Application,no,0,0,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
88,EP,A2,EP 1517671 A2,002-886-604-486-522,2005-03-30,2005,EP 03742204 A,2003-06-26,US 0320070 W;;US 39212802 P,2002-06-26,DOSAGE FORMS FOR INCREASING THE SOLUBILITY AND EXTENDING THE RELEASE OF DRUGS SUCH AS E.G. TOPIRAMATE AND PHENYTON,,ALZA CORP,EDGREN DAVID;;WONG PATRICK S L;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;BHATTI GURDISH;;LI SHAOLING;;AYER ATUL;;TO WINNIE,,https://lens.org/002-886-604-486-522,Patent Application,yes,0,0,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,1,0,,,See references of WO 2004002447A3,DISCONTINUED
89,CA,A1,CA 2489688 A1,076-948-786-705-620,2004-01-08,2004,CA 2489688 A,2003-06-26,US 39212802 P;;US 0320070 W,2002-06-26,DOSAGE FORMS FOR INCREASING THE SOLUBILITY AND EXTENDING THERELEASE OF DRUGS SUCH AS E.G. TOPIRAMATE AND PHENYTON,"Dosage forms and devices for enhancing controlled delivery of pharmaceutical agents by use of a drug core composition containing a polymer carrier (e.g. polyethylene oxide) and a surfactant (e.g. polyoxyl stearate, poloxamer) tha t increases the solubility of the pharmaceutical agent are described. The present invention provides a means of delivering high doses of lowly soluble drug in oral drug delivery systems that are convenient to swallow, for once- a- day administration. Osmotic devices are described.",ALZA CORP,LI SHAOLING;;AYER ATUL;;JAO FRANK;;SKLUZACEK ROBERT;;BHATTI GURDISH;;EDGREN DAVID;;TO WINNIE;;LAM ANDREW;;LI SHU;;WONG PATRICK S L,,https://lens.org/076-948-786-705-620,Patent Application,no,0,0,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,DISCONTINUED
90,WO,A3,WO 2004/002447 A3,087-280-673-965-399,2004-06-10,2004,US 0320070 W,2003-06-26,US 39212802 P,2002-06-26,DOSAGE FORMS FOR INCREASING THE SOLUBILITY AND EXTENDING THE RELEASE OF DRUGS SUCH AS E.G. TOPIRAMATE AND PHENYTON,"Dosage forms and devices for enhancing controlled delivery of pharmaceutical agents by use of a drug core composition containing a polymer carrier (e.g. polyethylene oxide) and a surfactant (e.g. polyoxyl stearate, poloxamer) that increases the solubility of the pharmaceutical agent are described. The present invention provides a means of delivering high doses of lowly soluble drug in oral drug delivery systems that are convenient to swallow, for once-a-day administration. Osmotic devices are described.",ALZA CORP,EDGREN DAVID;;WONG PATRICK S L;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;LAM ANDREW;;BHATTI GURDISH;;LI SHAOLING;;AYER ATUL;;TO WINNIE,,https://lens.org/087-280-673-965-399,Search Report,yes,7,0,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/00;;A61K9/22;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,PENDING
91,TW,A,TW 200500098 A,131-999-052-602-385,2005-01-01,2005,TW 92117729 A,2003-06-27,US 39212802 P,2002-06-26,Methods and dosage forms for increasing solubility of drug compositions for controlled delivery,"Dosage forms and devices for enhancing controlled delivery of pharmaceutical agents by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a means of delivering high doses of lowly soluble drug in oral drug delivery systems that are convenient to swallow, for once-a-day administration.",ALZA CORP,EDGREN DAVID;;WONG PATRICK S L;;JAO FRANK;;SKLUZACEK ROBERT;;LI SHU;;ANDREW LAM;;GURDIH BHATTI;;SHAOLING LI;;ATUL AYER;;WINNIE TO,,https://lens.org/131-999-052-602-385,Patent of Addition,no,0,0,11,63,0,A61K31/4166;;A61K31/4166;;A61K9/0004;;A61K9/0004;;A61K31/35;;A61K31/35;;A61K47/34;;A61K47/34;;A61P25/08,A61K9/22;;A61K9/00;;A61K31/35;;A61K31/4166;;A61K47/34;;A61P25/08,,0,0,,,,PENDING
92,BR,A2,BR PI0613326 A2,108-812-171-980-278,2011-01-04,2011,BR PI0613326 A,2006-05-25,US 68739405 P;;US 39898606 A;;US 2006/0020415 W,2005-06-03,ferramenta manualmente operada e hidraulicamente atuada,"FERRAMENTA MANUALMENTE OPERADA E HIDRAULICAMENTE ATUADA. Uma ferramenta manualmente operada, atuada hidraulicamente, a bateria, incluindo um corpo formando um eixo geométrico longitudinal da ferramenta, uma bateria disposta deslocada do eixo geométrico longitudinal da ferramenta e localizada ao longo do eixo geométrico longitudinal da ferramenta, um motor conectado à bateria, uma bomba de fluido hidráulico conectada ao motor, tal como através de uma transmissão, um êmbolo conectado de modo móvel ao corpo e adaptado para ser movido em relação ao corpo por um fluido hidráulico bombeado pela bomba de fluido hidráulico, e uma cabeça operativa adaptada para ser atuada pelo êmbolo. A ferramenta inclui uma seção principal em uma configuração em linha ao longo do eixo geométrico longitudinal da ferramenta. O eixo geométrico longitudinal central da bateria sendo deslocado do eixo geométrico longitudinal da ferramenta.",FCI AMERICAS TECHNOLOGY INC,GEIBEL DEAN;;BECK ALAN D;;MONTMINY ARMAND T;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L;;AYER JOHN W;;LEFAVOUR JOHN D,,https://lens.org/108-812-171-980-278,Patent Application,no,0,0,10,10,0,B25B27/10;;B25B27/10,B21J9/18,,0,0,,,,DISCONTINUED
93,US,B2,US 7464578 B2,055-579-566-933-08X,2008-12-16,2008,US 39898606 A,2006-04-05,US 39898606 A;;US 68739405 P,2005-06-03,"Hand-held, portable, battery-powered hydraulic tool","A hand-held, battery-powered, hydraulically-actuated tool including a frame forming a tool longitudinal axis; a battery offset from the tool longitudinal axis; and located along the tool longitudinal axis a motor connected to the battery; a hydraulic fluid pump connected to the motor, such as by a transmission; a ram movably connected to the frame and adapted to be moved relative to the frame by hydraulic fluid pumped by the hydraulic fluid pump; and a working head adapted to be actuated by the ram. The tool includes a main section situated in an in-line configuration along the tool longitudinal axis. A center longitudinal axis of the battery is offset from the tool longitudinal axis.",FCI AMERICAS TECHNOLOGY INC,AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,FCI AMERICAS TECHNOLOGY INC (2006-04-03);;HUBBELL INCORPORATED (2010-11-04);;BURNDY TECHNOLOGY LLC (2010-09-10),https://lens.org/055-579-566-933-08X,Granted Patent,yes,104,35,10,10,0,B25B27/10;;B25B27/10,B21D9/18;;B21D7/06,72/453.15;;72/453.16;;72/407;;60/477,3,0,,,"1. Parts List, Fairmont EK425 Battery Powered Crimping Tool, 4 pages, 2004.;;2. FCI 2005 Master Catalog, pp. 581-590.;;Patent Abstract of Japan, Yasufusa, T. et al., ""Oil Tank Structure For Charging Type Hydraulic Tool"", Publication No. 08-011065, Application No. 06-145874.",ACTIVE
94,CN,B,CN 101500723 B,085-010-600-548-516,2011-10-12,2011,CN 200680019546 A,2006-05-25,US 2006/0020415 W;;US 68739405 P;;US 39898606 A,2005-06-03,"Hand-held, portable, battery-powered hydraulic tool","A hand-held, battery-powered, hydraulically-actuated tool including a frame forming a tool longitudinal axis; a battery offset from the tool longitudinal axis; and located along the tool longitudinal axis; a motor connected to the battery; a hydraulic fluid pump connected to the motor, such as by a transmission; a piston movably connected to the frame and adapted to be moved relative to the frameby hydraulic fluid pumped by the hydraulic fluid pump; and a working head adapted to be actuated by the piston. The tool includes a main section situated in an in-line configuration along the tool longitudinal axis. A center longitudinal axis of the battery is offset from the tool longitudinal axis.",FRAMATOME CONNECTORS INT,GEIBEL DEAN E;;BECK ALAN D;;AYER JOHN W;;MILLEN SAMUEL L;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;MONTMINY ARMAND T;;CHADBOURNE CHRISTOPHER G,HUBBELL INC. (2012-02-07),https://lens.org/085-010-600-548-516,Granted Patent,no,0,1,10,10,0,B25B27/10;;B25B27/10,B21D9/18;;B21D7/06,,0,0,,,,INACTIVE
95,CA,A1,CA 2608234 A1,073-048-259-024-265,2006-12-14,2006,CA 2608234 A,2006-05-25,US 68739405 P;;US 39898606 A;;US 2006/0020415 W,2005-06-03,"HAND-HELD, PORTABLE, BATTERY-POWERED HYDRAULIC TOOL",,FCI AMERICAS TECHNOLOGY INC,LEFAVOUR JOHN D;;GEIBEL DEAN E;;POIRIER ROBERT M;;BECK ALAN D;;MILLEN SAMUEL L;;MONTMINY ARMAND T;;CHADBOURNE CHRISTOPHER G;;AYER JOHN W,,https://lens.org/073-048-259-024-265,Patent Application,no,0,0,10,10,0,B25B27/10;;B25B27/10,B21J9/18,,0,0,,,,DISCONTINUED
96,US,A1,US 2006/0272381 A1,149-488-719-211-825,2006-12-07,2006,US 39898606 A,2006-04-05,US 39898606 A;;US 68739405 P,2005-06-03,"Hand-held, portable, battery-powered hydraulic tool","A hand-held, battery-powered, hydraulically-actuated tool including a frame forming a tool longitudinal axis; a battery offset from the tool longitudinal axis; and located along the tool longitudinal axis a motor connected to the battery; a hydraulic fluid pump connected to the motor, such as by a transmission; a ram movably connected to the frame and adapted to be moved relative to the frame by hydraulic fluid pumped by the hydraulic fluid pump; and a working head adapted to be actuated by the ram. The tool includes a main section situated in an in-line configuration along the tool longitudinal axis. A center longitudinal axis of the battery is offset from the tool longitudinal axis.",FCI AMERICAS TECHNOLOGY INC,AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,FCI AMERICAS TECHNOLOGY INC (2006-04-03);;HUBBELL INCORPORATED (2010-11-04);;BURNDY TECHNOLOGY LLC (2010-09-10),https://lens.org/149-488-719-211-825,Patent Application,yes,99,43,10,10,0,B25B27/10;;B25B27/10,B21J9/18,72/453.16,0,0,,,,ACTIVE
97,CN,A,CN 102328294 A,139-227-190-196-689,2012-01-25,2012,CN 201110259754 A,2006-05-25,US 68739405 P;;US 39898606 A,2005-06-03,"Hand-held, hydraulically-actuated tool","The invention relates to a hand-held, hydraulically-actuated tool which includes a hydraulic pump, a motor connected with the hydraulic pump, a battery, and a user controller connecting the battery with the motor, wherein the user controller includes a toggle member which has a first end part and a second end part. The first end part is movable and can actuate an electri switch, and the second end part is also movable adn can actuate a hydraulic discharge valve. The invension also relates to a hand-held, battery-powered, hydraulically-actuated tool which includes an assembling unit, a housing, and a battery. The assembling unit is roughly in an axial type and includes a motor, a pump, and a jaw assembly. The housing is partially connected with the assembling unit, and includes a part which is partially arranged on the assembling unit and has a cross section which is in a three-protruding-part shape. The battery is connected with the rear end of the housing.",FCI AMERICAS TECHNOLOGY INC,AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,"BURNDY TECHNOLOGY CO., LTD. (2012-07-17);;FCI AMERICA TECHNOLOGY, INC. (2012-07-17);;HUBBELL INC. (2012-07-17)",https://lens.org/139-227-190-196-689,Patent Application,no,0,3,10,10,0,B25B27/10;;B25B27/10,B25B27/02,,0,0,,,,DISCONTINUED
98,WO,A2,WO 2006/132820 A2,030-084-980-753-074,2006-12-14,2006,US 2006/0020415 W,2006-05-25,US 68739405 P;;US 39898606 A,2005-06-03,"HAND-HELD, PORTABLE, BATTERY-POWERED HYDRAULIC TOOL","A hand-held, battery-powered, hydraulically-actuated tool including a frame forming a tool longitudinal axis; a battery offset from the tool longitudinal axis; and located along the tool longitudinal axis a motor connected to the battery; a hydraulic fluid pump connected to the motor, such as by a transmission; a ram movably connected to the frame and adapted to be moved relative to the frame by hydraulic fluid pumped by the hydraulic fluid pump; and a working head adapted to be actuated by the ram. The tool includes a main section situated in an in-line configuration along the tool longitudinal axis. A center longitudinal axis of the battery is offset from the tool longitudinal axis.",FCI AMERICAS TECHNOLOGY INC;;FRAMATOME CONNECTORS INT;;AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,,https://lens.org/030-084-980-753-074,Patent Application,yes,0,4,10,10,0,B25B27/10;;B25B27/10,B21J9/18,,0,0,,,,PENDING
99,WO,A3,WO 2006/132820 A3,065-143-929-869-861,2009-04-16,2009,US 2006/0020415 W,2006-05-25,US 68739405 P;;US 39898606 A,2005-06-03,"HAND-HELD, PORTABLE, BATTERY-POWERED HYDRAULIC TOOL","A hand-held, battery-powered, hydraulically-actuated tool including a frame forming a tool longitudinal axis; a battery offset from the tool longitudinal axis; and located along the tool longitudinal axis a motor connected to the battery; a hydraulic fluid pump connected to the motor, such as by a transmission; a ram movably connected to the frame and adapted to be moved relative to the frame by hydraulic fluid pumped by the hydraulic fluid pump; and a working head adapted to be actuated by the ram. The tool includes a main section situated in an in-line configuration along the tool longitudinal axis. A center longitudinal axis of the battery is offset from the tool longitudinal axis.",FCI AMERICAS TECHNOLOGY INC;;FRAMATOME CONNECTORS INT;;AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,,https://lens.org/065-143-929-869-861,Search Report,yes,4,0,10,10,0,B25B27/10;;B25B27/10,B21D9/18;;B21D7/06,,0,0,,,,PENDING
100,EP,A2,EP 1901866 A2,046-840-198-154-233,2008-03-26,2008,EP 06771278 A,2006-05-25,US 2006/0020415 W;;US 68739405 P;;US 39898606 A,2005-06-03,"HAND-HELD, PORTABLE, BATTERY-POWERED HYDRAULIC TOOL",,FRAMATOME CONNECTORS INT,AYER JOHN W;;GEIBEL DEAN E;;BECK ALAN D;;MONTMINY ARMAND T;;LEFAVOUR JOHN D;;POIRIER ROBERT M;;CHADBOURNE CHRISTOPHER G;;MILLEN SAMUEL L,HUBBELL INCORPORATED (2011-05-11);;BURNDY TECHNOLOGY LLC (2010-05-05),https://lens.org/046-840-198-154-233,Patent Application,yes,0,0,10,10,0,B25B27/10;;B25B27/10,B21J9/18,,0,0,,,,DISCONTINUED
101,US,A1,US 2007/0243254 A1,186-955-347-133-863,2007-10-18,2007,US 73782907 A,2007-06-28,US 73782907 A;;US 2437804 A;;US 2433004 A;;US 62897003 A;;US 60657503 A;;US 53345103 P;;US 53311203 P;;US 39999302 P;;US 46851903 P;;US 39212802 P,2002-06-26,NOVEL DRUG COMPOSITIONS AND DOSAGE FORMS OF TOPIRAMATE,The present invention is directed to novel drug compositions and dosage forms comprising said drug compositions. The drug compositions of the present invention comprise a pharmaceutical agent and a solubilizing agent. The drug compositions of the present invention are particularly advantageous for use with low solubility and/or low dissolution rate pharmaceutical agents. The present invention is further directed to methods for manufacturing of said drug compositions and dosage forms. The present invention is further directed to methods of treatment comprising administration of said drug compositions and dosage forms.,EDGREN DAVID;;JAO FRANK;;KIMBEL RHEA;;SHIVANAND PADMAJA;;AYER ATUL D;;BHATTI GURDISH;;LAM ANDREW;;LI SHU;;SKLUZACEK ROBERT;;TO WINNIE;;WONG PATRICK S;;LI SHAOLING;;YAM NOYMI;;SEROFFF SYLVIA L,EDGREN DAVID;;JAO FRANK;;KIMBEL RHEA;;SHIVANAND PADMAJA;;AYER ATUL D;;BHATTI GURDISH;;LAM ANDREW;;LI SHU;;SKLUZACEK ROBERT;;TO WINNIE;;WONG PATRICK S;;LI SHAOLING;;YAM NOYMI;;SEROFFF SYLVIA L,,https://lens.org/186-955-347-133-863,Patent Application,yes,0,16,1,63,0,A61K9/0004;;A61P25/06;;A61P25/08;;A61K9/0004,A61P25/06;;A61K9/24;;A61P25/08,424/471,0,0,,,,DISCONTINUED
